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 i 
Summary 
This thesis describes LINC00920, a tumor-associated lncRNA identified in the transcriptome dataset 
of the International Cancer Genome Consortium-Early Onset Prostate Cancer (ICGC-EOPC) cohort. 
SiRNA-mediated knockdown of LINC00920 negatively affected proliferation, colony formation, and 
migration of PC-3 prostate cancer cells. Gene set enrichment analysis of microarray expression data 
revealed perturbation of pathways related to cell cycle, cell division, apoptosis, and cell movement. 
Focused pathway analysis of the top LINC00920-deregulated genes showed an inverse relationship 
between the lncRNA expression and FOXO signaling. Furthermore, as measured by qPCR, 
knockdown of LINC00920 activated canonical FOXO targets GADD45A, BCL2L11, and PMAIP1 
while overexpression of the lncRNA reversed this effect. 
In both The Cancer Genome Atlas-Prostate Adenocarcinoma (TCGA-PRAD) and ICGC-EOPC 
cohorts, LINC00920 positively correlated with ERG overexpression. The regulatory influence of ERG 
on the lncRNA was then established using cell line models of ERG overexpression, chromatin 
immunoprecipitation (ChIP) of ERG at the LINC00920 promoter, and promoter luciferase assays 
using wild-type and mutant promoter fragments.  
To address the question of how LINC00920 elicits its associated cellular phenotypes with 
consideration to its presence across cytosolic, nucleoplasmic, and chromatin compartments, chromatin 
isolation by RNA purification (ChIRP) followed by high throughput DNA sequencing (ChIRP-seq) 
and mass spectrometry (ChIRP-MS) were conducted. At the chromatin level, LINC00920 was found 
primarily associating with heterochromatin regions. LINC00920 occupancy was also be detected in a 
subset of promoter regions and putative enhancer loci. Interestingly, the lncRNA trace across the 
mappable genome bore a resemblance to that of the enhancer-associated histone mark H3K4me1, 
suggesting a role for LINC00920 at enhancer elements. At the protein level, most of the identified 
LINC00920 interacting partners are well established RNA binding proteins typically associated with 
the process of transcription. Among the LINC00920-precipitated proteins robustly identified in three 
biological replicates were two 14-3-3 isoforms—14-3-3ε and 14-3-3ζ. Binding of LINC00920 to 14-3-
3ε but not to 14-3-3ζ was validated by RNA immunoprecipitation (RIP) and affinity purification of 
recombinant 14-3-3ε on streptavidin beads using biotinylated LINC00920.  
FOXO activity is mitigated by AKT phosphorylation. FOXO phosphorylation triggers 14-3-3/FOXO 
complex formation, leading to nuclear exportation. Current results indicate the repressive influence of 
LINC00920 on FOXO signaling as well as the positive interaction between the transcript and 14-3-3ε. 
Considering these observations, a rational hypothesis emerged wherein LINC00920/14-3-3ε binding 
further stabilizes the 14-3-3ε/FOXO complex, resulting in a more efficient sequestration and 
consequent deactivation of FOXO.  
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Altogether, this thesis contributes a novel mechanism for a tumor-associated lncRNA in the context of 
ERG-overexpressing prostate cancer cells. Beginning with the transcriptome analysis of the ICGC-
EOPC cohort, and later the TCGA-PRAD dataset, LINC00920 was identified to be an ERG-driven 
transcript. Ultimately, molecular characterization of LINC00920 by ChIRP-MS has revealed its 
apparent role in modulating FOXO in conjunction with 14-3-3ε, resulting in reduced expression of a 
subset of tumor suppressive FOXO targets. Since ERG fusions are clonal events while PTEN deletions 
are subclonal, driving LINC00920 transcription could be a strategy, in part, for ERG-positive cells to 
alleviate the influence of an intact PTEN, paving the way for tumorigenesis. 
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Zusammenfassung 
Diese Dissertation beschreibt LINC00920, eine tumorassoziierte lncRNA, die im Transkriptom-
Datensatz der International Cancer Genome Consortium-Early Onset Prostate Cancer (ICGC-EOPC) 
Kohorte identifiziert wurde. SiRNA-vermittelter Knockdown von LINC00920 reduzierte die 
Proliferation, Koloniebildung und Migration von PC-3-Zellen. Eine Gen-Set-Anreicherungsanalyse 
von Microarray-Expressionsdaten zeigte, dass Gene, die im Zellzyklus, sowie bei Zellteilung, 
Apoptose und Zellbewegung eine Rolle spielen, dereguliert waren. Die am stärksten von LINC00920 
deregulierten Gene waren invers mit Aktivität des FOXO Signalweges azzoziiert. Knockdown von 
LINC00920 führte zu einer erhöhten Transkription der kanonischen FOXO Zielgene GADD45A, 
BCL2L11 und PMAIP1, während die Überexpression von LINC00920 diesen Effekt umkehrte. 
Sowohl im „The Cancer Genome Atlas-Prostate Adenocarcinoma“ (TCGA-PRAD) Datensatz als auch 
in der ICGC-EOPC Kohorte korrelierte LINC00920 mit dem TMPRSS2/ERG-Fusionssstatus der 
Tumoren, d.h. ERG-Überexpression. Die Regulation von LINC00920 durch ERG wurde mittels 
Chromatin-Immunpräzipitation (ChIP) und Luciferase-Tests mit Wildtyp- und Mutanten- Promotor-
Sequenzen nachgewiesen. 
Um die Bindungspartner von LINC00920 im Zyto- bzw. Nukleoplasma sowie im Chromatin zu 
identifizieren wurden Chromatinisolierung durch RNA-Präzipitation (ChIRP), gefolgt von 
Hochdurchsatz DNA-Sequenzierung (ChIRP-Seq) bzw. Massenspektrometrie (ChIRP-MS) 
durchgeführt. Hierbei wurde LINC00920 primär mit Heterochromatin assoziiert gefunden und war v.a. 
in Promotor- und Enhancerregionen angereichert. Die Genom-weite Verteilung von LINC00920 zeigte 
eine Ähnlichkeit mit der Histonmarkierung H3K4me1, was auf eine regulatorische Rolle von 
LINC00920 in Enhancer-Elementen hinweist. Auf Proteinebene waren die meisten der identifizierten 
LINC00920 Interaktionspartner gut etablierte RNA-Bindungsproteine, welche typischerweise mit dem 
Transkriptionsprozess verbunden sind. Zu den LINC00920-präzipitierten Proteinen gehörten zwei 14-
3-3 Isoformen: 14-3-3ε und 14-3-3ζ. Die Bindung von LINC00920 an 14-3-3ε, aber nicht an 14-3-3ζ 
wurde durch RNA-Immunpräzipitation (RIP) und Affinitätsreinigung von rekombinantem 14-3-3ε auf 
Streptavidin-Beads mittels biotinylierter LINC00920 nachgewiesen. 
Die Aktivität von FOXO wird durch AKT Phosphorylierung reduziert, welche wiederum die Bildung 
von 14-3-3/FOXO-Komplexen auslöst, was zu einem Kernexport führt. Die Ergebnisse deuten auf den 
repressiven Einfluss von LINC00920 auf den FOXO-Signalweg durch Bindung an das 14-3-3ε  
Protein hin. Basierend auf diesen Beobachtungen wurde gezeigt, dass die LINC00920/14-3-3ε-
Bindung den 14-3-3ε/FOXO-Komplex stabilisiert, was zu einem erhöhten Abbau von FOXO und 
erhöhter Aktivität des AKT-Signalweges führt. Da ERG-Fusionen klonale Ereignisse darstellen, 
während PTEN-Deletionen subklonal sind, könnte die erhöhte LINC00920-Transkription eine 
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Strategie ERG-positiver Zellen sein, um den Einfluss der Tumorsuppression durch PTEN zu 
reduzieren und den Weg für die Tumorentstehung oder -progression zu ebnen. 
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1. Introduction 
1.1. Cellular physiology of the prostate 
The human prostate is an exocrine gland located at the base of the bladder which is responsible for the 
production of a slightly alkaline fluid that protects and nourishes the sperm in the semen [1]. 
Organized as a pseudostratified epithelium, the prostate is comprised of three types of terminally 
differentiated epithelial cells—the luminal, basal, and neuroendocrine (NE) cells (Figure 1-1) [2].  
Luminal cells line the prostatic lumen and produce secretory proteins such as prostate-specific antigen 
(PSA). In addition, luminal cells characteristically express high levels of luminal cytokeratins (CK8 
and CK18), NKX 3.1, and the androgen receptor (AR) [2, 3]. Basal cells are found between the 
basement membrane and the luminal layer. These cells express high levels of basal cytokeratins 
(CK14, CK5), CK19, GSTP1, and the stem cell transcription factor p63, but very low levels of AR [3]. 
NE cells are very rare and considered to be the least characterized prostatic cell population. These cells 
are androgen independent and are identified by their expression of NE differentiation markers such as 
neuron-specific enolase (NSE/ENO2), chromogranin A (CHGA), chromogranin B (CHGB), and 
synaptophysin (SYP) [4, 5]. While the physiological function of NE cells within the prostate is not yet 
fully understood, their secretory products imply possible roles in regulation, differentiation, and 
proliferation of luminal and basal cells through exocrine, endocrine, paracrine, and autocrine 
mechanisms [4].  
 
Figure 1-1. The prostate epithelium.  Luminal cells produce secretory proteins and 
characteristically express luminal markers such as CK8, CK18, NKX3.1, and AR. Basal cells 
are found between the luminal layer and the basal lamina. These cells express high levels of 
CK14, CK5, CK19, GSTP1, and p63. A small population of neuroendocrine cells is present 
along the basal layer. These cells express high levels of neuroendocrine markers CHGA, 
CHGB, ENO2, and SYP.   
Based on the expression of characteristic protein markers, prostate tumor phenotypes can be classified 
as either luminal or basal. However, definitive information on the cell of origin of prostate cancer 
(PCa) remains elusive and is the focus of active investigations. There have been efforts to correlate the 
cellular phenotype (i.e., luminal or basal) of tumors with clinical courses, but a clear consensus has yet 
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to be reached. One study reported that while luminal-type tumors can arise from basal cells, lesions of 
luminal origin are more aggressive and present a molecular signature that correlates with worse patient 
outcomes [6]. In addition, a study aiming to associate tumor phenotype with clinical response has 
revealed that a subset of luminal PCa exhibited the poorest diseases prognoses. Interestingly, the same 
luminal subset also correlated with response to androgen deprivation therapy (ADT) after 
prostatectomy [7]. On the other hand, it has been reported that a gene expression signature specific for 
human prostate basal stem cells is enriched in advanced metastatic disease, suggesting a common 
transcriptional program [8]. Adding to the complexity of prostatic cell dynamics are other cell types 
present within the surrounding stroma. These include fibroblasts, endothelial cells, immune cells, 
nerve fibers and associated ganglia, and smooth muscle cells—all of which could influence the 
maintenance and progression of the disease by molding the physical and biochemical tumor 
microenvironment. 
1.2. Epidemiology and risk factors of prostate cancer 
In western countries, PCa is the most frequently diagnosed malignancy in men. Since 2015, annual 
estimates of 1 million new cases and 300,000 mortalities have been reported for the disease [9]. 
Established non-modifiable risk factors for PCa development include age, race, and family history 
[10]. Among these, age is the most relevant component as reflected by the increasing standardized 
incidence rates in elderly men (Figure 1-2A) [11]. Extrapolations derived from autopsy studies 
suggest that most men would develop PCa if they lived longer than 100 years old [12]. Indeed, 
asymptomatic prostate malignancies have incidentally been found at autopsies, pointing to the 
tendency of localized PCa to remain undetected for many years before becoming clinically relevant.  
 PCa incidence is highest in more developed countries, which can partly be attributed to healthcare 
accessibility, specifically of screening and early detection programs [13]. Meanwhile, mortality rate is 
highest among men of African descent (Figure 1-2B). This is supported by a number of 
epidemiological studies with corroborating data on the increased prevalence and poorer outcomes of 
PCa in men of African descent compared to Caucasian and Asian males [14-16].  
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Figure 1-2. (A) Age-specific incidence and mortality rates of prostate cancer in the U.S. 
through 2011-2015. Data source: Surveillance, Epidemiology, and End Results (SEER) 
Program, National Cancer Institute [11]. (B) 2018 estimate of age-standardized incidence and 
mortality rates of prostate cancer in different world areas. Data source: International Agency 
for Research of Cancer (IARC) [9]. 
 
Multiple lines of evidence [17-20] indicate that prostate cancer is among the most heritable cancer 
entities together with malignancies of the stomach, colorectum, lung, and breast [17]. Multiple 
analyses of the Nordic twin registry have shown statistically significant heritable factors underlying 
PCa development. From these studies, risk attributed to heritable factors was quantified to be at 42% 
[17], 58% [19], and 57% [20]. In addition, an independent familial PCa study cohort in the 
Netherlands reported a 2.9-fold increased risk of PCa development for first-degree relatives of 
diagnosed patients [18]. Family-based linkage studies on European populations have identified 
multiple genes implicated in hereditary prostate cancer. Among them are HPC1, PCAP, HPCX, 
CAPB, and HOXB13[21-23]. In African American populations, 12q24, 1q24-5, 2p16, and 2p21 were 
identified linkage PCa loci [24, 25]. 1p36 was determined as a susceptibility locus by two independent 
studies on Japanese [26] and African American [25] cohorts. Over 100 PCa-related SNPs were also 
identified across populations based on genome-wide association studies [27-30]. In 2018, a genotype 
meta-analysis of more than 140,000 men revealed 63 novel PCa susceptibility loci [31].  
Although many genetic factors have been identified to contribute to PCa development, genetic testing 
for hereditary PCa or clinical recommendations based on genetic information have yet to reach the 
clinical setting in the same way as successful genetic markers have with respect to other cancer 
entities. The only gene that could potentially break this translational barrier in the near future is 
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BRCA2. Germline mutations in BRCA2 have shown promise as biomarkers for  clinically aggressive 
PCa as well as for treatment response in metastatic disease [32, 33]. 
1.3. Development and progression of prostate lesions 
Prostate cancers develop in a step-wise manner starting from prostate intraepithelial neoplasia (PIN) 
which is characterized by hyperproliferation of luminal cells resulting in dysplasia along the ducts 
(Figure 1-3A). The lesion then progresses to localized (confined to the prostate gland) 
adenocarcinoma, and becomes locally invasive adenocarcinoma once the basal cell layer has been 
degraded and neoplastic cells begin to penetrate through the basal lamina [2]. Metastatic seeding is 
initiated by cells draining into adjacent lymph nodes [34]. Metastatic colonization then occurs in 
distant organs, most commonly in the bone, liver, and lungs [35]. Bone metastases originating from 
the prostate often manifest as osteoblastic lesions which cause hypercalcemia, frequent fractures, and 
severe pain.  
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Figure 1-3. Prostate cancer development and progression. (A) Prostate intraepithelial 
neoplasia (PIN) initiates tumor formation. Metastasis begins upon colonization of cancer cells 
at proximal lymph nodes, and eventually at distant organs. At initial diagnosis, therapy options 
for localized PCa include active surveillance, radical prostatectomy (RP), and radiotherapy 
(RT). Androgen deprivation therapy (ADT) is administered to high-risk localized tumors, of 
which a large proportion will eventually acquire resistance (CRPC). In parallel, locally 
advanced adenocarcinoma can also be refractory to ADT and exhibit de novo resistance. 
Systemic therapies are administered to castrate-resistant and metastatic tumors. Hormone-naive 
metastatic tumors initially respond to ADT but similarly progress to metastatic CRPC 
(mCRPC). (B) Neuroendocrine PCa (NEPC) is a highly aggressive clinical subtype with poor 
prognosis. De novo NEPC has been suggested to originate from transformed prostatic 
neuroendocrine cells. Alternatively, multiple lines of evidence support the transdifferentiation 
model of androgen-deprived adenocarcinomas to neuroendocrine carcinomas.  
 
1.4. PCa diagnostics 
The rise of PCa incidence since the mid-1990s has been partially attributed to the implementation of 
the blood-based PSA screening in the U.S. and Europe. However, overtreatment of the disease—
where patients undergo therapeutic courses that eventually bore no clinical benefit—became a 
consequence of increased PCa diagnoses. As a result, recommendation for non-discriminate PSA 
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screening has now been withdrawn by the U.S. Preventive Task Force (USPTF) [36] while the 
European Association of Urology-European Society for Radiotherapy and Oncology-International 
Society of Geriatric Oncology (EAU-ESTRO-SIOG) limits PSA testing to men with elevated risk of 
the disease [37].  
PSA levels in the blood at midlife have been shown to be indicative of the risk of cancer at the time of 
testing. More recently, it has also been demonstrated to be useful as a predictive risk assessment tool 
for metastasis and cancer specific death in a subset of patients [38]. However, since PSA is not a 
cancer-specific marker, definitive diagnosis can only be made—following assessment of elevated PSA 
concentration (>4 ng/mL) and prostate enlargement—upon microscopic evaluation of prostate tissue 
sampled through needle biopsy. Conventionally, transrectal ultrasound (TRUS) is used to perform a 
systematic prostate biopsy [39]. A pathologist then scores the biopsies according to the Gleason 
grading system. Scores of primary and secondary patterns are combined to account for morphologic 
heterogeneity [40]. Ultimately, clinicians base the final diagnosis regarding the risk of tumor 
progression on a combined assessment of PSA levels, Gleason patterns, and clinical stage.  
1.5. Management of PCa 
Approximately 80-90% of newly diagnosed cases involve localized and regionally confined disease 
[41, 42]. In such early phases, prostatectomy and radiation therapy (RT) can be curative, with 99% of 
patients achieving 5-year relative survival [43]. Nevertheless, about one-third of patients who have 
undergone radical protastectomy (RP) and up to half of patients treated with radiation therapy will 
develop biochemically recurrent disease (rising PSA levels) [42]. Surgery and radiation therapy can be 
performed as salvage treatments. In non-responsive cases, androgen deprivation therapy (ADT) is the 
next line of treatment. ADT can delay the progression of disease since PCa cells are, for the most part, 
heavily reliant on sustained androgen signaling. Patients typically respond well to initial ADT but 
eventual androgen refraction inevitably occurs [44]. Once tumors become resistant to ADT, the 
disease has advanced to castration resistant PCa (CRPC) (Figure 1-3A). CRPC is treated with 
androgen blockade and/or systemic chemotherapy to which patient response rate has been reported to 
be about 50% [45]. Treatment modalities for prostate cancer have increased in recent years. However, 
state-of-the-art systemic therapies can only prolong late-stage patient survival for a few months [46]. 
1.5.1. Local therapies 
The primary therapeutic options for localized PCa are expectant management, radical prostatectomy, 
and radiation therapy (Figure 1-3A). Expectant management monitors disease progression without 
treatment and can be further classified into observation (or watchful waiting) and active surveillance 
[39]. Watchful waiting involving palliative care is undertaken for frail or elderly men with more 
aggressive comorbidities that will most likely out-compete the localized tumor [47]. Active 
surveillance is intended for younger men diagnosed with low-grade cancer (Gleason score of 6 or 
less), with the aim of delaying treatment and its side-effects until the disease progresses [48]. 
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Surveillance policies vary, but patients with low-risk tumors are routinely monitored using serum PSA 
tests, prostate biopsies, and MRI [49]. Due to longer life expectancy, men under active surveillance are 
followed closely, and treatment is initiated once clinical assessments worsen with the intent to reach a 
curative window [50].  
Since considerable risks are associated with operative procedures and post-operative recovery, 
treatment of localized cancer with RP is an option limited to men with life expectancy of at least 10 
years [51, 52]. Radiation therapy approaches for the treatment of localized PCa include external beam 
radiation therapy (EBRT), stereotactic body radiotherapy (SBRT), brachytherapy, and proton therapy. 
With the evolution of radiation therapy and imaging techniques, safer administration of higher doses 
of radiation at localized regions has become possible. Alternative local therapeutic strategies under 
development for clinical application are cryotherapy, and high-intensity focal ultrasound (HIFU). 
Cryotherapy or cryoablation is a minimally invasive procedure that damages tumor tissues by targeted 
exposure of lesions to pressurized argon and helium gases [53]. HIFU uses ultrasonic wave 
transmission to damage tissues by mechanical and thermal means [54]. Vascular-targeted 
photodynamic therapy (VPT) is an emerging treatment modality wherein a tumor vasculature 
photosensitizer drug is intravenously administered and a specific wavelength of light is delivered to 
the tissue of interest resulting in the erosion of vessel anatomy and ablation of tumor tissue [55]. These 
local therapies were developed with the aim of mitigating side-effects and long-term toxicities that 
come with RP and RT. Nonetheless, further studies are still necessary to compare the effectiveness of 
these measures against the standard of care [39, 49]. 
1.5.2. Systemic therapies 
Upon progression to metastatic disease, therapy is shifted from local treatments to systemic 
chemotherapy (Figure 1-3A). Docetaxel and cabazitaxel are the first-line and second-line 
chemotherapeutics, respectively, administered to patients with metastatic PCa [35]. Both drugs are 
taxanes that induce cell cycle arrest and inhibit AR translocation into the nucleus by stabilizing 
microtubular structures [56]. Radium-223 (
223
Ra) is administered intravenously to patients with bone 
metastases. 
223
Ra is an alpha particle emitter that selectively targets osteoblastic metastases [57]. 
Sipuleucel-T therapy is an autologous cellular immunotherapy in which dendritic cells are harvested 
from patients and activated ex vivo by prostatic acid phosphatase (PAP) and granulocyte-macrophage 
colony-stimulating factor (GM-CSF) [58]. Activated antigen-presenting cells are then infused into the 
patient causing T-cell proliferation and priming, enabling the immune cells to recognize and target 
prostatic tumor cells. Zoledronic acid, a bisphosphonate, and denosumab, a human monoclonal 
antibody against RANKL, are osteoprotective agents used to manage osteoclast-mediated bone 
resorption in recurrent metastatic PCa [59, 60]. Finally, tumors with small cell or neuroendocrine 
histology were found to be sensitive to platinum-based therapies (i.e., cisplatin, carboplatin, and 
oxaliplatin) [61].  
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1.5.3. Androgen signaling as a therapeutic target in PCa 
The androgen receptor (AR) is a ligand-dependent transcription factor that regulates the expression of 
genes that control male sexual development and differentiation [62]. AR activation and subsequent 
nuclear translocation is mediated by binding of its canonical ligands, 5α-dihydrotestosterone (DHT) 
and testosterone [44]. Androgen biosynthesis is initiated by the release of hypothalamic gonadotropin-
releasing hormone (GnRH), which stimulates luteinizing hormone (LH) secretion from the anterior 
pituitary gland, subsequently triggering testosterone production in the testes. Upon uptake from the 
circulation by prostate cells, testosterone is converted to the more potent metabolite DHT which binds 
with high affinity to AR, leading to nuclear translocation of the receptor. Nuclear AR homodimers 
then directly associate with androgen response elements (AREs) found at promoter regions of target 
genes such as PSA, TMPRSS2, NKX3.1, and PSMA (Figure 1-4) [63]. Since AR activation promotes 
cell growth and survival, AR activity is critically linked to PCa development and progression. Thus, 
disrupting AR signaling is an important therapeutic strategy against the disease. 
 
Figure 1-4. Androgen signaling in prostate cells. 
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Androgen deprivation therapy (ADT) is an adjuvant therapy with surgery or RT in high-risk localized 
disease, and a primary systemic therapy for men with metastatic PCa [47].  ADT is implemented in 
three ways: (i) bilateral orchiectomy (surgical castration); (ii) using luteinizing hormone-releasing 
hormone (LHRH, or gonadotropin-releasing hormone, GnRH) agonist or antagonist (medical 
castration); and (iii) administration of androgen synthesis inhibitors [64]. ADT can be augmented by 
androgen receptor blockade using AR antagonists [42], resulting in a regimen of complete androgen 
blockade [65]. It is well established that ADT provides initial clinical benefit. However, the majority 
of patients will become refractory to the treatment and progress to castration resistance within 2-3 
years [66]. 
Enzalutamide, abiraterone, and apalutamide are hormonal agents that suppress androgen signaling 
activity. Enzalutamide and apalutamide are androgen receptor antagonists while abiraterone is an 
irreversible inhibitor of CYP17A1, an enzyme required in the steroidogenesis pathway that 
synthesizes DHT [67]. Both pre- and post-chemotherapy administration of either enzalutamide or 
abiraterone delayed disease progression and improved overall survival in metastatic castration-
resistant prostate (mCRPC) cancer patients [68-71]. The next-generation androgen receptor inhibitor 
apalutamide has also been reported to prolong metastasis-free survival and time to tumor progression 
in non-metastatic CRPC [72]. 
1.6. Molecular features of PCa 
While the majority of prostate tumors follow an indolent course, a significant number of cases 
progress with highly heterogeneous clinical trajectories that ultimately lead to lethal outcomes [73]. 
Conversely, high proportions of low-risk tumors are treated non-discriminately with high-risk tumors. 
Such overtreatment negatively impacts a patient’s quality of life. The urgent need to identify clinically 
useful prognostic markers led to comprehensive and large-scale investigations into the genome of 
primary prostate tumors and mCRPC [74-80]. Numerous studies on the PCa transcriptome [75, 78, 81, 
82], epigenome [83-86], and proteome [87-89] have also been undertaken with the same intent of 
understanding the biology of prostate oncogenesis and identifying clinically relevant targets. 
The PCa genome harbors a relatively low mutational burden (approximately 1 mutation per megabase) 
compared to other tumor entities [75]. In contrast, multiple chromosomal gains and losses frequently 
occur. These DNA aberrations often lead to dysregulated processes implicated in, but not limited to, 
prostate development, cell-cycle regulation, cell survival, and chromatin organization [74, 90, 91]. 
Chromosome loss at 6p, 8p, 13q, and 16p are early events in prostate tumorigenesis, resulting in the 
inactivation of tumor suppressors NKX3.1 and RB1. Chromosomal alterations at the PTEN, TP53, and 
CDKN1 loci are also characteristic of the PCa genome. Frequent gains at chromosome 7 and 8q—
along the c-MYC locus—are similarly common. As the disease progresses, genome-wide somatic copy 
number alterations (SCNA) drastically increase, with quantified CNA burden values at 4-5% in 
primary tumors versus 32% in metastatic tumors [92].   
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1.6.1. Primary tumors 
A molecular taxonomy of primary prostate cancer has emerged based on integrated analyses of 
somatic mutations, copy number alterations, gene fusions, gene expression, and DNA methylation 
[75]. The tumor subtypes were defined as either harboring gene rearrangements of E-twenty-six (ETS) 
genes (i.e., ERG, ETV1, ETV4, and FLI1) or somatic mutations (i.e., SPOP, FOXA1, and IDH1). The 
most frequently occurring tumor class is characterized by the presence of ERG gene fusions (46%). 
These tumors overexpress the oncogenic transcription factor ERG through a translocation event on 
chromosome 21q that fuses ERG downstream of an androgen-regulated gene, most commonly, 
TMPRSS2 [93, 94]. TMPRSS2:ERG (T2E)-positive tumors demonstrate characteristic transcriptional 
and epigenetic profiles [86]. Numerous studies have contributed to the understanding of ERG function 
in the context of prostate cancer cells [86, 95-97]. As a transcription factor belonging to the ETS 
family, ERG specifically binds to the GGA(A/T) ETS domain motif and activates target genes such as 
MMP3, PLAT, and PLAU [93, 98]. Moreover, ERG has been shown to interact with the AR and the 
AP-1 complex [96, 99]. More recently, ERG has been implicated in perturbing the chromatin 
landscape in primary PCa tumors, affecting cis-regulatory elements and chromatin architecture via 
recruitment of chromatin modifiers [86, 95, 96].   
1.6.2. Advanced disease 
While the relative distribution of tumor subtypes described remains comparable between primary and 
metastatic lesions [75], increased CNAs and somatic mutations are apparent in advanced disease. 
Hallmark genetic alterations in metastatic PCa target the AR, PTEN-PI3K, WNT, cell cycle, and DNA 
repair pathways. About 70% of mCRPC cases harbor alterations in AR signaling, of which the 
majority involves direct AR amplification or mutation [76]. Mutations in genes cooperating with AR, 
such as ZBTB16, NCOR1, NCOR2, FOXA1, and SPOP were also identified. This high incidence of 
aberrations implies the significance of AR signaling to the viability of metastatic cells. Genetic 
alterations of genes belonging to the PTEN-PI3K pathway (i.e., PTEN, PIK3CA, PIK3CB, PIK3R1, 
and AKT1) occurred in almost half of the studied cohort. Members of the WNT signaling pathway 
including APC, CTNNB1, RNF43, ZNRF3, and RSPO2 were mutated in 18% of cases. Alterations in 
cell cycle-related genes including RB1, CDKN1B, CDKN2A/B, CDKN2C, CCND1, and CDK4 were 
observed in 20% of cases while genes involved in the DNA repair pathway, namely BRCA1/2, ATM, 
FANCA, RAD51B, RAD51C, MLH1, and MSH2 were found mutated in at least 22% of cases [76]. 
Neuroendocrine PCa (NEPC) is a highly aggressive clinical subtype occurring in about 2% of 
treatment-naïve cases (i.e., de novo) [100]. De novo NEPC has been suggested to arise from neoplastic 
transformation of normal prostatic neuroendocrine cells and subsequent outgrowth [101].  On the other 
hand, hormone-resistant tumors are hypothesized to transdifferentiate and terminally present the same 
histological features as de novo NEPC (i.e., treatment emergent) (Figure 1-3B) [102]. NEPC has a 
very poor prognosis and is characterized by rapid disease progression, recurrent bone lesions, and 
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increased metastatic spread, and declined survival. Aside from expression of neuroendocrine markers 
(e.g., SYP, CHGA, CHGB, NSE/ENO2), NEPC cells are characterized by increased concurrent loss of 
RB1 and TP53 [102, 103], upregulation of EZH2, n-MYC and AURKA [104], and attenuated AR and 
RE1-silencing transcription factor (REST) signaling [105]. 
1.7. Non-coding RNAs in cancer 
The genesis of different cell types harboring the same genomic information relies on impeccable gene 
expression regulation. The resulting transcriptional programs determine and impart molecular and 
functional properties to cells. In the decades following the groundbreaking discovery of DNA in the 
1950s, the central dogma of molecular biology, which asserts that genetic information encoded in the 
DNA flows via RNA towards protein synthesis, has significantly influenced the landscape of RNA 
research. Historically, RNA molecules were, for the most part, characterized only as temporary 
carriers of genetic information as mRNAs, components of the ribosome complex as rRNAs, or codon 
readers of the translation machinery as tRNAs [106]. In contrast, proteins were considered to be the 
functional terminal product of genetic information despite protein-coding exons constituting only 
about 2% of the human genome [107]. Pioneering works on model organisms demonstrated that non-
coding RNAs (ncRNAs) such as lin-4 [108], let-7 [109], and XIST [110] exhibit dynamic expression 
patterns and conserved functionalities. With the advent of high throughput sequencing technologies, it 
became clear that, in addition to protein-coding genes, non-coding transcripts are also expressed in a 
cell-type-specific manner during the course of cell development [111-113].  
In recent years, ncRNAs have been implicated in cellular processes involved in normal physiology, 
and their aberrant regulation has been associated with progression of multiple cancer entities [114]. 
While by no means definitive, ncRNAs are classified according to their size as short ncRNAs (18-21 
nucleotides), mid-size ncRNAs (20-200 nucleotides), and long non-coding RNAs (lncRNAs; >200 
nucleotides). Overall, microRNAs (miRNAs) and lncRNAs are among the most studied ncRNAs. 
They have been shown to be differentially expressed between tumors and their normal tissue 
counterparts in many cancer entities [115], suggesting functionality. Nonetheless, the biological roles 
of most ncRNAs remain unclear. Table 1-1 shows selected examples of each ncRNA class and their 
potential functional associations with cancer.  
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Table 1-1. Classes of non-coding RNAs and their functional implications in cancer. 
Name 
Size 
(nt) 
Examples 
Described 
function 
Cancer association References 
Short non-coding RNAs 
MicroRNAs 
(miRNAs) 
18-24 
miR-34,  
miR-200, 
miR-375, 
let-7 
Initiates RISC-
mediated degradation 
of target mRNA 
Perturbed expression in 
cancer resulting in 
dysregulation of target 
genes related to cancer 
hallmarks; harbors potential 
utility as biomarkers 
[114, 116-
118] 
PIWI-interacting 
RNAs (piRNAs) 
26-31 
piR-4987, 
piR-932, 
piR-20365 
Epigenetic and post-
transcriptional 
repression of 
transposons in germ 
line cells 
Commonly overexpressed 
in seminomas, breast, 
ovarian, and cervical 
cancers 
[119, 120] 
Mid-size non-coding RNAs 
Small nucleolar 
RNAs (snoRNAs) 
60-300  
SNORD50A, 
SNORD50, 
SNORD44, 
SNORD76 
Components of 
ribonucleoproteins; 
recruitment of 
modification enzymes 
to rRNAs; generation 
of miRNA-like 
ncRNAs 
Perturbed expression in 
cancer; in vitro functional 
assays demonstrate effect 
on cancer cell growth 
[121-124] 
Transfer RNAs 
(tRNAs) and 
derivatives: tRNA 
halves (tiRNAs) 
and tRNA-dervied 
small fragments 
(tRFs) 
76-90 
tRF-1, 
tRF-1001,  
CU1276 
Codon reading for 
protein translation; 
displacement of 
mRNA stabilizing 
proteins from 3’ UTR 
Perturbed expression of 
tRNA derivatives in some 
cancer entities; expression 
of certain tRNA derivatives 
are implicated in cell 
growth arrest 
[125, 126] 
Long non-coding RNAs 
Long intergenic 
non-coding RNAs 
(lincRNAs) 
>200 
XIST, 
MALAT1,  
NEAT1, 
NORAD, 
PCAT1,  
ARLNC1 
Epigenetic 
modification; post-
transcriptional 
modification; 
chromatin 
organization; protein 
scaffolding; miRNA 
sponging 
Differentially expressed in 
tumors; perturbed 
expression leads to 
dysregulation of cancer 
hallmark genes; potential 
utility as biomarkers 
[81, 127-130] 
Natural antisense 
transcripts (NATs) 
>200 
ANRIL,  
ZFAS1 
Modulation of sense 
transcription 
Overexpressed in tumors 
leading to downregulation 
of tumor suppressive genes 
[131-133] 
Pseudogenes >200 
PTENP1,  
BRAFP1,  
KRASP1 
Regulation of 
homologous genes 
through miRNA 
competition 
Perturbed expression in 
tumors resulting in 
differential expression of 
important oncogenes or 
tumor suppressors 
[134-136] 
Enhancer-
associated RNAs 
(eRNAs) 
>200 
CCAT1 eRNA,  
ACTRT1 eRNA, 
 PSA eRNA 
Augments enhancer 
function; maintains 
the active chromatin 
state of transcription 
locus 
Functional alterations of 
eRNAs have been 
demonstrated in multiple 
cancer entities including 
breast cancer, CRPC, 
colorectal cancer, and basal 
cell carcinoma 
[137-139] 
Transcribed 
ultraconserved 
non-coding RNAs 
(T-UCRs) 
>200 
Uc.8, 
Uc.73,  
Uc.300A 
 
Inhibition of miRNA 
processing; suggested 
to impact RNA 
processing and 
transcription 
Perturbed expression in 
colorectal cancer and 
neuroblastomas; aberrant 
expression affects apoptosis 
and cellular proliferation 
[140-142] 
Circular RNAs 
(circRNAs) 
>200 
Hsa_circ_0022383, 
Hsa_circ_0001946, 
Circ-ITCH, 
Circ-FOXO3 
Gene regulation 
through miRNA 
competition 
Demonstrated to play anti-
tumorigenic roles by 
sponging oncogenic 
miRNAs 
[143-145] 
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1.7.1. MiRNAs in cancer 
MiRNAs comprise a class of short ncRNAs ranging from 18 to 24 nucleotides in length [114]. These 
short ncRNas are well-established regulators of gene expression at the post-transcriptional level. 
MiRNAs target messenger RNAs either through translational repression or mRNA degradation via the 
RNA-induced silencing complex (RISC), with the latter being the predominant miRNA-mediated gene 
repression mechanism in mammals [146]. Transcription of miRNA genes by RNA polymerase II 
initially yields primary miRNAs (pri-miRNAs) which contain at least one stem loop structure. The 
DGCR8/DROSHA microprocessor complex cleaves the pri-miRNA at the base of the hairpin 
structure, yielding a pre-miRNA. The pre-miRNA is exported from the nucleus, through the nuclear 
pore complex, to the cytoplasm where the RNA is further processed by the RISC loading complex 
(RLC). The RLC harbors the endoribonuclease DICER1 which removes the loop of the pre-miRNA 
hairpin. The RNA duplex is then loaded into an Argonaut protein (AGO2 in humans) where the non-
guiding strand is degraded. Upon high-complementarity but imperfect base-pair binding of a target 
mRNA to the mature miRNA within the RISC, the resulting RNA duplex is cleaved by AGO2 
resulting in mRNA degradation [147, 148]. Because canonical miRNA target binding relies only on a 
short seed region along positions 2-7 [149], miRNAs can regulate multiple mRNA targets. 
Aberrant expression of miRNAs in human cancers is well established [150]. In prostate cancer, 
microarray- [151, 152] and deep sequencing-based [153] expression studies on benign and 
tumorigenic tissue have revealed differential expression of miRNAs. In prostate tumors, the most 
upregulated miRNAs include miR-375 [153, 154], miR-200c [153], and miR-141 [154] while miR-221, 
miR-222 [151], miR-143, and miR-145 [153] were among the most downregulated. The functional 
consequences of such expression dysregulation were investigated using in vitro PCa models. For 
example, both miR-375 and miR-220c were shown to target and repress SEC23A mRNA, whose 
protein product plays a role in shuttling proteins from the endoplasmic reticulum to the Golgi. This 
impairment in protein trafficking was implicated in reducing the presentation of MHC-I molecules on 
PCa cells, resulting in decreased tumor immunogenicity [153]. In an independent study, prostatic miR-
375 was also found to target the tumor suppressor CBX7, a member of the Polycomb repressive 
complex 1, expanding the miRNA regulatory network to include epigenetic modifiers [117]. In the 
same cancer entity, the tumor suppressive miR-34b was demonstrated to target DNA 
methyltransferases and histone deacetylases leading to partial demethylation and active chromatin 
modifications [155]. Indeed, numerous prostate cancer-associated miRNAs have already been 
described [156], and it is becoming apparent that certain miRNA signatures can be useful in clinical 
assessments. Consequently, defining these signatures and designing clinically feasible assays for 
miRNA quantification are currently at the forefront of active investigations. 
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1.7.2. The multiple functional modalities of lncRNAs 
LncRNAs are defined as transcripts at least 200 nucleotides long with minimal or completely without 
coding potential. These RNA molecules are processed similarly as messenger RNAs (mRNAs): they 
are transcribed by RNA polymerase II and can undergo 5’-capping, splicing, and 3’-polyadenylation. 
On the other hand, lncRNA genes are generally comprised of fewer exons relative to protein coding 
genes while the transcripts themselves are less abundant and more cell type-specific compared to 
mRNAs. Interestingly, while lncRNA genes have higher tendencies to be conserved compared to 
neutrally evolving ancestral repeat sequences, these non-coding genes are also under weaker selective 
pressure compared to protein coding genes [157]. For long intergenic RNAs (lincRNAs), only about 
12% of human and mouse genes are conserved in other species [158, 159]. Since lncRNA 
functionality presumably stems from its secondary structure in most cases, sequence alterations in 
lncRNA genes are more tolerated. This is in contrast to protein coding genes where base changes lead 
to altered codon usage, and by extension amino acid sequence, that would largely impact protein 
activity [160].    
At present, the number of annotated human lncRNAs has reached more than 150,000 [161]. Of these, 
only a few have been sufficiently characterized—mostly due to technical difficulties encountered in 
studying these transcripts at the resolution of mechanistic detail—leaving to speculation the function 
of the majority. Nonetheless, the mechanisms of lncRNA action that have been described to date [162-
165] have become precedent examples in establishing their roles in important cellular processes. 
LncRNA functions are oftentimes contingent upon the subcellular localization of the transcript. For 
nuclear-enriched lncRNAs, functional modalities include recruitment of chromatin modifiers to 
specific chromosomal loci [166-168], roles in mRNA processing [169], scaffolds for protein 
complexes [165, 170], and decoys for transcription factors [171]. In the cytoplasm, lncRNAs are 
thought to act as miRNA sponges [172, 173], protein sinks [129], and modulators of mRNA stability 
[174] (Figure 1-5). 
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Figure 1-5. Representative lncRNA modalities described in the cytoplasmic and nuclear 
compartments. 1, LncRNA/mRNA binding can result in decreased mRNA stability through 
recruitment of destabilizing factors. 2, Alternatively, lncRNA/mRNA binding can enhance 
mRNA stability through recruitment of an AU-rich element (ARE) binding protein that 
increases the stability of ARE-containing transcripts. 3, By disrupting the interaction between a 
transcription factor and the importin complex, a lncRNA can affect the localization of the host 
transcription factor. 4, Increased gene expression can result from miRNA competition between 
lncRNAs and cognate mRNA targets. 5, By acting as a protein sequestering factor for RNA 
binding proteins that establish mRNA stability, a lncRNA may affect the regulation of cognate 
mRNA targets. 6, Transcription of certain genes may be modulated by lncRNAs acting as 
decoys that titer away transcription factors from specific chromosomal loci. 7, Protein complex 
assembly can be mediated by a transcript acting as a physical scaffold. 8, LncRNAs have been 
implicated in the recruitment of chromatin remodeling complexes at certain chromosomal loci. 
9, While being transcribed, lncRNAs can act to tether chromatin modifiers and facilitate 
chromatin remodeling in cis regions. 10, LncRNAs may mediate long-range interactions of 
regulatory elements such as enhancers by facilitating chromosomal looping. 11, LncRNAs may 
affect splicing by masking splice sites through base complementarity binding to nascent 
mRNA. 
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1.7.3. Established roles of lncRNAs in PCa development and progression 
Numerous lncRNAs exhibit differential expression in PCa, and some have been reported to regulate 
key functions in cells including proliferation, invasion and metastasis, induction of angiogenesis, 
apoptosis, and androgen signaling. Despite this, mechanistic insights on the functional roles of a large 
proportion of lncRNAs remain unknown. Below are examples of prominent PCa-associated lncRNAs 
and their elucidated functions. Comprehensive reviews of lncRNAs implicated in PCa development 
and progression are available elsewhere [175, 176]. 
1.7.3.1. Prostate Cancer Antigen 3 (PCA3) 
PCA3 is a clinically relevant PCa biomarker overexpressed in at least 95% of primary tumors [177]. 
Shown to be involved in epithelial-to-mesenchymal transition (EMT), PCA3 silencing in LNCaP cells 
increased the expression of epithelial markers E-cadherin, Claudin-3, and CK18, and decreased the 
mesenchymal marker vimentin [178]. Moreover, PCA3 knockdown resulted in reduced AR signaling, 
as reflected by downregulation of AR target genes PSA and PCGEM1, and overall mitigation of cell 
growth and viability [178, 179]. 
1.7.3.2. C-Terminal Binding Protein 1 Antisense (CTBP1-AS) 
CTBP1-AS is an androgen responsive lncRNA transcribed in the antisense direction of CTBP1, which 
encodes an AR corepressor. CTBP1-AS is upregulated in prostate cancers, enhancing hormone-
dependent and castration-resistant tumor growth. The nuclear-enriched lncRNA interacts with PSF, a 
transcriptional repressor, and recruits the repressive HDAC-Sin3A complex to the CTBP1 promoter 
resulting in histone deacetylation. CTBP1-AS also guides the PSF complex in trans to mediate histone 
deacetylation at regulatory regions of androgen-repressed genes, including cell cycle regulators 
TP53and SMAD3 [180]. 
1.7.3.3. Prostate Cancer Associated Transcript 1 (PCAT1) 
PCAT1 was first described to be upregulated in a subset of metastatic and high-grade localized PCa 
[81]. Lentiviral PCAT1 overexpression in RWPE-1 benign immortalized prostate cells resulted in 
increased cell proliferation. In contrast, PCAT1 knockdown reduced the proliferative capacity of the 
cells. Expression profiling analysis also revealed perturbed cell cycle and mitotic pathways to be the 
most perturbed after PCAT1 knockdown [81]. Interestingly, reduced homologous recombination (HR) 
efficiency and consequent increased sensitivity to PARP inhibitors was observed in PCa cell lines 
expressing PCAT1. Subsequently, PCAT1 was characterized to be involved in regulating the 
expression of BRCA2, a DNA repair pathway gene crucial for mediating homologous repair [181].  
1.7.3.4. Second Chromosome Locus Associated with Prostate 1 (SChLAP1) 
SChLAP1 was found to be overexpressed in approximately 25% of a PCa cohort with combined 
primary and metastatic disease. The lncRNA was more frequently expressed in metastatic samples, 
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and correlated with ETS fusion events [164]. Gain-of function and loss-of-function of SChLAP1 both 
in vitro and in vivo revealed the role of the lncRNA in cell invasion and metastasis. At the molecular 
level, the nuclear-enriched SChLAP1 associates with and antagonizes the chromatin remodeling and 
tumor-suppressive SWI/SNF complex [164].   
1.7.3.5. Prostate Cancer Gene Expression Marker 1 (PCGEM1)  
The lncRNA PCGEM1 was found to be upregulated in high risk PCa patients [182, 183]. RNA 
immunoprecipitation revealed that PCGEM1 binds to AR at a specific post-translational modification 
site, and this binding enhances ligand-dependent and ligand-independent AR transcriptional programs, 
ultimately leading to increased cell proliferation [184].  
1.7.3.6. Androgen Receptor Regulated Long Non-coding RNA 1 (ARLNC1) 
ARLNC1 was initially identified to be an AR target through DHT stimulation experiments performed 
in both androgen-dependent LNCaP and VCaP cell lines [130]. Furthermore, ARLNC1 upregulation 
was observed in both a localized PCa cohort (n=500) and a metastatic cohort (n=100) compared with 
benign prostate samples. Interestingly, ARLNC1 knockdown resulted in significant repression of AR 
target genes, as well as both AR mRNA and protein levels, demonstrating a positive feedback loop 
between the lncRNA and AR signaling [130].  
1.7.4.  Technologies to dissect lncRNA function 
Upon identification of lncRNA for further investigation, establishment of genetic models 
demonstrating phenotypic changes upon perturbation of candidate transcript levels is critical in 
initiating its functional dissection [185]. Equally important is the elucidation of molecular processes 
the lncRNA is involved in. To address this, a number of technologies have been developed to identify 
RNA interactors—whether protein, chromatin, or other RNA molecules—and these methods can be 
classified as either protein-centric or RNA-centric. Fundamentally, protein-centric methods rely on 
purifying a protein to pulldown interacting RNA molecules which would then be identified through 
quantitative PCR or high-throughput sequencing. Conversely, RNA-centric methods employ tagged 
oligonucleotide probes antisense to the lncRNA of interest to isolate the transcript and its associating 
factors. The RNA interactome can then be determined through immunoblotting, mass spectrometry, 
qPCR, and high-throughput DNA sequencing. RNA-centric methods are utilized to identify novel 
RNA-binding proteins [186]. 
1.7.4.1. Protein-centric methods 
1.7.4.1.1. RNA Immunoprecipitation (RIP) 
RNA immunoprecipitation is arguably the most commonly used method for RNA-protein interaction 
analysis. Initially developed for native purification, RIP enables capture of complexes at physiological 
conditions. Since native protein conformations are preserved, RIP can identify both direct and indirect 
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binding partners. Binding strength between the captured RNA and RNA binding protein (RBP) is 
quantified through quantitative PCR as enrichment of the RNA by target-specific 
immunoprecipitation, normalized to a control immunoprecipitation. Modifications to the method 
include the use of ultraviolet (UV) light or chemical crosslinkers to preserve transient RNA-protein 
complexes and to perform stringent washing steps and minimize false-positives [187]. RIP can also be 
followed by high-throughput sequencing to obtain a transcriptome-wide view of protein-RNA 
interaction [185]. 
1.7.4.1.2. Crosslinked Immuniprecipitation (CLIP) 
In crosslinked immunoprecipitation, intact cells are irradiated by ultraviolet (UV) light to preserve 
RNA-protein complexes [188]. As a result, only RNAs directly bound to the protein are captured. 
Total RNA is partially digested by RNase A and the RNA-binding protein (RBP) is 
immunoprecipitated together with covalently crosslinked RNA. Because of the crosslinking step, 
strong washings can be performed to remove non-specifically bound RNA. Variations of the method 
include (i) high-throughput sequencing of RNA isolated by CLIP (HITS-CLIP), wherein 3’ RNA 
adapters are ligated to captured RNA to enable reverse transcription and subsequent DNA library 
preparation and sequencing [189]; (ii) photoactivatable ribonucleoside-enhanced CLIP (PAR-CLIP), 
wherein cells are cultured in media containing nucleotide analogs 4-thiouridine (4-SU) or 6-
thioguanosine (6-SG) which, upon incorporation into synthesized transcripts, can form crosslinks upon 
exposure to UV light [190]; and (iii) individual nucleotide resolution CLIP (iCLIP), wherein modified 
reverse transcription primers are used to circularize cDNA, and subsequent cleavage through the 
barcoded adaptor region can determine the exact position of RNA-protein interaction [191].  
1.7.4.2. RNA-centric methods 
1.7.4.2.1. Capture Hybrid Analysis of RNA Targets (CHART)  
CHART was first developed to map the genomic occupancy of roX2, a 600 nt lncRNA involved in 
dosage compensation in Drosophila [192]. In this method, RNA interactions are preserved by 
formaldehyde-crosslinking. Capture probes are designed by identifying high-accessibility regions of 
crosslinked lncRNA through RNase H digestion. Briefly, 20-mer synthetic DNA oligonucleotides are 
mixed with sheared chromatin lysate in the presence of RNase H which digests RNA-DNA hybrids. 
Biotinylated antisense capture oligos are designed after identification of RNase H-sensitivity sites by 
qPCR. CHART enrichment is then performed by hybridizing the chromatin lysate with custom-made 
probes, followed by bead capture of lncRNA-chromatin complex. After crosslink reversal by 
proteinase K digestion, DNA isolation is performed, followed by library preparation and deep 
sequencing. CHART has since been successful in mapping the chromatin binding sites of MALAT1 
and NEAT1 in human cells [193].   
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1.7.4.2.2. Chromatin Isolation by RNA Purification (ChIRP)  
ChIRP has a similar workflow as CHART. The difference between the methods lies in the design of 
capture probes and the choice of crosslinker. Whereas CHART utilizes formaldehyde crosslinking and 
requires RNase H mapping of accessibility sites on the target lncRNA, ChIRP employs glutaraldehyde 
crosslinking and tiling 20-mer DNA oligos that span the non-repetitive regions of the target transcript. 
The chromatin occupancy of the human telomerase RNA TERC has been mapped through this method 
(ChIRP-seq) [194]. Additionally, ChIRP has also been utilized to identify the Xist proteome by 
coupling mass spectrometry downstream of the lncRNA-protein capture (ChIRP-MS) [195]. 
1.7.4.2.3. RNA Antisense Purification (RAP)  
RAP is distinct from CHART and ChIRP by its use of long capture biotinylated probes—at least 60 nt 
in length—which results in very specific and stable RNA-DNA hybrids [196]. The choice of 
crosslinking agent depends on which molecular interaction is being investigated. Psoralens are the 
most suitable crosslinking reagents for identifying RNA-RNA interactions using RAP [197]. On the 
other hand, formaldehyde and UV crosslinking are used to analyze nucleic acid and protein 
interactions. RAP in tandem with deep sequencing (RAP-seq) was used to model the spreading of Xist 
across the inactive X chromosome upon initiation of X chromosome inactivation (XCI) [128]. Direct 
interaction of Xist with SHARP, resulting in HDAC3 activation and RNA polymerase II exclusion 
across the X-chromosome was identified through RAP-MS [127]. Through RAP, the lncRNA Firre 
whose gene locus escapes XCI, was found to localize to chromatin in cis and trans, associating with 
genes implicated in adipogenesis [198]. 
1.8. Aim and scope of the thesis 
Although numerous non-coding transcripts have been reported to correlate with PCa development and 
progression, there remains a paucity of lncRNAs with well elucidated functional roles. Accordingly, 
the aim of this thesis was to identify and functionally characterize PCa-associated lncRNAs. To this 
end, the transcriptome dataset of the International Cancer Genome Consortium-Early Onset Prostate 
Cancer (ICGC-EOPC) cohort was leveraged to identify previously uncharacterized non-coding 
transcripts differentially expressed in PCa tumors compared to normal prostatic tissue [80].  
PCa-associated lncRNAs were shortlisted and the top candidate was functionally characterized in 
vitro. Cellular processes and pathways dependent on the transcript were determined through gene 
expression arrays. Moreover, the gene regulatory mechanism driving the lncRNA expression in PCa 
cells was investigated. To further specify the molecular underpinnings of lncRNA function, the 
transcript interactome was identified by establishing and applying the RNA-centric technology ChIRP 
in tandem with high throughput sequencing and mass spectrometry. Relevant lncRNA-protein 
interactions were validated using parallel RNA-protein binding assessment methods such as RNA 
immunoprecipitation and affinity purification. Integrative analysis of lncRNA-dependent molecular 
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processes and protein interactome was performed to generate a mechanistic model of lncRNA function 
in PCa cells, and concomitantly provide novel insights into PCa and lncRNA biology. 
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2. Materials 
2.1. Materials for cell culture 
Table 2-1. Cell lines. 
Cell line Origin Supplier 
DU-145 Prostate carcinoma, derived from brain metastasis 
American Type Culture 
Collection  
(ATCC) 
LNCaP #126  
empty 
Prostate carcinoma, derived from lymph node metastasis; 
stably transfected with an empty expression cassette 
[97] 
LNCaP #126  
T/E III 
Prostate carcinoma, derived from lymph node metastasis; 
stably transfected with a tet-inducible TMPRSS2:ERGa 
expression cassette 
[97] 
LNCaP  
clone FGC 
Prostate carcinoma, derived from lymph node metastasis ATCC 
PC-3 Prostate carcinoma, derived from bone metastasis ATCC 
RWPE-1 Normal prostate epithelium ATCC 
VCaP Prostate carcinoma, derived from vertebral metastasis ATCC 
 
Table 2-2. Cell culture media and supplements. 
Materials/Media/Reagents Supplier 
Doxycycline Sigma-Aldrich 
Dulbecco Modified Eagle Medium (DMEM) Gibco
TM
 Thermo Fisher Scientific 
Dulbecco's Phosphate-Buffered Saline (DPBS) Gibco
TM
 Thermo Fisher Scientific 
Fetal Bovine Serum (FBS) Gibco
TM
 Thermo Fisher Scientific 
Hygromycin B Gibco
TM
 Thermo Fisher Scientific 
Kaighn's Modification of Ham's F-12 Medium  
(F-12K Medium) 
ATCC 
Keratinocyte Serum-Free Medium  
(Keratinocyte-SFM) 
Bovine Pituitary Extract (BPE) 
Epidermal Growth Factor (EGF) 
Gibco
TM
 Thermo Fisher Scientific 
Opti-MEM™ I Reduced Serum Media Gibco
TM
 Thermo Fisher Scientific 
Roswell Park Memorial Institute 1640 Medium (RPMI 
1640 Medium) 
Gibco
TM
 Thermo Fisher Scientific 
Tet System Approved FBS (Tet-FBS) Clontech 
Trypsin-EDTA (0.25%), phenol red  Gibco
TM
 Thermo Fisher Scientific 
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2.2. Materials for molecular biology 
Table 2-3. Vectors. 
Vector Application Supplier 
pAAVsi2 Renilla reporter vector [199] 
pcDNA
TM
3.1(+) 
Mammalian expression 
vector 
Invitrogen
TM
 Thermo Fisher Scientific 
pCR®2.1-TOPO® Cloning vector Invitrogen
TM
 Thermo Fisher Scientific 
pCR®4Blunt-TOPO® Cloning vector Invitrogen
TM
 Thermo Fisher Scientific 
pGL4.10[luc2] 
Firefly luc reporter 
vector 
Promega 
 
Table 2-4. Antibodies used for western blot (WB). 
Target protein Source Isotype Supplier Application 
Working 
dilution 
GAPDH Rabbit IgG 
#2118, Cell Signaling 
Technology 
1
o 
WB 1:1000 
H3 Rabbit polyclonal 
#9715, Cell Signaling 
Technology 
1
o 
WB 1:1000 
HPRT1 Rabbit IgG ab109021, Abcam 1
o 
WB 1:5000 
FOXO1  Rabbit IgG 
#2880, Cell Signaling 
Technology 
1
o 
WB 1:1000 
FOXO3a Rabbit IgG 
#2497, Cell Signaling 
Technology 
1
o 
WB 1:1000 
14-3-3ε Rabbit polyclonal 
#9635, Cell Signaling 
Technology 
1
o 
WB 1:1000  
Rabbit IgG Goat   
#7074, Cell Signaling 
Technology 
2
o 
WB 1:10000 
 
Table 2-5. Antibodies used for chromatin immunoprecipitation (ChIP). 
Target protein Source Isotype Supplier Working dilution 
ERG Rabbit IgG ab92513, Abcam 2 µg/IP 
Rabbit IgG Rabbit  ab172730, Abcam 2 µg/IP 
 
Table 2-6. Antibodies used for RNA immunoprecipitation (RIP). 
Target Source Isotype Supplier Working dilution 
14-3-3ε Rabbit polyclonal 
#9635, Cell Signaling 
Technology 
3 µg/IP  
14-3-3ζ Rabbit IgG 
#7413, Cell Signaling 
Technology 
3 µg/IP  
Rabbit IgG Rabbit  
#2729, Cell Signaling 
Technology 
3 µg/IP 
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Table 2-7. Sequences of short interfering RNAs (siRNAs). 
Target gene Designation Target sequence 
Working 
concentration 
Supplier 
LINC00920 
siRNA-Q2 CAGGGCTTGGGAGATAAGACA 
10 nM (PC-3) 
35 nM (VCaP) 
Qiagen 
siRNA-Q2 CTGGCCATTCCTTAAGCTGAA 
10 nM (PC-3) 
35 nM (VCaP) 
Qiagen 
siRNA-D1 AGTAAGAACTATAAGGCTA 35 nM (PC-3) Dharmacon 
siRNA-D3 CCACAGAGTTGAATGAATT 35 nM (PC-3) Dharmacon 
siRNA-D4 GGAAAGGCCTATAGACACA 35 nM (PC-3) Dharmacon 
ERG 
siERG-7 CAGATCCTACGCTATGGAGTA 50 nM (VCaP) Qiagen 
siERG-8 CTCCACGGTTAATGCATGCTA 50 nM (VCaP) Qiagen 
ETV4 
siETV4-1 ATGGGCTATGGCTATGAGAAA 10 nM (PC-3) Qiagen 
siETV4-8 CCGCTCGCTCCGATACTATTA 10 nM (PC-3) Qiagen 
Scrambled 
control 
NTC proprietary as above Qiagen 
 
Table 2-8. Primer oligonucleotides used for full-length lncRNA and promoter 
amplification. 
Target gene Product 
Forward sequence 
(5’→3’) 
Reverse sequence 
(5’→3’) 
Supplier 
LINC00920 
Full-length 
cDNA 
AATCTTCACAGGGAAG
GAAGCAACAAAA 
TAGAATTTACATTTTAA
TAATTCTGAGACT 
Sigma-Aldrich 
LINC00844 
Full-length 
cDNA 
GTAGAGACAAAGGAAA
CACAGAGACATA 
TAGACAGACAATTCAA
GCAATTTATTGT 
Sigma-Aldrich 
LINC01082 
Full-length 
cDNA 
AAATTGGTCCCAGTTTT
CACCCTGC 
TTTTCTGTTTGAGACAT
ATTAAACAAGCT 
Sigma-Aldrich 
LINC00920 
Full-length 
promoter 
AGTAGATATCCATCTTC
AGGTTATGA 
TTCCCTGTGAAGATTCA
CTTCCTGCC 
Sigma-Aldrich 
 
Table 2-9. Primer oligonucleotides used for quantitative PCR (qPCR). 
Target Application* 
Forward sequence 
(5’→3’) 
Reverse sequence 
(5’→3’) 
Supplier 
RP11-867G23.3 UPL#42 
GGAAGAGCGACAC
TCACGAT 
GGACTTCAAGATCCG
AACCA 
Sigma-Aldrich 
LINC00920 UPL#19 
CCTGCCACACTCAA
GTGGA 
CCCGTGTGATGGAAG
AACTC 
Sigma-Aldrich 
RP11-3P17.5 UPL#51 
CACTGCCTTCTTGG
CCTTTA 
GGACCCTTTTCACAAC
ATGG 
Sigma-Aldrich 
RP11-395L14.4 UPL#41 
GCGTTGGGAACAA
TATGGAA 
ATGGGAACTGCGTGA
ATACC 
Sigma-Aldrich 
SNHG18 UPL#6 
CACATCCCTAAGCT
GCCATC 
CAGATACCCGGCTTTC
CTTT 
Sigma-Aldrich 
LINC00844 UPL#88 
GGTTTGGCTGGACT
GTGAGT 
CTTTCTGATTTCAATG
TTCTCTGC 
Sigma-Aldrich 
LINC01082 UPL#57 
CCACCCTGCAAGT
GAGAAG 
GGTTGTTTTTCTTCGG
TGCT 
Sigma-Aldrich 
NEAT1 UPL#42 
AGTGAATGTGCAC
CCTTGG 
AACAAACCACGGTCC
ATGA 
Sigma-Aldrich 
MALAT1 UPL#71 
GACCCTTCACCCCT
CACC 
TTATGGATCATGCCCA
CAAG 
Sigma-Aldrich 
HPRT1 UPL#73 
TGACCTTGATTTAT
TTTGCATACC 
CGAGCAAGACGTTCA
GTCCT 
Sigma-Aldrich 
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GAPDH UPL#60 
AGCCACATCGCTC
AGACAC 
GCCCAATACGACCAA
ATCC 
Sigma-Aldrich 
ERG UPL#64 
GGTTAATGCATGCT
AGAAACACA 
AGATGGTTGAGCAGC
TTTCG 
Sigma-Aldrich 
ETV4 UPL#83 
TTATGAGAAAGGC
ATCATGCAG 
CGGGCTCACACACAA
ACTT 
Sigma-Aldrich 
BCL2L11 UPL#86 
ACGGCCTATTCTCA
GAGGATTAT 
AAACTAAGGCAGCTTT
TTAAGTTAGC 
Sigma-Aldrich 
PMAIP1 UPL#28 
ACAGCAACAACAA
CAATGCAC 
CCACGAGGAACAAGT
GCAA 
Sigma-Aldrich 
GADD45A UPL#70 
GCCAAGCTGCTCA
ACGTC 
AGCCACATCTCTGTCG
TCGT 
Sigma-Aldrich 
FOXO3 UPL#22 
CCAGCCTAACCAG
GGAAGTT 
AGCCCATGTTGCTGAC
AGA 
Sigma-Aldrich 
FOXO3 UPL#62 
TCTGAATGATGGG
CTGACTG 
CTAGAGCTCCGCTGCA
TGA 
Sigma-Aldrich 
LINC00920 SYBR 
AGGACATCTGAAG
CTAAACATGGATC 
AATTCATTCAACTCTG
TGGTCTTGGAA 
Sigma-Aldrich 
LINC00844 SYBR 
TGGCAGAATTGGG
ATCTGACT 
AACTGGACATTGCAA
ACACTTT 
Sigma-Aldrich 
Non-genic chr 12 ChIP, ChIRP 
CTGTCCCTGGTCAA
GAGTGACTTCCCT 
ACAGAGTCAAAAACT
GCAAGGCTGC 
Sigma-Aldrich 
LINC00290#1 ChIP 
TCACAGGGAAGGA
AGCAACA 
GCCCAATGCCCTGTGT
CTAT 
Sigma-Aldrich 
LINC00290#2 ChIP 
GGGGATGTTTAAT
GTTGTTACGC 
TTCACTTCCTGCCCAG
AGTC 
Sigma-Aldrich 
LINC00290#3 ChIP 
TGTTTAATGTTGTT
ACGCAGGAA 
AGATTCACTTCCTGCC
CAGA 
Sigma-Aldrich 
HEXIM1 ChIRP 
TTTATTGGGGTGCT
CCGCTT 
GCAATCTGGGGAGCT
CAAGT 
Sigma-Aldrich 
PS2 ChIRP 
AGTGAGAGATGGC
CGGAAAA 
TCATGAGCTCCTTCCC
TTCC 
Sigma-Aldrich 
PNN ChIRP 
CGTGGATCGGAAG
AGAAGGG 
CTGTCGGACCGGGAA
TTCTT 
Sigma-Aldrich 
RNF40 ChIRP 
CCGCACATGGTTA
GGAGGTT 
TCCCGATCTGTGCATT
CGAG 
Sigma-Aldrich 
LINC00920#1 RIP 
TCACAGGGAAGGA
AGCAACA 
GCCCAATGCCCTGTGT
CTAT 
Sigma-Aldrich 
LINC00920#2 RIP 
GAGCACTACATAA
AGCAGCCA 
CCCCGGATGACTTTCA
CTCT 
Sigma-Aldrich 
LINC00920#3 RIP 
GCAGACACAGCAC
TAAGAACT 
TCTTATCTCCCAAGCC
CTGC 
Sigma-Aldrich 
LINC00920#4 RIP 
AGGACATCTGAAG
CTAAACATGGATC 
AATTCATTCAACTCTG
TGGTCTTGGAA 
Sigma-Aldrich 
LINC00920#5 RIP 
AAAGCCTGCGAGA
GAGAGAG 
AGAAAAGGTGACCAA
GGTGAC 
Sigma-Aldrich 
LINC00920#6 RIP 
ACTGGCTGGAGGA
GTAAGAAC 
CAATCAACCCTTACCT
TCCAGT 
Sigma-Aldrich 
LINC00920#7 RIP 
ACTGCAACCATTTT
CTAACTCTTAA 
CAAGTAAGCTACATTA
TGTTCCTGT 
Sigma-Aldrich 
LINC00920#8 RIP 
TTTATCTGCCTTGT
CGATACTCT 
AGAGCCAGTGACAAA
GGAAGA 
Sigma-Aldrich 
LINC00920#9 RIP 
TGTCACTGGCTCTG
TAAATTTGA 
TCTTGCAAAAGACAA
AGGGTTT 
Sigma-Aldrich 
LINC00920#10 RIP 
TGGATCAAGAGAG
ACAAAGTGT 
TGTAGTTTTCAGCATA
CAGGTCC 
Sigma-Aldrich 
SNORA55 RIP 
GTGGGGACAGATG
GTGCTAC 
CCCCAAGACAAATGG
AAAAC 
Sigma-Aldrich 
*UPL: Universal Probe Library assay; SYBR: SYBR green assay; ChIP: Chromatin immunoprecipitation; 
ChIRP: Chromatin Isolation by RNA Purification; RIP: RNA immunoprecipitation. 
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Table 2-10. Primer oligonucleotides used for site-directed mutagenesis of the LINC00920 
promoter. 
Target region Application* 
Forward sequence 
(5’→3’) 
Reverse sequence 
(5’→3’) 
Supplier 
ETS domain 1 SDM 
AGTAGATATCCATC
TTCAGGTTATGA 
TTCCCTGTGAAGATTCA
CTTGGTGCCCAGAGTC 
Sigma-Aldrich 
ETS domain 2 
SDM 
OE-PCR#1 
AGTAGATATCCATC
TTCAGGTTATGA 
CAGCACAGCTTGGTGCG
TAACAACA 
Sigma-Aldrich 
ETS domain 2 
SDM 
OE-PCR#2 
TGTTGTTACGCACC
AAGCTGTGCTG 
TTCCCTGTGAAGATTCA
CTTCCTGCC 
Sigma-Aldrich 
ETS domain 2 
SDM 
OE-PCR#3 
AGTAGATATCCATC
TTCAGGTTATGA 
TTCCCTGTGAAGATTCA
CTTCCTGCC 
Sigma-Aldrich 
*SDM: Site-directed mutagenesis; OE: overlap extension. Mutagenic bases are underlined. 
 
Table 2-11. Primer oligonucleotides used for rapid amplification of cDNA ends (RACE). 
Primer Application 
Forward sequence 
(5’→3’) 
Reverse sequence 
(5’→3’) 
Supplier 
GeneRacer™ 5′ 
Primer 
5’ RACE 
CGACTGGAGCACGA
GGACACTGA 
N/A 
Invitrogen
TM
 
Thermo Fisher 
Scientific 
GeneRacer™ 5′ 
Nested Primer 
5’ RACE 
GGACACTGACATGG
ACTGAAGGAGTA 
N/A 
Invitrogen
TM
 
Thermo Fisher 
Scientific 
GeneRacer™ 3′ 
Primer 
3’ RACE N/A 
GCTGTCAACGATAC
GCTACGTAACG 
Invitrogen
TM
 
Thermo Fisher 
Scientific 
GeneRacer™ 3′ 
Nested Primer 
3’ RACE N/A 
CGCTACGTAACGGC
ATGACAGTG 
Invitrogen
TM
 
Thermo Fisher 
Scientific 
RP11-867G23.3 5’ GSP RACE N/A 
GCCTGGGCAACAAG
AGCAAAACTCA 
Sigma-Aldrich 
     
RP11-867G23.3 
nested 
5’ GSP RACE N/A 
ATTGGGGCTTGGTGG
TTCGGAGAC 
Sigma-Aldrich 
LINC00920 5’ GSP RACE N/A 
CCCGTGTGATGGAA
GAACTCTAAGATG 
Sigma-Aldrich 
LINC00920 
nested 
5’ GSP RACE N/A 
GTTTTGCTTCAGGGC
TGTTGTCACC 
Sigma-Aldrich 
RP11-3P17.5 5’ GSP RACE N/A 
TTTTCACAACATGGC
GCCGAAAG 
Sigma-Aldrich 
RP11-3P17.5 
nested 
5’ GSP RACE N/A 
GGCATATGTTCGACT
GGCTCCTGAT 
Sigma-Aldrich 
RP11-395L14.4 5’ GSP RACE N/A 
TCTTTATGTTGAAGA
GAATGGCTAAAAA 
Sigma-Aldrich 
RP11-395L14.4 
nested 
5’ GSP RACE N/A 
ATGGGAACTGCGTG
AATACCATTCT 
Sigma-Aldrich 
SNHG18 5’ GSP RACE N/A 
GTTAGGTGAGGTCC
AGGTCATGCTG 
Sigma-Aldrich 
SNHG18 
nested 
5’ GSP RACE N/A 
ACCACAGATACCCG
GCTTTCCTTTG 
Sigma-Aldrich 
LINC00844 5’ GSP RACE N/A 
GTGAGTCAGATCCC
AATTCTGCC 
Sigma-Aldrich 
LINC00844 
nested 
5’ GSP RACE N/A 
AGCAAGGAGGTTTC
TTGCATGGCTAA 
Sigma-Aldrich 
LINC01082 5’ GSP RACE N/A 
CTGGTTGTTTTTCTT
CGGTGCTG 
Sigma-Aldrich 
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LINC01082 
nested 
5’ GSP RACE N/A 
ACATTCCTCGCATTC
CTGACGGTTG 
Sigma-Aldrich 
RP11-867G23.3 3’ GSP RACE 
TCCGAACCACCAAG
CCCCAATTCCCAGC 
N/A Sigma-Aldrich 
RP11-867G23.3 
nested 
3’ GSP RACE 
GCTTGGCAGAGAAG
GCCCCAGAAGT 
N/A Sigma-Aldrich 
LINC00920 3’ GSP RACE 
GGCCTCCCCAACATG
CTCACCTGCT 
N/A Sigma-Aldrich 
LINC00920 
nested 
3’ GSP RACE 
TGCCCAACTCATCTG
GATCTTCCTTTG 
N/A Sigma-Aldrich 
RP11-3P17.5 3’ GSP RACE 
TTGGCAACATCCAA
AGCATCGTAAT 
N/A Sigma-Aldrich 
RP11-3P17.5 
nested 
3’ GSP RACE 
GGGTGACGTGCGGA
TCTTCTTCTTT 
N/A Sigma-Aldrich 
RP11-395L14.4 3’ GSP RACE 
GCCGGGCTGAAGAA
AAGAAGAATGG 
N/A Sigma-Aldrich 
RP11-395L14.4 
nested 
3’ GSP RACE 
GGGGTGAGAGGAAT
GGGGAAATGTT 
N/A Sigma-Aldrich 
SNHG18 3’ GSP RACE 
TGTGGGCCATGAGT
GACCTTCAAAG 
N/A Sigma-Aldrich 
SNHG18 
nested 
3’ GSP RACE 
CCACCTCACAGCCA
AGTTCAAGGAA 
N/A Sigma-Aldrich 
LINC00844 3’ GSP RACE 
CCCAATTCTGCCATA
CTGTTTCTGGTTC 
N/A Sigma-Aldrich 
LINC00844 
nested 
3’ GSP RACE 
GGCAGAATTGGGAT
CTGACTCAC 
N/A Sigma-Aldrich 
LINC01082 3’ GSP RACE 
TCTATCGAGGCACAC
AGACAGACCA 
N/A Sigma-Aldrich 
LINC01082 
nested 
3’ GSP RACE 
CAGCCTGAAATGAA
GCCGGGATCAA 
N/A Sigma-Aldrich 
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Table 2-12. Antisense biotinylated oligonucleotides* used for chromatin isolation by RNA 
purification (ChIRP). 
No. lacZ pool (5’→3’) MALAT1 pool (5’→3’) LINC00920 pool (5’→3’) 
1 TGAATCCGTAATCATGGTCA GCTTAAGAGGGCAGGAGAGG TGTTGCTTCCTTCCCTGTGA 
2 CGCTATTACGCCAGCTGGCG GAGCTTCAGACCTTCTGAAC AGGCCTTTCCCTGCTCAGCC 
3 CTCAGGAAGATCGCACTCCA AGTGGCCCACTCTGATCTGC TCTAGGGAGGGCTGTTCTAG 
4 CATCGTAACCGTGCATCTGC TCAGGGCTTTACTTTCCATT CACTCTTCCCTATGCTTTGC 
5 ATAATTCGCGTCTGGCCTTC ATTCGATCACCTTCCGCCGC TGTTGTCACCAAGTTCTTAG 
6 GACGGCAAACGACTGTCCTG CATGCTACTCTTCTAAGTCT GTCTTATCTCCCAAGCCCTG 
7 TCCAGATAACTGCCGTCACT TCACCTTCGGTTTAATCTCT CACTTTGATTGTAGCTTTCA 
8 ATCATCATTAAAGCGAGTGG TTCCCGTACTTCTGTCTTCC TGGAAGTGGGTCCTTCTCTA 
9 GATAATTTCACCGCCGAAAG TCTACGTAAACACCCTCATC GCCCTCAGTTCAACGGGCTG 
10 AGTTTCGGGTTTTCGACGTT AATGCTAGTCCTCAGGATTT TGGACTCTCTCTCTCGCAGG 
11 CGACATCGCAGGCTTCTGCT TGTGGTTGCCAAGCCAAGCC CAGGATGTCACTTCAGTGAT 
12 TGACGGTTAACGCCTCGAAT GATTCATGAGTATAAGCCTG CTTGGGACTCATTTATAATG 
13 GTGTACCACAGCGGATGGTT GCCTCAGTTACACATCCAAA CTCCAGCCCTGTGTAATCCC 
14 GTTCGCTCATCGCCGGTAGC CTGTTAAGACCATCCCAAAA TGAGAATTCCCGTGTGATGG 
15 GATTAGCGCCGTGGCCTGAT TTTGGCCTACTCAAGCTCTT AGGCCTTCAGCTTAAGGAAT 
16 GCAAATAATATCGGTGGCCG TGCCCAAATTAATGCACTGG GACAAACCCTGGGTTTATTA 
17 TGGGCGTATTCGCAAAGGAT GAAATCCCTTCAGGATCATT TATAGTTCTTACTCCTCCAG 
18 CAGACGAAGCCGCCCTGTAA ATCATACTGCCAGGCTGGTT TCAATCAACCCTTACCTTCC 
19 TCGTTCGGCGTATCGCCAAA GACATTGCCTCTTCATTGTA CCTGTATATTTATGTTGGGA 
20 TTTGCCCGGATAAACGGAAC GAACTCCACAGCTCTTAAAA GAGCCTGGAATATTTGTATA 
21 GGAGCTCGTTATCGCTATGA TCTGATTCTAACAGCACATC ATGAGAAGCCTTTGGGAAAA 
22 CATGCGGTCGCGTTCGGTTG CCATGTGCCTGGAATTATTA CTTGAAAGAGGGAATGATTT 
23 TGCCAACGCTTATTACCCAG AAGGATGAAATGCCTCTGCA TATCGACAAGGCAGATAAAA 
24 AGCGGTGCACGGGTGAACTG TCTAATAGCAGCGGGATCAG GAGTTGGGCAAATTAACAAA 
25 GTCAATGCGGGTCGCTTCAC AAGACTGTTGCTTGTTTGGA ACAGAGCCAGTGACAAAGGA 
26 CACGCGTGAGCGGTCGTAAT ACTAGTGGTTCCCAATCCCC CAAAGGGTTTCATAAAGTTG 
27 GGTAATCGCCATTTGACCAC CTTAGGATAATAGCGCTTTG CACTTACTGTAGAATGCTTA 
28 TTGCGGCCCTAATCCGAGCC GGCGATGTGGCAGAGAAGTT TCTCTTGATCCATCACTCAT 
29 TTCGCTCGGGAAGACGTACG GTTCCCACCCAGCATTACAG GTTAGATGGTAACCAAGAAT 
30 TGTTGACTGTAGCGGCTGAT GTCCTGGAAACCAGGAGTGC TTCTGAGACTTCCAATTCAT 
*Manufactured by siTOOLs Biotech GmbH 
Table 2-13. Index primers used for ChIRP-seq DNA library preparation. 
ChIRP-seq 
library 
Index 
primer 
Index primer sequence (5’→3’) 
Index primer 
sequence read 
Supplier 
P28 lacZ #5 
CAAGCAGAAGACGGCATACGAGATC
ACTGTGTGACTGGAGTTCAGACGTGT
GCTCTTCCGATC-s*-T 
ACAGTG 
New England 
Biolabs 
P28 
LINC00920 
#6 
CAAGCAGAAGACGGCATACGAGATA
TTGGCGTGACTGGAGTTCAGACGTGT
GCTCTTCCGATC-s*-T 
GCCAAT 
New England 
Biolabs 
P29 lacZ #10 
CAAGCAGAAGACGGCATACGAGATA
AGCTAGTGACTGGAGTTCAGACGTGT
GCTCTTCCGATC-s*-T 
TAGCTT 
New England 
Biolabs 
P29 
LINC00920 
#12 
CAAGCAGAAGACGGCATACGAGATT
ACAAGGTGACTGGAGTTCAGACGTGT
GCTCTTCCGATC-s*-T 
CTTGTA 
New England 
Biolabs 
P30 lacZ #2 
CAAGCAGAAGACGGCATACGAGATA
CATCGGTGACTGGAGTTCAGACGTGT
GCTCTTCCGATC-s*-T 
CGATGT 
New England 
Biolabs 
P30 
LINC00920 
#4 
CAAGCAGAAGACGGCATACGAGATT
GGTCAGTGACTGGAGTTCAGACGTGT
GCTCTTCCGATC-s*-T 
TGACCA 
New England 
Biolabs 
*Phosphorothioate bond 
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Table 2-14. Enzymes. 
Enzyme/Master Mix Supplier 
ABsolute Blue qPCR Master Mix (2X) Thermo Scientific
TM 
Thermo Fisher Scientific 
ABsolute qPCR Master Mix (2X) Thermo Scientific
TM 
Thermo Fisher Scientific 
Benzonase nuclease Merck Millipore 
CutSmart® Buffer (10x) New England Biolabs 
DNase I (RNase-Free) Qiagen 
DNase I (RNase-free)  New England Biolabs 
DreamTaq Green PCR Master Mix (2X) Thermo Scientific
TM 
Thermo Fisher Scientific 
NheI-HF New England Biolabs 
NotI-HF New England Biolabs 
Proteinase K Invitrogen
TM
 Thermo Fisher Scientific 
RNase A Qiagen 
RNase H New England Biolabs 
SpeI-HF New England Biolabs 
T4 DNA Ligase New England Biolabs 
T7 RNA Polymerase  New England Biolabs 
Taq DNA Polymerase New England Biolabs 
XbaI New England Biolabs 
XhoI New England Biolabs 
 
Table 2-15. Reagents, chemicals, and materials. 
Reagent/Material Supplier 
1,4-Dithiothreitol (DTT) Carl Roth GmbH 
4-20% Mini-PROTEAN® TGX
TM 
precast protein gel Bio-Rad 
Absolute ethanol Fisher Scientific GmbH 
Acetone Fisher Scientific GmbH 
Agar Carl Roth GmbH 
Agarose Fisher Scientific GmbH 
Agencourt AMPure XP beads  Beckman Coulter 
Alkaline Phosphatase (Calf Intestinal) New England Biolabs 
Ampicillin AppliChem 
Biotin RNA labeling mix  Roche 
Bovine Serum Albumin (BSA) Sigma-Aldrich 
Cell Proliferation Reagent WST-1 Roche 
ChIP-grade protein G magnetic beads Cell Signaling Technology 
cOmplete, Mini protein inhibitor cocktail Roche 
cOmplete, Mini protein inhibitor cocktail (EDTA-free) Roche 
Crystal violet solution (1% aqueous) Sigma-Aldrich 
Dimethyl pimelimidate (DMP) 
Thermo Scientific
TM
 Thermo Fisher 
Scientific 
Dimethyl sulfoxide (DMSO) AppliChem 
DNA Gel Loading Dye (6X) 
Thermo Scientific
TM
 Thermo Fisher 
Scientific 
Dynabeads
TM
 MyOne
TM
 Streptavidin C1  Invitrogen
TM 
Thermo Fisher Scientific 
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Dynabeads
TM
 Protein G magnetic beads  Invitrogen
TM 
Thermo Fisher Scientific 
Dynabeads™ M-270 Streptavidin beads Invitrogen
TM 
Thermo Fisher Scientific 
E. coli poly(A) polymerase  New England Biolabs 
EDTA (Disodium salt) Gerbu Biotechnik GmbH 
Ethanolamine  Merck Millipore 
Ethidium bromide (0.5% solution) Carl Roth GmbH 
Formaldehyde (16% w/v), Methanol-free 
Thermo Scientific
TM
 Thermo Fisher 
Scientific 
Formaldehyde (37% w/w) Fisher Scientific GmbH 
Formamide Carl Roth GmbH 
GeneRuler DNA 1 kb Ladder  
Thermo Scientific
TM
 Thermo Fisher 
Scientific 
GeneRuler DNA 100 bp Plus Ladder  
Thermo Scientific
TM
 Thermo Fisher 
Scientific 
GeneRuler DNA Ladder Mix 
Thermo Scientific
TM
 Thermo Fisher 
Scientific 
Glutaraldehyde (25%) Sigma-Aldrich 
Glycerol (87%) VWR 
Glycine Gerbu Biotechnik GmbH 
GlycoBlue coprecipitant Invitrogen
TM 
Thermo Fisher Scientific 
HEPES Sigma-Aldrich 
Human Prostate Total RNA (Lot # 0903001) Invitrogen
TM 
Thermo Fisher Scientific 
Ipatasertib (GDC-0068) Target Molecule 
KCl Carl Roth GmbH 
LiCl Sigma-Aldrich 
Lipofectamine
TM
 2000 Invitrogen
TM 
Thermo Fisher Scientific 
Lipofectamine
TM
 RNAiMAX Invitrogen
TM 
Thermo Fisher Scientific 
Methanol Fisher Scientific GmbH 
MgCl2∙6H2O Sigma-Aldrich 
MOPS  Gerbu Biotechnik GmbH 
Na3VO4 Sigma-Aldrich 
NaCl Fisher Scientific GmbH 
NaF Carl Roth GmbH 
NaHCO3 Fisher Scientific GmbH 
NEBNext® Multiplex Oligos for Illumina® (Index Primer 
Set 1) 
New England Biolabs 
N-lauroylsarcosine sodium salt (20% solution) Sigma-Aldrich 
NP-40 (Igepal® CA-630) Sigma-Aldrich 
Nuclease-Free Water Invitrogen
TM 
Thermo Fisher Scientific 
One Shot
TM
 TOP10 chemically competent E. coli cells  Invitrogen
TM 
Thermo Fisher Scientific 
PageRuler Prestained Protein Ladder 
Thermo Scientific
TM
 Thermo Fisher 
Scientific 
Phenol/chloroform/isoamyl alcohol 125:24:1 mixture pH 
4.3 
Fisher Scientific GmbH 
Phenylmethane sulfonyl fluoride (PMSF) Cell Signaling Technology 
PhosSTOP phosphatase inhibitor cocktail Roche 
Phusion® High-Fidelity DNA Polymerase New England Biolabs 
Premix Ex Taq
TM
 master mix  Takara Bio 
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Recombinant human 14-3-3ε protein  Abcam 
RNAse-away Carl Roth GmbH 
Roti®-Load 1 protein loading buffer  Carl Roth GmbH 
S.O.C medium  Invitrogen
TM 
Thermo Fisher Scientific 
Saline-sodium citrate buffer (SSC buffer, 20X) Sigma-Aldrich 
SC79  Sigma-Aldrich 
Sodium acetate AppliChem 
Sodium deoxycholate Sigma-Aldrich 
Sodium dodecyl sulfate Fisher Scientific GmbH 
ssRNA ladder New England Biolabs 
Sucrose Sigma-Aldrich 
Superase In
TM
 RNase inhibitor  Invitrogen
TM 
Thermo Fisher Scientific 
SuperSignal™ West Dura Extended Duration Substrate 
Thermo Scientific
TM
 Thermo Fisher 
Scientific 
SYBR® Gold nucleic acid gel stain Invitrogen
TM 
Thermo Fisher Scientific 
Trichloroacetic acid (TCA) Sigma-Aldrich 
Triethanolamine  Sigma-Aldrich 
Tris base Sigma-Aldrich 
Tris(2-carboxyethyl)phosphine  
(TCEP, 0.5 M) 
Sigma-Aldrich 
Triton X-100 Sigma-Aldrich 
Tryptone Carl Roth GmbH 
Tween® 20 Sigma-Aldrich 
UltraPure Phenol:Chloroform:Isoamyl Alcohol (25:24:1, 
v/v)  
Invitrogen
TM 
Thermo Fisher Scientific 
UltraPure TAE Buffer (10X) Invitrogen
TM 
Thermo Fisher Scientific 
Universal Probe Library (UPL) Roche 
Yeast extract Gerbu Biotechnik GmbH 
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Table 2-16. Kits. 
Kit Supplier 
Dual-Glo® Luciferase Assay Kit Promega 
GeneRacer® Kit with SuperScript® III RT and Zero Blunt® 
TOPO® PCR Cloning Kit for Sequencing 
Invitrogen
TM
 Thermo Fisher Scientific 
High Pure PCR Template Preparation Kit Roche 
High Sensitivity DNA Kit  Agilent Technologies 
miRNeasy® Mini Kit  Qiagen 
NEBNext Ultra II DNA Library Preparation Kit for 
Illumina  
New England Biolabs 
BCA Protein Assay Kit  Pierce
TM 
Thermo Fisher Scientific 
Silver Stain Kit Pierce
TM 
Thermo Fisher Scientific 
QIAprep Spin Maxiprep Kit  Qiagen 
QIAprep Spin Miniprep Kit  Qiagen 
QIAquick Gel Extraction Kit Qiagen 
Qubit® dsDNA HS assay Kit Invitrogen
TM
 Thermo Fisher Scientific 
RevertAid H Minus First Strand cDNA Synthesis Kit  
Thermo Scientific
TM
 Thermo Fisher 
Scientific 
RNA 6000 Nano Kit  Agilent Technologies 
RNeasy® Mini Kit  Qiagen 
 
2.3. General laboratory materials and equipment. 
Table 2-17. Consumables. 
Consumable Supplier 
Bioruptor® microtubes (1.5 mL) Diagenode 
Black, flat- and clear-bottomed 96-well plate Perkin-Elmer 
Cell culture dish (150 mm) TPP 
Cell culture flask (175 cm²) TPP 
Cell culture flask (25 cm²) TPP 
Cell culture flask (75 cm²) TPP 
Countess Cell Counting Chamber Slides Invitrogen
TM 
Thermo Fisher Scientific 
Cryovials (1.8-mL) Neolab 
DNA LoBind tubes (1.5 mL) Eppendorf 
Falcon
TM
 round bottom tubes (14-mL) Fisher Scientific GmbH 
Falcon
TM
 cell culture dish (12-well) Fisher Scientific GmbH 
Falcon
TM
 cell culture dish (24-well) Fisher Scientific GmbH 
Falcon
TM
 cell culture dish (6-well) Fisher Scientific GmbH 
Falcon
TM
 cell scrapers Fisher Scientific GmbH 
Falcon
TM
 conical tubes (50-mL, 15-mL) Fisher Scientific GmbH 
Filter tips (1250-µL, 200-µL, 20-µL, 10-µL) Neptune Scientific 
LightCycler® 480 qPCR plate (384-well) Roche 
LightCycler® 480 qPCR plate sealing foil Roche 
Microflex™ XCEED™ Powder-Free Nitrile Examination 
Gloves 
Fisher Scientific 
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PCR tubes (200 µL) Starlab 
Safe-Lock tubes (5-mL, 2-mL, 1.5-mL, 0.5-mL) Eppendorf 
Serological pipettes (50-mL, 25-mL, 10-mL, 5-mL, 2-mL) Corning 
ThinCert
TM 
well insert (8-µm) Greiner Bio-One 
 
Table 2-18. Laboratory equipment. 
Equipment  Supplier 
2100 Bioanalyzer  Agilent Technologies 
Axiovert 40 CFL inverted microscope Carl Zeiss 
Bacterial incubator Infors HAT 
Bioruptor® Pico sonication device  Diagenode 
ChemiDoc
TM
 XRS+  Bio-Rad 
Countess II FL Automated Cell Counter Invitrogen
TM 
Thermo Fisher Scientific 
Electronic micropipette (200 µL) Sartorius  
HERA Safe cell culture hood Thermo Scientific 
Heracell
TM
 VIOS 160i CO2 incubator Thermo Scientific 
Heraeus
TM
 Fresco 21 refrigerated microcentrifuge (2-/1.5-
mL) 
Thermo Scientific 
Heraeus
TM
 Megafuge
TM
 16 cell culture centrifuge Thermo Scientific 
Hybaid Maxi 14 hybridization oven Thermo Scientific 
Infinite M200 microplate reader TECAN 
LightCycler® 480 II  Roche 
MagnaRack (1.5-mL) Life Technologies 
Magnetic stand (96-well) Ambion 
Micropipettes (1000-µL, 200-µL, 20-µL, 10-µL, 2-µL) Gilson 
Mini-PROTEAN®  Bio-Rad 
Mr. Frosty cryobox Nalgene 
NanoDrop 1000  Thermo Fisher 
Pipette controller (Pipetboy) Integra biosciences 
PTC-225 gradient thermal cycler  MJ Research 
QUANTUM UV transilluminator Vilber Lourmat 
Qubit® Fluorometer  Life Technologies 
Refrigerated centrifuge (50-/15-mL) Sigma 
Speed Vac DNA 120  vacuum concentrator Thermo Scientific 
ThermoMixer® Comfort heat block Eppendorf 
Trans-Blot Turbo  Bio-Rad 
Vortex Genie  Scientific Industries 
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2.4. Data analysis 
Table 2-19. Programs and softwares. 
Software Reference/Supplier 
Coding Potential Assessment Tool Version 2.0.0 [200] 
Coding Potential Calculator Version 2.0  [201] 
Genomic Regions Enrichment of Annotations Tool 
(GREAT) Version 3.0.0 
[202] 
GSEAPreranked Desktop Application Version 3.0 [203] 
i-control
TM
 Version 1.6 TECAN 
Image Lab
TM
 6.0 Bio-Rad 
ImageJ 1.52h [204] 
Ingenuity Pathway Analysis (IPA) Build 486617M Qiagen 
LightCycler® 480 Software Release 1.5.0 Roche 
OpenCFU Version 3.9.0 [205] 
Quantum Capt UV Imaging System Version 15.10 Vilber Lourmat 
Rstudio Version 1.0.136 [206] 
SnapGene® Viewer Version 3.3.4 GSL Biotech 
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3. Methods 
3.1. Cell culture 
3.1.1. Propagation and maintenance 
PC-3 cells were cultured in F-12K medium supplemented with 10% fetal bovine serum (FBS) at 37
o
C 
in a humidified incubator with 5% CO2. VCaP cells were cultured in Dulbecco Modified Eagle 
Medium (DMEM) with 10% FBS. RWPE-1 cells were cultured in Keratinocyte serum-free medium 
supplemented with 0.05 mg/mL bovine pituitary extract (BPE), and 5 ng/mL epidermal growth factor 
(EGF). DU-145 and parental LNCaP cells were cultured in RPMI 1640 with 10% FBS. Tet-inducible 
LNCaP #126 cell clones were cultured in RPMI 1640 supplemented with 10% tet-free FBS, and 80 
µg/mL Hygromycin B [97]. Cells were maintained until 70-80% confluency and then split into new 
culture flasks. Briefly, attached cells were washed with 1X phosphate-buffered saline (PBS) and 
chemically detached using 0.25% trypsin-EDTA. Trypsin inactivation was performed by adding 2X 
volume of complete medium to the cell suspension. Cells were centrifuged at 400 g, room temperature 
for 2 min and the pellet was resuspended in complete growth medium. The resulting single-cell 
suspension was seeded into new flasks at the desired density.  
Cells were routinely tested for mycoplasma contamination and were authenticated by single nucleotide 
polymorphisms (SNP)-profiling (Multiplexion GmbH).  
3.1.2. Cryopreservation 
Cells were trypsinized from culture flasks and washed twice with 1X PBS. For PC-3, VCaP, LNCaP, 
and DU-145, cells were resuspended in their respective complete growth media supplemented with 5% 
(v/v) cell culture-grade dimethyl sulfoxide (DMSO) at a concentration of 1 x 10
6
 cells/mL. For 
RWPE-1, cells were resuspended in complete growth medium supplemented with 10% (v/v) DMSO 
and 15% FBS. One million cells were aliquoted in cryovials and stored short-term in a freezing 
container at -80
o
C. Frozen cryovials were subsequently transferred into liquid nitrogen for long-term 
storage. 
3.1.3. Gene knockdown via short interfering RNAs (siRNAs) 
Cells were seeded to reach at least 60% confluency 24 h prior to transfection. On the day of 
transfection, maintenance medium was refreshed. For a 6-well plate format, Lipofectamine
®
 
RNAiMAX:siRNA dilutions were prepared as follows. First, 8 µL RNAiMAX was diluted with 66.6 
µL Opti-MEM™ I Reduced Serum Media. For 10 nM siRNA transfections, 2.9 µL of 10 µM siRNA 
was similarly diluted with 66.6 µL Opti-MEM™. The RNAiMAX and siRNA dilutions were 
combined and mixed throroughly and incubated for 5 min at room temperature. One hundred twenty 
microliters of RNAiMAX:siRNA dilution was then added to the cells of one well. From these values, 
siRNA transfection reactions were scaled up or down depending on the surface area of the culture 
vessel and the siRNA concentration determined for optimal knockdown efficiency. Unless otherwise 
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stated, cells were harvested for RNA and/or protein isolation 48 h post transfection, or were used for 
subsequent functional assays. Table 2-7 lists the siRNA sequences used in this study, and their 
optimal working concentrations. 
3.1.4. Plasmid transfection in cell lines 
Cells were seeded to reach at least 80% confluency 24 h prior to transfection. On the day of 
transfection, maintenance medium was refreshed. For a 6-well plate format, Lipofectamine
TM
 
2000:plasmid DNA dilutions were prepared as follows. For each well, 5.76 µL Lipofectamine
 TM
 2000 
was diluted in Opti-MEM™ to a final volume of 144 µL. Next, 720 ng plasmid was similarly diluted 
with Opti-MEM™ to a final volume of 144 µL. Both dilutions were mixed and incubated at room 
temperature for 5 min. Two hundred microliters of Lipofectamine
TM
 2000:DNA dilution was added to 
the cells. After 6 h, cell medium was refreshed and cells were maintained for 48-72 h. 
Lipofectamine
TM
 2000 and DNA amounts were scaled accordingly depending on the culture format. 
For luciferase assays, cells in each 96-well were transfected in the same manner as described except 
with 0.35 µL Lipofectamine
TM
 2000 and 100 ng total plasmid DNA, diluted to 50 µL with Opti-
MEM™ each. One hundred microliter mix was applied to each well and the cells were incubated for 
48 h before proceeding to doxycycline induction. 
3.1.5. Functional assays 
3.1.5.1. Cell proliferation 
Cells were trypsinized 24 h post transfection from the culture vessel, washed, and resuspended in 
complete medium at a concentration of 5 x 10
4
 cells/mL. One hundred microliters of cell suspension 
corresponding to 5000 cells were seeded per well into 3 96-well plates (corresponding to 48-, 72-, and 
96-h time points) in triplicate and incubated at 37
o
C in a humidified incubator with 5% CO2. To 
quantify cell proliferation, untreated, pre-counted cells were seeded in triplicate to generate a standard 
curve. Ten microliters of pre-warmed cell proliferation reagent WST-1 was added to all wells. Signals 
were developed for 1-3 h in the cell culture incubator, until a red to yellow color shift was observed. 
The absorbance value of each well at 440 nm was measured using a TECAN Infinite M200 reader 
with the i-control
TM
 (version 1.6) software. Cell counts per well were calculated from the generated 
standard curve. 
3.1.5.2. Colony formation 
Transfected cells were seeded into duplicate wells in a 6-well plate format at a density of 1.3 x 10
3
 
cells/3 mL of complete medium. The plates were maintained for 9 days at which point the cell 
colonies were stained with crystal violet. Briefly, cells were washed with ice-cold 1X PBS and fixed 
on ice with 100% methanol for 30 min. The cells were washed with 1X PBS and afterwards stained 
with 0.005% crystal violet at room temperature for 1 h. The staining solution was removed and the 
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cells were washed again. Cell colonies were air-dried and imaged using the ChemiDoc
TM
 XRS+ 
system with Image Lab
TM
 software. Colony quantification was performed using OpenCFU [205]. 
3.1.5.3. Cell migration 
Transfected cells were washed and resuspended in serum-free medium at a concentration of 5 x 10
5
 
cells/mL. Meanwhile, 700 µL of complete growth medium was added in wells of a 24-well plate. A 8-
µm ThinCert
TM  
for 24-well plates was then placed in each well to complete the migration assembly 
(Figure 3-1). Two hundred microliters of serum-free cell suspension, corresponding to 1 x 10
5
 cells, 
was seeded in duplicate migration assemblies. The plates were then incubated for 24 h. To quantify 
cell migration, cells at the bottom of the migration inserts were either stained with crystal violet or 
trypsinized for WST-1 analysis. To stain cells, the insert was emptied of medium and the bottom was 
submerged in 100% methanol for 30 min and washed 4 times in deionized water. The interior of the 
insert was cleaned with cotton swabs. Each insert bottom was then submerged in 0.05% crystal violet 
for 30 min and washed twice with deionized water. The inserts were air-dried overnight. Stained cells 
were manually counted using a light microscope in three fields of view per insert. Alternatively, 
migratory cells were quantified using a colorimetric method. Briefly, the media within the insert was 
aspirated and the insert was placed in a well containing 500 µL of 0.25% trypsin-EDTA. 
Trypsinization was performed at 37
o
C for 10 min. The insert was agitated to release the loosened cells 
from the bottom of the membrane. Trypsin was quenched by adding an equal volume of complete 
medium and the detached cells were collected by centrifugation at 400 g for 5 min. The cell pellet was 
resuspended in 100 µL complete medium and seeded into a 96-well plate. The WST-1 method 
described above was then performed to determine the cell number per well.  
 
Figure 3-1. Schematic of the culture well assembly for cell migration assay. 
 
3.1.6. Tet-induction of LNCaP #126 cells 
ERG overexpression was induced in LNCaP #126 clones by shifting the medium to RPMI 1640 
supplemented with 10% tet-free FBS (Clontech), and 50 ng/mL doxycycline as described [97]. Cells 
were harvested or further treated 48 h post induction. 
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3.1.7. Ipatasertib treatment of transfected PC-3 cells 
Forty-eight hours post siRNA transfection, cells were treated with ipatasertib (GDC-0068) by shifting 
the culture medium to that supplemented with 300 nM of inhibitor [207]. Cells were harvested after 24 
h for RNA isolation. 
3.2. General molecular biology techniques 
3.2.1. Genomic DNA isolation 
For cell line contamination and authentication tests, genomic DNA was isolated using High Pure PCR 
Template Preparation Kit according to the manufacturer’s protocol. Template DNA for LINC00920 
promoter amplification was isolated from PC-3 cells using the same procedure. 
3.2.2. RNA extraction and cDNA synthesis 
Unless otherwise specified, RNA from cell lines was isolated using RNeasy® Mini Kit following the 
manufacturer’s protocol including the optional DNase-I digestion step. Prior to RNA extraction, cells 
were washed twice with 1X PBS. RNA from each column was eluted in 30 µL nuclease-free water, 
quantified by NanoDrop 1000, and stored at -80
o
C until use. Complementary DNA was synthesized 
from 2000 ng RNA input using RevertAid H Minus First Strand cDNA Synthesis Kit. Briefly, 1 µL of 
100 µM random hexamer primer was added to 2000 ng RNA and resulting volume was filled up to 12 
µL with nuclease-free water. The reaction mixture was incubated at 65
o
C for 5 min and placed on ice 
for 1-2 min. Four microliters of 5X reaction buffer, 1µL of 20 U/µL RiboLock RNase inhibitor, 2 µL 
of 10 mM dNTP mix, and 1 µL of 200 U/µL RevertAid H Minus M-MuLV Reverse Transcriptase 
were added to the reaction mixture which was then incubated at 42
o
C for 1 h. The reaction was 
terminated by heating at 70
o
C for 5 min, and the synthesized cDNA was stored at -20
o
C until further 
use. 
3.2.3. Protein isolation and quantification 
Cells from one well of a 6-well plate were washed twice with 1 mL 1X PBS and resuspended in 60 µL 
1X RIPA buffer (150 mM NaCl, 1.0% NP-40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl 
sulfate [SDS], 50 mM Tris pH 8.0) supplemented with 1X cOmplete, Mini protein inhibitor, and 1X 
PhosSTOP phosphatase inhibitor cocktails. Cell lysis was facilitated by incubation on ice for 45 min. 
The resulting protein lysate was clarified by centrifugation at 12000 rpm, 4
o
C for 15 min. The 
supernatant was transferred to a clean tube and stored at -80
o
C until use. Protein quantification was 
performed using the microplate procedure of the Pierce
TM
 BCA Protein Assay Kit.  
3.2.4. SDS-polyacrylamide gel electrophoresis 
Prior to electrophoresis, 20 ng of protein was denatured at 95
o
C in 1X Roti®-Load 1 protein loading 
buffer for 5 min. The samples, together with PageRuler
TM
 prestained protein ladder, were loaded into 
4-20% Mini-PROTEAN® TGX
TM 
precast protein gels. Gel electrophoresis was performed through 1X 
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Laemmli running buffer (0.025 M Tris, 0.192 M glycine, 0.1% SDS) at 200V using the Mini-
PROTEAN® system.  
3.2.5. Western blotting 
Protein transfer onto polyvinylidene difluoride (PVDF) membrane was facilitated using the Trans-Blot 
Turbo system (Bio-Rad). Briefly, transfer stacks were saturated with 1X transfer buffer (5X Trans-
Blot® Turbo
TM
 transfer buffer: 100% ethanol: deionized water, 3:1:1) and the PVDF membrane was 
activated in 100% ethanol prior to assembly of the blotting sandwich. One transfer stack was placed 
on the bottom (+) cassette, followed by the PVDF membrane, the mini polyacrylamide gel, and 
another transfer stack. The top (-) cassette was secured over the assembly and protein transfer was 
conducted using the MIXED MW blotting program (1.5 V, 7 min). The blotted membrane was then 
blocked in 10 mL of blocking buffer (5% bovine serum albumin in 1X PBS-T) at room temperature 
for 1 h. The membrane was transferred into the primary antibody solution and incubated with rotation 
at 4
o
C overnight. Next day, the blot was washed for 5-, 10-, and 15- min, respectively, with the 
washing buffer (1X PBS-T) and incubated with the appropriate secondary antibody solution at room 
temperature for 1 h. The secondary antibody is conjugated to horseradish peroxidase (HRP) for 
chemiluminescent detection. Excess antibody was removed by washing the membrane for 5-, 10-, and 
15- min, respectively, with the washing buffer. When probing for phosphorylated proteins, blocking 
and washing buffers as well as antibody solutions were supplemented with 50 mM NaF and 1 mM 
Na3VO4.  
Chemiluminescent immunoblot signals were developed using the SuperSignal™ West Dura Extended 
Duration Substrate and imaged by the ChemiDoc
TM
 XRS+ system with Image Lab
TM
 software. Band 
intensities were quantified using Fiji [204]. Table 2-4 lists the antibodies used in this study and their 
respective working dilutions. 
3.2.6. Silver staining 
To visualize resolved proteins, polyacrylamide gels were silver-stained using the Pierce
TM
 Silver Stain 
kit. Briefly, the gel was washed twice with deionized water for 5 min and then fixed with 30% ethanol: 
10% acetic acid solution twice for 15 min. The gel was transferred into a proprietary sensitizer 
solution for 1 min and washed twice with deionized water. The gel was incubated with the stain 
working solution (<0.25 % w/w AgNO3) for 30 min and afterwards washed twice with deionized 
water. Protein bands were visualized in the developer solution (1-5% w/w Na2CO3). Upon reaching the 
desired band intensity, the reaction was stopped with 5% acetic acid. 
3.2.7. Agarose gel electrophoresis 
Agarose gels were casted by heating and dissolving an appropriate amount of agarose in 1X TAE 
buffer. Prior to casting, 10 µL of 0.5% ethidium bromide solution was added to the molten agarose. 
Sufficient DNA loading dye stock was combined with approximately 100 ng of DNA to make a 1X 
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loading dye:sample solution. The samples, together with a DNA ladder mix, were loaded into the 
agarose gel submerged in 1X TAE.  Gel electrophoresis was performed at 100 V and the gel was 
imaged on a UV transilluminator.  
3.2.8. PCR amplification of LINC00920 cDNA and LINC00920 promoter fragments 
Phusion® High-Fidelity DNA polymerase was used to amplify the full-length LINC00920 cDNA and 
promoter fragments. Each reaction mixture consisted of 1X Phusion HF buffer, 0.2 mM dNTPs, 1 μM 
of each forward and reverse primers (Table 2-8), 3% v/v DMSO, 0.2 μL of Phusion DNA polymerase, 
20 ng of cDNA or genomic DNA template and enough nuclease-free water to reach the final volume 
of 20 μL. Temperature cycling was performed on the PTC-225 gradient thermal cycler. Template 
DNA was initially denatured at 98
o
C for 2.5 min, followed by 30 cycles of denaturation (30 s at 98
o
C), 
annealing (30 s at 55
o
C) and extension (2 min at 72
o
C). The final extension step was extended to 10 
min. Successful amplification of PCR products were verified by electrophoresing 2-μL aliquots 
through 1% agarose- 1X Tris-Acetate-EDTA (TAE) gels. Amplicons were visualized by staining with 
ethidium bromide and viewing under UV light. Bands with the expected fragment size were cut from 
the gel and purified using QIAquick gel extraction kit using the manufacturer’s protocol. After elution 
in nuclease-free water, DNA was quantified by NanoDrop 1000, and stored at -20
o
C.  
3.2.9. Quantitative PCR 
Quantitative PCR was performed in the LightCycler® 480 II system using assays described below 
adapted to a 384-well plate format. Crossing point-PCR-cycle (Cp) values were generated by the 
LightCycler® 480 software (release 1.5.0) using the second derivative method. Relative expression 
levels were calculated by obtaining the difference of the median Cp value of triplicate reactions 
corresponding to the housekeeping gene and the gene of interest (∆𝐶𝑝). Next, the difference in ∆𝐶𝑝 
values of the control and treated samples was computed ( ∆∆𝐶𝑝), and normalized by calculating 
2−ΔΔCp, respectively. Table 2-9 lists the qPCR primers used in this study. 
3.2.9.1. Universal Probe Library (UPL) assay 
Each qPCR reaction consisted of 10 µL 2X ABsolute qPCR master mix or 2X Premix Ex Taq
TM
 
master mix, 0.2 µL of 10 µM Universal Probe Library probe, 0.4 µL of 20 µM forward and reverse 
primer pool, 5 µL of 4ng/µL cDNA template, and nuclease-free water to reach 20 µL. Template DNA 
was initially denatured at 95
o
C for 10 min, followed by 45 cycles of denaturation (10 s at 95
o
C), 
annealing (30 s at 55
o
C) and extension (1 s at 72
o
C). The reaction was cooled down to 40
o
C 
indefinitely. 
3.2.9.2. SYBR assay 
Each qPCR reaction consisted of 5 µL 2X ABsolute Blue qPCR master mix, 0.5 µL 20 µM forward 
and reverse primer pool, 5 µL 4ng/µL cDNA template, and nuclease-free water to reach 11 µL. 
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Template DNA was initially denatured at 95
o
C for 15 min, followed by 40 cycles of denaturation (15 s 
at 95
o
C), annealing (30 s at 60
o
C) and extension (60 s at 72
o
C). Following the amplification cycling, a 
melt curve analysis was performed by heating the reaction to 95
o
C for 30 s followed by cooling to 
60
o
C for 30 s. A final denaturation step was held at 97
o
C wherein the fluorescence signals at 5
o
C-
temperature increments were continuously acquired. The reaction was cooled down to 40
o
C 
indefinitely. 
3.2.10. Cloning 
3.2.10.1. TOPO insertion 
TOPO technology was used to clone: (i) amplified lncRNA cDNA into pCR®4Blunt-TOPO®; and (ii) 
LINC00920 promoter fragments into pCR®2.1-TOPO®. LINC00920 promoter fragments were first 
A-tailed prior to cloning. To this end, a 25-µL reaction volume consisting of 10 µL of purified PCR 
product, 1X ThermoPol® buffer, 200 µM ATP, 0.5 U Taq DNA polymerase, and nuclease-free water 
was incubated at 72
o
C for 20 min. DNA insertion into both TOPO vectors was facilitated by mixing 5 
ng TOPO vector, 0.5 µL salt solution (1.2 M NaCl, 0.06 M MgCl2), and enough purified PCR product 
to reach a 3-µL reaction volume. The TOPO reaction was incubated at room temperature for 30 min 
and stored at 4
o
C until use. 
3.2.10.2. Sticky-end ligation 
Subcloning by sticky-end ligation was performed to shuttle: (i) full-length lncRNA cDNA from 
pCR®4Blunt-TOPO® into pcDNA
TM
3.1(+); and (ii) LINC00920 promoter fragments from pCR®2.1-
TOPO® into pGL4.10[luc2]. Table 3-1 lists the enzyme combinations for digesting the donor and 
acceptor vectors. 
Table 3-1. Vectors and restriction enzymes used for subcloning. 
Vector Description 
Restriction  
enzyme pair 
pCR®4Blunt-TOPO® constructs 
Harbors full-length lncRNA cDNA SpeI*, NotI 
pcDNA
TM
3.1(+) 
Mammalian expression vector NheI*, NotI 
pCR®2.1-TOPO® constructs 
Harbors LINC00920 promoter fragments SpeI*, XhoI 
pGL4.10[luc2] 
Firefly luciferase reporter vector NheI*, XhoI 
*These restriction enzymes generate compatible cohesive ends. 
Each restriction enzyme double digestion reaction contains 1X CutSmart buffer, 20 U of each enzyme, 
1.5 µg plasmid DNA, and enough nuclease-free water to reach a 50-µL volume. The samples were 
incubated at 37
o
C for 30 min and afterwards deactivated by heating to 80
o
C for 20 min. Linearized 
acceptor vectors were dephosphorylated by adding 5 µL 10X CutSmart buffer, 5 µL 10 U/µL alkaline 
phosphatase, and 40 µL nuclease-free water to the digestion reaction. The mixture was incubated at 
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37
o
C for 30 min and then heated to 65
o
C for 5 min to terminate the reaction. DNA digests were 
resolved in 1% agarose gels and gel-purified. 
DNA inserts were ligated into acceptor vectors by mixing 1X T4 DNA ligase buffer, 75 ng linearized 
and dephosphorylated acceptor vector, 25 ng DNA insert, 400 U T4 DNA ligase, and enough 
nuclease-free water to reach a 20-µL reaction volume. The samples were incubated overnight at 16
o
C 
and inactivated by heating to 65
o
C for 10 min.  
3.2.10.3. Bacterial transformation and colony screening 
One Shot
TM
 TOP10 chemically competent E. coli cells were thawed on ice. Three microliters of 
ligation reaction was added into 30 µL competent cells and the mixture was incubated on ice for 30 
min. Cells were heated to 42
o
C for 30 s and chilled for 1 min. Two hundred fifty microliters of pre-
warmed S.O.C. medium was added into the cells which were allowed to recover by incubation with 
shaking (200 rpm) at 37
o
C for 1 h. Transformed cells were plated at 1:5 and 1:2 dilutions onto 
LB/ampicillin/X-gal plates and incubated overnight at 37
o
C. White colonies were further screened for 
the correct insert sequence by colony PCR. Briefly, colonies were separately inoculated into 10-µL 
volume PCR mixture containing 1X DreamTaq Green PCR master mix, 0.2 µM each of forward and 
reverse primers, and nuclease-free water. Template DNA from cells was initially denatured at 95
o
C for 
5 min and 30 s, followed by 30 cycles of denaturation (30 s at 98
o
C), annealing (30 s at 55
o
C) and 
extension (60 s at 72
o
C). The final extension step was extended to 10 min. Successful amplification of 
PCR products were verified by electrophoresing 2-μL aliquots through 1% agarose- 1X TAE gels. 
3.2.10.4. Plasmid extraction 
Insert-positive colonies were inoculated into 3 mL Luria-Bertani (LB) broth (1% tryptone, 0.5% yeast 
extract, 0.17 M NaCl) supplemented with 100 µg/mL ampicillin and grown overnight with shaking at 
37
o
C. Plasmid extraction was performed using QIAprep Spin Miniprep kit following the 
manufacturer’s protocol. Plasmid DNA was resuspended in nuclease-free water and stored at -20
o
C. 
Insert sequence fidelity was assessed by Sanger sequencing (GATC, Eurofins Genomics). Scaled-up 
plasmid production was performed by inoculating positive transformants into 100-mL culture medium. 
Plasmid DNA was prepared using QIAprep Spin Maxiprep kit. 
3.2.10.5. Preparation of glycerol stocks 
Glycerol stocks were prepared from bacterial clones by mixing an equal volume of 87% sterile 
glycerol to 250-µL culture aliquots. Stocks were stored long-term at -80
o
C. 
3.2.11. Site-directed mutagenesis by overlap-extension PCR 
The 1000 bp LINC00920 promoter amplified from PC-3-derived genomic DNA was cloned into 
pCR®2.1-TOPO®. To introduce the GG>CC transversions in ETS domain 1, a mutagenic reverse 
primer was paired with a wild-type forward primer (Table 2-10) in amplifying the 1000 bp promoter 
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region using the pCR®2.1-TOPO® construct as template. In contrast, overlap extension-PCR was 
performed to introduce the double nucleotide mutations in ETS domain 2 which is further upstream 
the LINC00920 TSS. Intermediate fragments were amplified using Phusion® High-Fidelity DNA 
polymerase as described in section 3.2.8 with primers listed in Table 2-10. Equal amounts of the 
intermediates were then used as template for the third round of PCR which fused the two mutant 
fragments, yielding the full-length promoter region. Mutants were then cloned into pCR®2.1-TOPO® 
and sticky cloning ends were generated by restriction enzyme digestion in preparation for subcloning 
into pGL4.10[luc2]. 
3.3. Molecular characterization of lncRNAs 
3.3.1. Rapid amplification of cDNA ends (RACE) 
3.3.1.1. 5’-RACE 
RACE experiments were performed using the GeneRacer™ Kit. 5’-RACE was initiated by 
dephosphorylation of total human prostate RNA. Two thousand nanograms of RNA was mixed with 
1X calf intestinal phosphatase, 40 U RNaseOut
TM
, 1 U calf intestinal phosphatase, and nuclease-free 
water to a final volume of 10 µL. The sample was incubated at 50
o
C for 1 h, and then cooled on ice. 
Next, 90 µL nuclease-free water and 100 µL phenol:chloroform:isoamyl alcohol (25:24:1) were added 
to precipitate RNA. After mixing, the sample was centrifuged at 21,000 g, room temperature for 5 
min. The aqueous phase was transferred into a new tube where 2 µL 10 mg/mL mussel glycogen, 10 
µL 3 M pH 5.2 sodium acetate, and 220 µL 95% ethanol were added. The sample was cooled on dry-
ice for 10 min and afterwards centrifuged at 21,000 g, 4
o
C for 20 min. The RNA pellet was washed 
once with 70% ethanol and resuspended in 7 µL nuclease-free water. The mRNA cap structure was 
then removed by incubating the dephosphorylated RNA at 37
o
C for 1 hour with 1X tobacco acid 
pyrophosphatase buffer, 40 U RNaseOut
TM
, and 0.5 U tobacco acid pyrophosphatase. RNA was 
precipitated by phenol:chloroform:isoamyl alcohol as described above. To prime 5’-ends, an RNA 
oligo ligation step was performed by mixing decapped RNA with 0.25 µg GeneRacer
TM
 oligo, 1X T4 
RNA ligase buffer, 1 mM ATP, 40 U RNaseOut
TM
, and 5 U T4 RNA ligase. The sample was 
incubated at 37
o
C for 1 h, and RNA was once again precipitated. Purified RNA was reverse-
transcribed as described in section 3.2.2, and 5’-ends of lncRNAs were amplified as described in 
section 3.2.8 using GeneRacer
TM
 5’ primer and a gene-specific 5’-end reverse primer (Table 2-11). 
The resulting PCR product was used in a subsequent nested PCR using the GeneRacer
TM
 5’ nested 
primer and a more upstream gene-specific 5’-end reverse primer.  
3.3.1.2. 3’-RACE 
Total human prostate RNA was reverse-transcribed by mixing 2000 ng RNA with 900 ng 
GeneRacer™ Oligo dT Primer, 10 nmol dNTP mix, and nuclease-free water to a final volume of 13 
µL. The sample was incubated at 65
o
C for 5 min and chilled on ice for 1 min. Next, 1X first strand 
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buffer, 0.1 µmol DTT, 40 U RNaseOut
TM
, and 200 U SuperScript
TM
 III reverse transcriptase were 
added to the denatured RNA. Reverse-transcription was facilitated at 50
o
C for 1 h, and afterwards 
terminated by heating to 70
o
C for 15 min. The sample was chilled on ice and RNA digestion was 
carried out by incubating the sample with 2 U RNase H at 37
o
C for 20 min. Gene-specific 
amplification of 3’-ends was performed as described in section 3.2.8 using a gene-specific 3’-end 
forward primer and the GeneRacer
TM
 3’ primer (Table 2-11). As with 5’-RACE, a nested PCR was 
subsequently performed using a more downstream gene-specific 3’-end forward primer and the 
GeneRacer
TM
 3’ nested primer. 
3.3.1.3. Cloning and sequence analysis 
Successful amplification of 5’- and 3’-ends were verified by electrophoresing 2-μL aliquots through 
1% agarose- 1X TAE gels. Amplicons were visualized by staining with ethidium bromide and viewing 
under UV light. DNA bands were cut from the gel and purified using QIAquick gel extraction kit 
using the manufacturer’s protocol, and cloned into pCR
TM
4Blunt-TOPO® as described in section 
3.2.10.1. Sequences of lncRNA ends were determined by Sanger sequencing (GATC, Eurofins 
Genomics) and aligned with annotated tracks using the UCSC genome browser. 
3.3.2. Coding potential analysis 
LINC00920 sequence as determined by RACE was used to survey the coding potential of the 
transcript. Sequences of control coding mRNAs, lncRNAs, and LINC00920 were loaded into Coding 
Potential Assessment Tool (CPAT; Version 2.0.0, URL: http://lilab.research.bcm.edu/cpat/) and the 
hg19 assembly was selected as reference genome. Sequences were similarly loaded into Coding 
Potential Calculator (CPC; Version 2.0 beta, URL: http://cpc2.cbi.pku.edu.cn/). Hg19 PhyloCSF 
tracks were extracted from the Track Data Hubs and visualized in the UCSC genome browser 
spanning the chromosomal locus of LINC00290. 
3.3.3. Subcellular fractionation 
A fractionation protocol [208] was adapted to prepare cytoplasmic, nucleoplasmic, and chromatin 
lysates from PC-3, VCaP, and LNCaP cells for eventual RNA extraction. Thirty million cells were 
resuspended in 400 µL ice-cold cytoplasmic buffer (0.15% NP-40, 10 mM Tris-HCl pH 7.5, 150 mM 
mM NaCl) and incubated on ice for 10 min. Five hundred microliters of ice-cold sucrose buffer (10 
mM Tris-HCl pH 7.5, 150 mM NaCl, 0.7 M sucrose) was layered on the cell suspension and the tubes 
were centrifuged at 13000 rpm, 4
o
C for 10 min. The supernatant corresponding to the cytoplasmic 
fraction was collected, leaving approximately 100 µL liquid with the pellet to minimize nuclear 
contamination. The remaining nuclear pellet was resuspended in 250 µL ice-cold glycerol buffer (20 
mM Tris-HCl pH 7.9, 75 mM NaCl, 0.5 mM EDTA pH 8.0, 50% glycerol, 0.85 mM DTT) and an 
equal volume of ice-cold nuclei lysis buffer (20 mM HEPES pH 7.6, 7.5 mM MgCl2, 0.2 mM EDTA 
pH 8.0, 0.3 M NaCl, 1 M urea, 1% NP-40, 1 mM DTT) was added. After mixing, the samples were 
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incubated on ice for 1 min. The soluble nucleoplasmic and chromatin fractions were separated by 
centrifugation at 14000 rpm, 4
o
C for 2 min. In collecting the nucleoplasmic fraction, approximately 
100 µL liquid was left with the chromatin pellet to minimize cross-contamination. The chromatin 
pellet was resuspended in 50 µL ice-cold 1X PBS. RNA from all subcellular fractions was extracted 
using RNeasy® Mini Kit as described in section 3.2.2, followed by cDNA synthesis. Relative 
enrichments of HPRT1, GAPDH, LINC00920, NEAT1, and MALAT1 transcripts in each fraction were 
measured by qPCR. 
3.4. Gene expression profiling 
3.4.1. RNA preparation and quality assessment 
Three biological replicates of LINC00920 knockdown in PC-3 cells using siRNA-Q2, siRNA-Q3, and 
scrambled control ( 
Table 2-7) were performed in a 6-well plate format. Forty-eight hours post transfection, RNA was 
extracted as described in section 3.2.2 and quantified by NanoDrop 1000. RNA quality was assessed 
using the RNA 6000 Nano kit with the 2100 Bioanalyzer. RNA samples were diluted to 50 ng/µL in 
20-µL volumes and submitted to the Genomics and Proteomics Core Facility of the DKFZ where gene 
expression profiling was performed using the Human HT-12 v4 Expression Bead Chip from Illumina.  
3.4.2. Gene Set Enrichment Analysis (GSEA) 
Gene Set Enrichment Analysis tool was used to identify perturbed biological pathways upon lncRNA 
knockdown. Expression fold-change values of all analyzed genes generated from the biological 
replicates of microarray experiments were used to prepare .rnk files for each siRNA knockdown 
condition. Using .rnk files as input, enrichment analysis of canonical pathways and gene ontology 
gene sets was performed using GSEAPreranked (desktop application version 3.0) with permutations 
value set to 1000. 
3.4.3. Ingenuity Pathway Analysis (IPA) 
Top 1000 upregulated and top 1000 downregulated genes upon LINC00920 knockdown were 
overlapped for the two independent siRNA experiments. For siRNA-Q2, this cutoff translated to genes 
having fold-change values greater than 1.223946 or less than 0.8010429. Likewise, for siRNA-Q3 the 
cut-off included genes with fold-change values greater than 1.349623 or less than 0.735197. 
Expression values of the common genes in both siRNA knockdowns were derived from the siRNA-Q3 
knockdown dataset. Altogether, 315 genes (Supplementary Table 9-2) and their corresponding 
expression fold-change values were loaded into the IPA (build 486617M) core analysis tool. 
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3.5. Validation of LINC00920 regulation by ERG 
3.5.1. Expression correlation analysis 
Fragments Per Kilobase of transcript per Million mapped reads upper quartile (FPKM-UQ+1) values 
of ERG and LINC00920 in the TCGA-PRAD RNA-seq data were extracted from the UCSC Xena 
platform [209]. Expression correlation analyses were carried out for both ICGC-EOPC (n=135) and 
TCGA-PRAD (n=551) cohorts using the R cor() function executed in RStudio (version 1.0.136). 
3.5.2. Promoter analysis and ERG binding site prediction 
Raw H3K27ac, H3K4me3, and RNA polymerase II ChIP-seq data were downloaded from the NCBI 
Gene Expression Omnibus (GSE57498) [210]. All data analyses subsequently described were 
conducted on the Galaxy public server (URL: usegalaxy.org) [211]. Quality assessment of .fastq files 
was performed using FastQC (version 0.11.5) [212]. Overrepresented sequences corresponding to 
adapter sequences were clipped using the clip adapter sequences tool (version 1.0.1). Reads were 
filtered using the filter by quality tool (version 1.0.0) with the quality cut-off value set at 20 and the 
percent of bases in sequence reaching the cut-off was set at 90%. Read ends (quality score = 20) were 
trimmed using FASTQ quality trimmer (version 1.0.0) [213]. Afterwards, trimmed reads were mapped 
to the human hg19 reference genome using Bowtie2 (version 1.1.2) [214]. SAMtools [215] was used 
to sequentially remove multi-mapping reads, sort the resulting .bam files, and remove PCR duplicates. 
BigWig files were generated from the clean .bam files using bamCoverage (version 2.5.0.0) [216] with 
bin size set to 25 bases. Finally, the bigwig files were visualized in the UCSC genome browser [217]. 
Promoter sequence 1000 bp upstream the annotated LINC00920 transcription start site was extracted 
from the UCSC Genome Browser. ERG binding motifs along the promoter sequence were scanned 
and scored using JASPAR CORE [218] at a threshold of 85%. 
3.5.3. Chromatin immunoprecipitation (ChIP) 
3.5.3.1. Crosslinking of VCaP cells 
VCaP cells were washed with 1X PBS and fixed with 1 mL of 1% formaldehyde per 1 x 10
6
 cells at 
room temperature for 20 min. The reaction was quenched by adding 1/10 volume of 1.25 M glycine 
and rocking the cell suspension for 5 min. Cells were washed twice with ice-cold 1X PBS. 
Cytoplasmic lysis was performed by resuspending cells in ice-cold cytoplasmic lysis buffer (150 mM 
NaCl, 20 mM EDTA pH 8.0, 50 mM Tris-HCl pH 7.5, 0.5% NP-40, 1% Triton X-100, 20 mM NaF) 
supplemented with 1X cOmplete, Mini protein inhibitor cocktail and 1X phenylmethane sulfonyl 
fluoride (PMSF). The remaining nuclear pellet was collected by centrifugation at 12,000 g, 4
o
C for 2 
min, snap-frozen, and stored at -80
o
C. 
 46 
3.5.3.2. Chromatin preparation 
Chromatin lysates were prepared by first resuspending the nuclear pellet in a nuclear lysis buffer (150 
mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 50 mM Tris-HCl pH 8.0, 20 mM EDTA pH 8.0, 20 
mM NaF, 0.1% SDS) supplemented with 1X cOmplete, Mini protein inhibitor cocktail and 1X PMSF, 
at a density of 3 x 10
6
 cells/150 µL. Nuclear lysis was performed on ice for 15 min and the resulting 
lysate was aliquoted into 1.5 mL Bioruptor® microtubes (150 µL/tube). Chromatin preparations were 
then sonicated at 4
o
C using the Bioruptor® Pico sonication device for 13 cycles applying the 30-
second on/off high setting. The lysates were pooled and clarified by centrifugation at 8,000 g, 4
o
C for 
10 min. 
3.5.3.3. Immunoprecipitation 
Chromatin lysate volume equivalent to 4 x 10
6
 cells and 30 µL of ChIP-grade protein G magnetic 
beads were used for each immunoprecipitation reaction. Prior to use for lysate pre-clearing, 30 µL 
magnetic beads were pre-washed with nuclear lysis buffer. Chromatin lysate was diluted to 600 µL 
with the nuclear lysis buffer and added into the washed beads and pre-cleared by rotating at 4
o
C for 2 
h. The beads were separated on a magnetic rack and the cleared lysate was transferred into a new tube. 
A volume corresponding to the 2% input sample was aliquoted and 2 µg of antibody (Table 2-5) was 
added to the remaining lysate. Antibody hybridization was facilitated by overnight rotation at 4
o
C. 
Next day, 30 µL of pre-washed magnetic beads was added to the reaction tube and hybridized at 4
o
C 
for 2 h. 
3.5.3.4. Bead washing and DNA isolation 
The magnetic beads were collected and washed sequentially using the following ice-cold buffers 
supplemented with 1X PMSF: once with the nuclear lysis buffer, once with high-salt buffer (50 mM 
Tris pH 7.9, 500 mM NaCl, 1 mM EDTA pH 8.0, 1% Triton X-100, 0.1% sodium deoxycholate, 0.1% 
SDS), once with Li buffer (20 mM Tris pH 7.9, 1 mM EDTA pH 8.0, 250 mM LiCl, 0.5% NP-40, 
0.1% sodium deoxycholate), and twice with 10 mM Tris pH 7.9. Chromatin elution was performed by 
adding 150 µL elution buffer (50 mM Tris pH 7.9, 1 mM EDTA pH 8.0, 1% SDS, 50 mM NaHCO3, 
300 mM NaCl) and 2 µL RNase A to the input and beads. Reaction tubes were incubated at 65
o
C with 
shaking overnight. Afterwards, 2 µL Proteinase K (20 mg/mL) was added to each reaction followed by 
incubation at 60
o
C for 1 h to reverse chemical crosslinks. The magnetic beads were discarded and 
DNA was isolated from the eluate using UltraPure Phenol:Chloroform:Isoamyl Alcohol (25:24:1, v/v). 
Briefly, 300 µL phenol:chloroform:isoamyl alcohol was mixed with the eluate for 10 min. The 
samples were centrifuged at room temperature, 14000 rpm for 5 min. The aqueous layer was 
transferred into a new tube wherein 3 µL GlycoBlue coprecipitant, 120 µL 3M pH 5.2 sodium acetate, 
and 900 µL 100% ethanol were added. DNA was precipitated overnight at -20
o
C. To collect the 
precipitated DNA, the samples were centrifuged at 4
o
C, 14,000 rpm for 30 min. The pellet was washed 
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with 70% ethanol, air-dried, and reconstituted in 100 µL nuclease-free water. Five microliters of DNA 
was used in subsequent qPCR assays. 
3.5.3.5. ChIP-qPCR 
To quantify DNA enrichments, SYBR assays were performed as described in section 3.2.9.2. using 
primers in Table 2-9. Percent of input using Cp values were calculated as: 
% 𝑖𝑛𝑝𝑢𝑡 =  100% × 2𝐴𝐼−𝐶𝑝𝑝𝑢𝑙𝑙𝑑𝑜𝑤𝑛 
where  
𝑎𝑑𝑗𝑢𝑠𝑡𝑒𝑑 𝑖𝑛𝑝𝑢𝑡 (𝐴𝐼)  =  𝐶𝑝𝑖𝑛𝑝𝑢𝑡 − 𝑙𝑜𝑔2(
𝑣𝑜𝑙𝑢𝑚𝑒𝑝𝑢𝑙𝑙𝑑𝑜𝑤𝑛
𝑣𝑜𝑙𝑢𝑚𝑒𝑖𝑛𝑝𝑢𝑡
). 
3.5.4. Promoter luciferase assay 
LNCaP #126 T/E cells were seeded into black, flat- and clear-bottomed 96-well plates (2 x 10
4
 cells in 
75 µL complete medium/well) for 48 h. Next, doxycycline treatment was carried out for another 48 h 
as previously described (section 3.1.6). Control and doxycycline-treated cells were then co-transfected 
using Lipofectamine® 2000 with the generated pGL4.10[luc2] construct containing either wild-type or 
mutant LINC00920 promoter fragments and pAAVpsi2 in 10:1 ratio (90 ng:10 ng). pAAVpsi2 
encodes the Renilla luciferase gene (hRluc) under the control of the SV40 promoter and enhancer 
[199]. The latter vector was used to uncouple the luminescence signals from the effects of varying 
transfection efficiencies across wells, effectively normalizing luminescence derived from the firefly 
luc2 reporter gene. After 48 h, firefly and Renilla luminescence signals were developed using the 
Dual-Glo® Luciferase assay system following the manufacturer’s protocol. Luminescence signals 
were measured using TECAN Infinite M200 with the i-control
TM
 (version 1.6) software.    
3.6. Chromatin isolation by RNA purification (ChIRP) 
3.6.1. Crosslinking of PC-3 cells 
To preserve RNA/DNA/protein interactions, PC-3 cells were fixed using either 1% glutaraldehyde 
(ChIRP-seq) or 3% formaldehyde (ChIRP-MS). The crosslinking procedures for both reagents are 
similar. Briefly, cells were trypsinized and washed twice with 1X PBS. Cells were resuspended in the 
chemical crosslinker at a concentration of 1 x 10
6
 cells/ 1 mL 1% glutaraldehyde or 3% formaldehyde 
in 1X PBS and incubated with rocking at room temperature for 10 min (glutaraldehyde) or 30 min 
(formaldehyde). Crosslinkers were then quenched with 1:10 volume of 1.25 M glycine for 5 min. Cells 
were collected by centrifugation at 1,000 g, 4
o
C for 5 min, and washed thrice with ice-cold 1X PBS. 
Cell pellets were collected in 1.5 mL tubes and snap-frozen on dry-ice. 
3.6.2. Cell lysate preparation 
Crosslinked cells were thawed on ice and resuspended in ChIRP cell lysis buffer (50 mM Tris-HCl pH 
7.5, 10 mM EDTA pH 8.0, 1% SDS) supplemented with 1X cOmplete, Mini protein inhibitor, 1X 
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PMSF, and 0.05 U/µL Superase In
TM
 RNase inhibitor at a density of 2 x 10
4
 cells/mL. Cell lysis was 
facilitated by incubation on ice for 15 min. Next, 300-µL volumes of cell suspension were aliquoted 
into 1.5 mL Bioruptor® microtubes and sonicated at 4
o
C using the Bioruptor® Pico sonication device 
for 35 cycles with the 30-second on/off high setting. Sheared lysates were pooled and clarified by 
centrifugation at 12,000 rpm, 4
o
C for 10 min. 
3.6.3. ChIRP-seq 
For each pulldown reaction (i.e., lacZ, LINC00920), sheared cell lysate equivalent to 6 x 107 
glutaraldehyde-fixed cells was diluted to 5 mL with ChIRP hybridization buffer (750 mM NaCl, 1% 
SDS, 50 mM Tris-Cl pH 7.5, 1 mM EDTA, 15% formamide) supplemented with 1X cOmplete, Mini 
protein inhibitor, 1X PMSF, and 0.05 U/µL Superase In
TM
 RNase inhibitor. In parallel, 100 µL slurry 
of Dynabeads
TM
 MyOne
TM
 Streptavidin C1 was pre-washed with hybridization buffer. The cell lysate 
was then pre-cleared by mixing with washed beads at 37
o
C for 30 min. The beads were magnetically 
separated and discarded. An aliquot corresponding to 0.5% input from the cleared lysate was set aside 
and stored at -80
o
C. Three hundred picomoles of pooled oligos (Table 2-12) was denatured at 75
o
C for 
2 min, cooled on ice, and added to the clarified lysate. Hybridization was facilitated by rotation 
overnight at 37
o
C. Next day, 300 µL of bead slurry was pre-washed with the hybridization buffer and 
added into the hybridization reaction. Biotinylated complexes were captured on the beads by 
incubation with rocking at 37
o
C for 30 min. Afterwards, the beads were collected and the supernatant 
was discarded. The beads were then washed 5 times with 1 mL ChIRP wash buffer (2X saline-sodium 
citrate buffer, 0.5% SDS, 1X PMSF) at 37
o
C for 5 min. During the last wash, 25 µL of the bead slurry 
was aliquoted for RNA isolation. The remaining beads were then collected for DNA isolation. 
3.6.3.1. RNA isolation 
Prior to RNA isolation, crosslink reversal was performed on input samples and capture beads by 
proteinase K digestion. Briefly, samples were resuspended in 95 µL proteinase K buffer (100 mM 
NaCl, 10 mM Tris-HCl pH 7.5, 1 mM EDTA pH 8.0, 0.5% SDS) and supplemented with 5 µL of 20 
mg/mL proteinase K. Tubes were incubated at 65
o
C with shaking for 45 min, followed by enzyme 
deactivation at 95
o
C for 10 min. RNA from the samples were subsequently isolated using miRNeasy® 
Mini kit following the manufacturer’s protocol, including the optional DNase-I digestion step. 
3.6.3.2. DNA isolation 
DNA bound to the beads was eluted by resuspending the beads in 150 µL high salt elution buffer (50 
mM Tris pH 7.9, 1 mM EDTA pH 8.0, 1% SDS, 50 mM NaHCO3, 300 mM NaCl) supplemented with 
15 µg RNase A and 15 U RNase H and incubating at 37
o
C for 30 min. This step was done twice. The 
beads were then discarded and 15 µL proteinase K was added to the supernatant. Crosslink reversal 
was facilitated by incubating the samples overnight at 50
o
C. DNA isolation was performed using 
phenol:chloroform:isoamyl alcohol as previously described in section 3.5.3.4., with the final 
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reconstitution volume decreased to 20 µL. DNA concentrations were measured by Qubit® 
Fluorometer using the Qubit® dsDNA HS assay kit. Three to ten nanograms of precipitated DNA was 
used for subsequent library preparation. 
3.6.3.3. Library preparation 
The NEBNext Ultra II DNA library preparation kit for Illumina and NEBNext Multiplex Oligos for 
Illumina, Index Primers Set 1 were used, following the manufacturer’s protocols with some 
modifications, to prepare sequencing DNA libraries from ChIRP-DNA. Due to the low amounts of 
input DNA, the NEBNext adapter was diluted 25-fold (1:25) in 10 mM Tris-HCl, pH 8.0 with 10 mM 
NaCl. Size-selection step prior to amplification was not performed due to the same reason of low 
DNA input. Index primer combination for the libraries was chosen to enable multiplex sequencing. 
Table 2-13 shows the index primers matched with each library. PCR enrichment was performed using 
12-15 amplification cycles. To remove primer duplexes, a final bead clean up was performed using 
Agencourt AMPure XP beads. Quality assessment of libraries was performed using the DNA High 
Sensitivity kit with 2100 Bioanalyzer. The libraries were pooled at an equimolar concentration (10 nM 
per library in 30 µL volume) and the resulting multiplexed sample was submitted to the Genomics and 
Proteomics Core Facility of the DKFZ. Single-read, 50-bp sequencing in a single lane of the HiSeq 
2000 sequencing platform was employed to obtain a depth of at least 20 million reads per library. 
3.6.3.4. Analyses of high-throughput sequencing data 
3.6.3.4.1. Genomic enrichment analysis 
ChIRP-seq data were initially obtained as raw de-multiplexed .fastq files. Additionally, raw H3K27ac, 
H3K4me3, H3K4me1, H3K4me3, and RNA polymerase II ChIP-seq data were downloaded from the 
NCBI Gene Expression Omnibus (GSE57498) [210]. These files were pre-processed as described in 
section 3.5.2 to generate clean .bam files. Next, the hg19 genome was split into bins of 10 kbp and 
read coverages were computed using multiBamSummary (version 2.5.0.0). The matrix output was 
processed by plotCorrelation (version 2.5.0.0) to generate the correlation heatmap.  
To map ChIRP-seq and ChIP-seq reads across annotated genomic features, each dataset was first 
normalized with control signals (i.e., lacZ ChIRP or input ChIP) using bamCompare (version 2.5.0.0) 
(--binsize 50). In mapping LINC00920 occupancy across genic regions, the .bed file containing genic 
locations in the hg19 genome build was extracted from the UCSC browser. Computed matrices were 
aligned with the .bed file using plotHeatmap (version 2.5.0.0) wherein gene lengths were normalized 
to 10 kbp with 2-kb extensions upstream the transcription start sites and downstream the transcription 
end sites. Promoter and enhancer enrichment analyses were performed in an analogous manner. 
Genomic regions annotated as promoters or enhancers in the PC-3 genome were extracted as .bed files 
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from NCBI Gene Expression Omnibus (GSE73785) [219]. Normalized matrices were then aligned 
with the corresponding .bed file using plotHeatmap in reference-point mode.  
To cluster the promoter regions based on similarity in LINC00920 score distribution, k-means 
clustering was activated in plotHeatmap where the number of clusters to compute was set to 4. 
To determine the biological relevance of LINC00920 enrichment in cluster 1 promoters, promoter loci 
were analyzed using Genomic Regions Enrichment of Annotations Tool (GREAT) [202] with species 
assembly set to hg19 and background region set to the whole genome.  
3.6.3.4.2. Peak calling 
Model-based analysis of ChIP-seq 2 (MACS2) was used to identify the chromatin binding sites of 
LINC00920. The bandwidth fragment size was set to 150 (--bw 150); lower and upper mfold 
boundaries were set to 10 and 30, respectively (--mfold 10 30); q-value was set to 0.001 (--qvalue 
0.001); and broad peak calling was performed (--broad) using the shifting model. Peaks were called 
for each replicate separately using paired lacZ pulldowns as normalizing controls. High confidence 
peaks (n=2985) were identified by overlapping called peaks among the replicates and setting a fold-
change cutoff value of 10. Peaks were annotated with genomic features using published chromatin 
state and characterization (ChromHMM) data generated specifically for the PC-3 genome [219]. 
3.6.3.4.3. Motif discovery 
Genomic sequences of the top 1000 MACS2-called peaks (ranked by fold-enrichment) were extracted 
from the hg19 build of the human genome using the Extract Genomic DNA (version 3.0.3) function of 
Galaxy. The sequences were then used to identify DNA motifs using the default parameters of MEME 
(version 4.6.0) [220]. 
3.6.4. ChIRP-MS 
For each pulldown reaction (i.e., lacZ, LINC00920), sheared cell lysate equivalent to 2 x 108 
formaldehyde-fixed cells was diluted to 10 mL with ChIRP hybridization buffer (750 mM NaCl, 1% 
SDS, 50 mM Tris-Cl pH 7.5, 1 mM EDTA, 15% formamide) supplemented with 1X cOmplete, Mini 
protein inhibitor, 1X PMSF, and 0.05 U/µL Superase In
TM
 RNase inhibitor. In parallel, 200 µL slurry 
of Dynabeads
TM
 MyOne
TM
 Streptavidin C1 was pre-washed with the hybridization buffer. The cell 
lysate was then pre-cleared by mixing with the washed beads at 37
o
C with gentle rocking for 30 min. 
The beads were magnetically separated and discarded. An aliquot corresponding to 0.5% input from 
the cleared lysate was set aside and stored at -80
o
C. Six hundred picomoles of pooled oligos (Table 
2-12) were denatured at 75
o
C for 2 min and placed on ice. Denatured oligos were added to the clarified 
lysate and hybridization was facilitated by rotation overnight at 37
o
C. Next day, 600 µL bead slurry 
was pre-washed with hybridization buffer and added into the hybridization reaction. Biotinylated 
complexes were captured on the beads by incubation with rocking at 37
o
C for 30 min. Afterwards, the 
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beads were collected and the supernatant was discarded. The beads were then washed 5 times with 1 
mL ChIRP wash buffer at 37
o
C for 5 min. During the last wash, 25 µL of the bead slurry was 
aliquoted for RNA isolation. The remaining beads were then collected for protein elution. 
3.6.4.1. Protein elution 
Beads were resuspended in 800 µL benzonase elution buffer (20 mM Tris-HCl pH 7.9, 0.05% N-
lauroylsarcosine, 2 mM MgCl2, 0.5 mM Tris[2-carboxyethyl]phosphine) followed by addition of 125 
U of Benzonase® non-specific nuclease. Protein elution was facilitated by overnight digestion at 37
o
C. 
Next day, the beads were discarded and proteins were precipitated by adding trichloroacetic acid to a 
final concentration of 25%. The samples were incubated overnight at 4
o
C. Precipitated proteins were 
collected by centrifugation at 16,000 g, 4
o
C for 1 h. The supernatant was removed and the pellet was 
washed once with 100% ice-cold acetone. Protein pellets were air-dried and snap-frozen on dry ice 
and submitted to the mass spectrometry-based Protein Analysis Unit of the Genomics and Proteomics 
Core Facility, DKFZ. 
3.6.5. Analysis of identified proteins 
An enrichment ratio of 1.2 (LINC00920 ChIRP:lacZ ChIRP) was set to identify candidate LINC00920-
interacting proteins. Enriched proteins common to 3 biological replicates were investigated by 
computing gene set overlaps in the molecular signatures database (MsigDB) [221] using the BioCarta, 
KEGG, Reactome, and gene ontology gene sets. 
3.7. Validation of RNA-protein interaction 
3.7.1. RNA immunoprecipitation (RIP) 
3.7.1.1. Crosslinking of VCaP cells 
VCaP cells were washed with 1X PBS and fixed with 1 mL of 1% glutaraldehyde per 1 x 10
6
 cells at 
room temperature for 10 min. The reaction was quenched by adding 1/10 volume of 1.25 M glycine 
and rocking for 5 min. Cells were collected by centrifugation at 1,000 g, 4
o
C for 5 min, and washed 
thrice with ice-cold 1X PBS. Cell pellets were collected in 1.5 mL tubes and snap-frozen on dry-ice. 
3.7.1.2. Cell lysate preparation 
Cell lysis was performed by resuspending cells in ice-cold RIP buffer (150 mM KCl, 25 mM Tris-HCl 
pH 7.5, 5 mM EDTA, 0.5 mM dithiothreitol, 0.5% NP-40) supplemented with 1X cOmplete, Mini 
protein inhibitor, 1X PMSF, and 0.05 U/µL Superase In
TM
 RNase inhibitor at a density of 3 x 10
6
 
cells/150 µL. Samples were incubated on ice for 15 min and the resulting lysate was aliquoted into 1.5 
mL Bioruptor® microtubes (150 µL/tube). Cell lysates were sonicated at 4
o
C using the Bioruptor® 
Pico sonication device for 13 cycles applying the 30-second on/off high setting. The lysates were 
pooled into 400 µL volumes and supplemented with 28 U Superase In
TM
 RNase inhibitor and 5.5 U 
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TURBO
TM
 DNase. Chromatin digestion was facilitated by incubating the samples at 37
o
C for 15 min. 
The reaction was quenched by adding EDTA pH 8.0 to a final concentration of 15 mM. Lysates were 
clarified by centrifugation at 8000 g, 4
o
C for 10 min, transferred into new tubes, and snap-frozen on 
dry-ice.  
3.7.1.3. Immunoprecipitation 
Cell lysate volume equivalent to 7.5 x 10
6
 cells and 45 µL of ChIP-grade protein G magnetic beads 
were used for each immunoprecipitation reaction. Prior to use for pre-clearing, 30 µL magnetic beads 
were pre-washed with RIP buffer. The cell lysate was diluted to 500 µL with RIP buffer and added 
into the washed beads and pre-cleared by rotating at 4
o
C for 2 h. The beads were separated on a 
magnetic rack and the cleared lysate was transferred into a new tube. A volume corresponding to 5% 
input sample was aliquoted and 3 µg of antibody (Table 2-6) was added to the remaining lysate. 
Magnetic beads from 45 µL slurry were pre-washed and added into the hybridization reaction. 
Samples were incubated overnight with rotation at 4
o
C.  
3.7.1.4. Bead washing and RNA isolation 
Magnetic beads were collected and washed 4 times with ice-cold RIP wash buffer (3X SSC buffer, 1 
mM EDTA pH 8.0, 0.1% Tween-20, 1X PMSF) and once with ice-cold 1X PBS supplemented with 
1X PMSF. Crosslink reversal of input and beads was performed by adding 95 µL proteinase K buffer 
and 5 µL of proteinase K (20 mg/mL). Tubes were incubated at 65
o
C with shaking for 45 min, 
followed by enzyme deactivation at 95
o
C for 10 min. RNA from the samples were subsequently 
isolated using phenol/chloroform/isoamyl alcohol (125:24:1 mixture pH 4.3). Briefly, 100 µL of the 
phenol/chloroform/isoamyl alcohol reagent was mixed with the samples. After centrifugation at 
21,000 g, room temperature for 10 min, the upper aqueous phase was transferred into a fresh tube and 
mixed with 1 volume of chloroform. The samples were centrifuged at 20,000 g, room temperature for 
10 min and the upper aqueous phase was transferred into a fresh tube. To precipitate RNA, 3 µL 
GlycoBlue, 0.1 volume of 3 M pH 5.2 sodium acetate, and 1 volume of 100% isopropanol were added 
to the samples. After overnight incubation at -20
o
C, the RNA pellet was collected by centrifugation at 
20,000 g, 4
o
C for 30 min. The RNA was washed once with ice-cold 80% ethanol, air-dried, and 
resuspended in 11 µL nuclease-free water. Complementary DNA was synthesized as described in 
section 3.2.2 using the entirety of reconstituted RNA. Each 20 µL cDNA reaction volume was then 
diluted to 100 µL with nuclease-free water. Five microliters of cDNA was used in subsequent qPCR 
assays. 
3.7.1.5. RIP-qPCR 
RNA enrichments were quantified by qPCR as described in section 5.2.5 using primers in Table 2-9. 
Fold enrichment values were calculated as follows: 
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𝐹𝑜𝑙𝑑 𝑒𝑛𝑟𝑖𝑐ℎ𝑚𝑒𝑛𝑡 =  2[(𝐴𝐼 − 𝐶𝑝𝑝𝑢𝑙𝑙𝑑𝑜𝑤𝑛)14−3−3 𝐼𝑃 − (𝐴𝐼 − 𝐶𝑝𝑝𝑢𝑙𝑙𝑑𝑜𝑤𝑛)𝐼𝑔𝐺 𝐼𝑃]  
=
100% × (2𝐴𝐼−𝐶𝑝𝑝𝑢𝑙𝑙𝑑𝑜𝑤𝑛)14−3−3 𝐼𝑃
100% × (2𝐴𝐼−𝐶𝑝𝑝𝑢𝑙𝑙𝑑𝑜𝑤𝑛)𝐼𝑔𝐺 𝐼𝑃
 
=
% 𝑜𝑓 𝑖𝑛𝑝𝑢𝑡14−3−3 𝐼𝑃
% 𝑜𝑓 𝑖𝑛𝑝𝑢𝑡𝐼𝑔𝐺 𝐼𝑃
 
3.7.2. Affinity purification 
3.7.2.1. In vitro transcription 
Biotinylated LINC00920 RNA was generated by using T7 RNA polymerase with a biotin RNA 
labeling mix to transcribe the full length lncRNA cDNA previously cloned in pcDNA3.1(+). The 
vector harbors a T7 promoter upstream its multiple cloning site which can be used for in vitro 
transcriptional activation. Briefly, sequence-verified pcDNA3.1(+)_LINC00920 was digested with 
XbaI to obtain a linearized DNA template which was subsequently purified as described in section 
3.2.1. A linearized vector containing the Fluc gene was used as positive control for the reaction. Each 
20 µL transcription reaction consisted of 1X transcription buffer, 1X biotin labeling mix, 100 U T7 
RNA polymerase, 500-1000 ng DNA template, and nuclease-free water. The reaction mixtures were 
incubated at 37
o
C for 2 hours. To remove template DNA, the reaction volume was brought up to 50 
µL with nuclease-free water, supplemented with 4 U of RNase-free DNase-I, and incubated at 37
o
C 
for 15 min. The RNA product was purified using the RNeasy® Mini Kit. Optional poly-A tailing was 
performed by mixing 2000 ng purified RNA with 1X E. coli poly(A) polymerase reaction buffer, 1 
mM ATP, 0.5 U/µL Superase In
TM
 RNase inhibitor, and nuclease-free water to a final volume of 20 
µL. The reaction was incubated at 37
o
C for 30 min followed by RNA purification. RNA yield was 
quantified using NanoDrop 1000. RNA quality was assessed by electrophoresing 100 ng of sample 
through 1% agarose/1X MOPS/6% formaldehyde gels. RNA bands were visualized by staining with 
1X SYBR® Gold nucleic acid gel stain and viewing under UV light. 
3.7.2.2. Hybridization and purification 
Recombinant human 14-3-3ε protein (ab54317) was obtained from Abcam. For each affinity 
pulldown, 300 ng of recombinant protein and 0.5 pmol purified biotinylated RNA were hybridized. A 
day prior to the experiment, 50 µL Dynabeads™ M-270 Streptavidin bead slurry was washed and 
blocked with 0.1% BSA overnight at 4
o
C. Next day, 0.5 pmol RNA was diluted to 50 µL with RNA 
structure buffer (10 mM Tris-HCl pH 7.5, 0.1 mM KCl, 10 mM MgCl2) and denatured at 75
o
C for 2 
min and placed on ice. The recombinant protein was diluted to 1 mL with EMSA buffer (20 mM 
HEPES pH 7.6, 50 mM KCl, 3 mM MgCl2, 1 mM EDTA pH 8.0, 5 mM DTT) supplemented with 1X 
cOmplete, Mini protein inhibitor, 1X PMSF, and 0.05 U/µL Superase In
TM
 RNase inhibitor. RNase A 
treatment was performed by adding the enzyme at a final concentration of 10 µg/mL. Denatured RNA 
was then added to the protein solution and the tubes were incubated with rotation at room temperature 
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for 2 hours. Blocked beads were washed thrice with EMSA buffer and added to the hybridization 
solution. Bead capture was facilitated at room temperature for 10 min. The beads were magnetically 
separated and washed 5 times with ice-cold RIP wash buffer. Proteins were eluted by resuspending the 
beads in 30 µL 1X Roti®-Load 1 protein loading buffer followed by incubation at 95
o
C for 5 min. The 
beads were separated and discarded while the supernatant was used for polyacrylamide gel 
electrophoresis and western blot as described in sections 3.2.4 and 3.2.5.  
3.8. Statistical analyses 
All quantitative data were presented as mean ± standard error (SE). Unpaired t-test was used to accept 
or reject the null hypothesis that there was no significant difference between the control and treated 
conditions with respect to cellular phenotypes (i.e., cell proliferation, colony formation, cell 
migration), expression levels (i.e., relative gene expression, luciferase assays), and enrichment values 
(i.e., as determined by ChIP-, RAP-, and ChIRP-qPCR). 
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4. Results 
4.1. Long non-coding RNA candidate selection 
Differentially expressed lncRNAs from the ICGC-EOPC whole transcriptome sequencing data were 
screened for promising candidates that may play a role in prostate cancer development or progression. 
This cohort consisted of 125 prostate tumor and 10 normal tissue specimens that were sampled from 
early onset PCa patients (i.e., under the age of 50). A DeSeq analysis was previously performed on the 
transcriptome data (Figure 4-1) and the lncRNA selection process was guided by the following 
criteria: (i) the non-coding transcript must be of the long intergenic RNA (lincRNA) biotype; (ii) there 
should not be a gene in the antisense orientation; (iii) the lncRNA must have at least 2 exons; (iv) the 
average transcript count (i.e., baseMean value) must be at least 500 for either the tumor or normal 
sample group; (v) a significant (p value<0.05) up- or downregulation must be observed between the 
tumor and normal sample group (log2FC >|1|); (vi) the presence of specific genetic and epigenetic 
elements within the 50 kbp locus of the candidate gene (e.g., active transcription marks, CpG islands, 
oncogenes, or tumor suppressor genes); (vii) and expression profiles in agreement with annotations in 
relevant databases (i.e., TCGA [75], MiTranscriptome [222]). Subsequently, 7 lncRNAs were 
considered for further investigation (Figure 4-1 and Table 4-1). 
 
Figure 4-1. MA plot of 7,335 long intergenic RNAs (lincRNAs) analyzed by DeSeq. Red 
points represent significantly upregulated transcripts (p>0.05, log2[fold change]>1.2). Blue 
points represent significantly downregulated transcripts (p>0.05, log2[fold change]<1.2). 
Labelled points correspond to shortlisted lncRNA candidates further investigated in this study.  
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Table 4-1. Summary of DeSeq analysis and annotations of selected PCa-related lncRNAs. 
Candidate 
Relative 
expression 
Highest 
baseMean 
count  
(tumor or 
normal) 
Fold-
change  
over  
normal 
tissue 
p-value 
Available 
annotation 
RP11-867G23.3 
ENST00000501708.1
# Upregulated 3903.975 5.845 0.018 None 
RP11-3P17.5 
ENST00000602890.1
#
 
Upregulated 873.214 5.201 0.022 
Upregulated in 
prostate tumors
§
 
LINC00920 
ENST00000499966.1
#
 
Upregulated 538.437 3.270 0.014 
Upregulated in lung, 
breast, colorectal 
carcinoma*; 
correlates with ERG 
mRNA expression
§
 
LINC00844 
ENST00000432535.1
#
 
Downregulated 6331.756 0.067 1.11 x10
-10
 
Downregulated in 
breast, lung, 
prostate tumors* 
LINC01082 
ENST00000601250.1
#
 
Downregulated 1457.759 0.153 1.26 x 10
-11
 
Downregulated in 
colorectal, prostate 
tumors* 
RP11-395L14.4 
ENST00000416105.1
#
 
Downregulated 1573.445 0.169 4.96 x 10
-11
 
Downregulated in 
prostate tumors with 
TP53 mutation
§
 
SNHG18 
ENST00000508179.1
#
 
Downregulated 1885.687 0.320 8.54 x 10
-5
 
Downregulated in 
breast, lung, 
prostate tumors* 
#
Ensembl transcript ID; 
§
TANRIC annotation; *TCGA annotation;  
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Figure 4-2. Transcript quantitation of the short-listed lncRNAs in the ICGC-EOPC 
dataset. FPKM: fragments per kilobase per million mapped reads. 
4.2. Selected lncRNAs exhibit characteristic expression profiles in prostatic cell lines 
LNCaP, VCaP, DU-145, and PC-3 cells were used as prostate cancer models to validate lncRNA 
expression in vitro. LncRNA expression levels from these metastatic lines were compared with the 
benign prostate epithelial cell line RWPE-1 to assess the relative expression (Figure 4-3). The 
transcription level of each lncRNA candidate varied among cell lines, which was not surprising given 
the unique genetic background and phenotype of the cells. At the same time, this further corroborates 
widespread reporting of lncRNAs being highly cell type-specific [157, 159, 223-225]. Candidates 
determined to be upregulated in the ICGC-EOPC cohort (i.e., RP11-867G23.3, LINC00920, and 
RP11-3P17.5) were overexpressed only in specific cell lines (Figure 4-3A). Briefly, RP11-867G23.3 
was found to be highly expressed in VCaP, while LINC00920 was upregulated in both VCaP and PC-3 
cells. On the other hand, RP11-3P17.5 appeared to have comparable expression levels across all cell 
lines including RWPE-1. A similar generalization of cell-type specific expression can also be made for 
the downregulated candidates (i.e., LINC00844, LINC01082, SNHG18, and RP11-395L14.4) (Figure 
4-3B and 3C). For RP11-395L14.4, amplification signals were detected only in RWPE-1, DU-145, 
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and PC-3. SNHG18 was measurable only in RWPE-1 and PC-3 cells. LINC00844 and LINC01082 
were not detected in any of the cell lines tested using a threshold Cp value of 35, but their expression 
was validated in normal prostate tissue using a standard reference RNA source (Invitrogen
TM
 Thermo 
Fisher Scientific; Figure 4-3C). 
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Figure 4-3. Representative expression profiles of lncRNA targets in indicated prostatic 
cell lines. (A) Upregulated lncRNAs. (B) Downregulated lncRNAs with measurable signals. 
Broken lines denote fold change = 1. Number signs (#) denote infinitely small or undetectable 
qPCR signals (i.e., Cp>35 or Cp=0). Changes in gene expression were analyzed using RWPE-1 
as the normalizing control (*p≤0.05; **p≤0.01; ***p≤0.001). (C) Downregulated lncRNAs 
that were undetectable in all prostate cancer cell lines by qPCR. Broken lines denote the 
threshold Cp value of 35 cycles. HuPros: standard human prostate RNA sample. 
4.3. Rapid amplification of cDNA ends reveals polyadenylation of candidate lncRNAs 
At present, lncRNA annotation remains highly dynamic and subject to frequent revisions [226, 227]. 
Rapid amplification of cDNA ends (RACE) [228] was performed on the selected lncRNAs to 
determine the correct gene transcription start site, the actual length of transcript, and the presence of 
polyadenylation at the 3’ terminal end. Amplification of transcript cDNA was performed using 
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standard human prostate as RNA source. The cDNA ends of all lncRNA candidates except RP11-
867G23.3—for which amplified end fragments consistently mapped to non-specific genomic 
regions—and RP11-3P17.5—whose 5’-end could not be primed—were successfully amplified, 
aligned, and cloned (Figure 4-4). Since an oligo dT primer was used for cDNA synthesis, 3’-end 
amplification was limited to transcripts harboring a polyadenylated tail. Indeed, it was possible to 
amplify the 3’-ends of RP11-3P17.5, LINC00920, LINC00844, LINC01082, RP11-395L14.4, and 
SNHG18 these transcripts do possess this post-transcriptional modification. 
For the most part, the transcript termini validated by RACE aligned correspondingly and with high 
fidelity to reference sequence databases. However, length divergence of a few nucleotides is apparent 
in many cases. This may be due to the cell-type specificity of transcript isoforms, as the RACE 
experiments were exclusively performed on prostatic RNA. It is also worth noting that reference 
annotations for RP11-3P17.5 (Figure 4-4A), LINC00844 (Figure 4-4C) and LINC01082 (Figure 
4-4D) were missing from the UCSC Genes track, while LINC00920 annotations from UCSC Genes 
and GENCODE (Figure 4-4B) showed dissimilar 3’ ends. A detailed inspection of LINC00920 exon 2 
sequence revealed eight polyadenylation signals (i.e., AATAAA or ATTAAA motifs), two of which 
could putatively enable transcript processing that would result in the 3’-end determined by RACE 
(Figure 4-4G). Similarly, polyadenylation signals preceeding the 3’-ends of LINC00844 and SNHG18 
were also observed (Figure 4-4H and 4I). Interestingly, for transcripts with more than one splice 
variant, specifically RP11-395L14.4 (Figure 4-4E) and SNHG18 (Figure 4-4F), sequencing of cDNA 
ends appeared to identify the most likely predominant splice isoform in the context of prostate cells. 
Altogether, these observations highlight the cell-type specificity of gene transcription as well as the 
current limitations of reference sequence databases, specifically in annotating lncRNAs.  
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Figure 4-4. Aligned sequences of cloned cDNA ends derived from RACE experiments.  
(A) RP11-3P17.5; (B) LINC00920; (C) LINC00844, (D) LINC01082; (E) RP11-395L14.4; (F) 
SNHG18. Purple tracks correspond to UCSC Genes. Green tracks correspond to GENCODE 
comprehensive annotation. Black tracks correspond to transcript termini identified by RACE. 
Detailed views of LINC00920 exon 2 (G), LINC00844 exon 2 (H), and SNHG18 exon 3 (I) 
based on the GENCODE annotation. The labelled gray bar correspond to the cloned 3’-end of 
the lncRNA. Polyadenylation signals are indicated by colored bars. Putative polyadenylation 
signals for the RACE transcript are in green. 
 
Due to the incomplete information on the transcript structure of RP11-867G23.2 and RP11-3P17.5, 
the candidate list was shortened to the five remaining lncRNAs. Table 4-2 summarizes the RACE 
experiment results. 
Table 4-2. Summary of RACE results. 
Candidate 
Annotated transcript  
length (nt)* 
5’-end 3’-end 
Transcript length  
based on prostate RNA 
RACE (nt) 
RP11-867G23.3 
ENST00000501708.1 
2792 Not cloned Not cloned n/a 
RP11-3P17.5 
ENST00000602890.1 
248 Not cloned Cloned n/a 
LINC00920 
ENST00000499966.1 
2147 Cloned Cloned 1567 
LINC00844 
ENST00000432535.1 
477 Cloned Cloned 407 
LINC01082 
ENST00000601250.1 
441 Cloned Cloned 490 
RP11-395L14.4 
ENST00000416105.1 
537 Cloned Cloned 580 
SNHG18 
ENST00000508179.1 
1799 Cloned Cloned 1533 
*Ensembl release 75 – Feb. 2014; n/a: not analyzed 
4.4. Amplification and cloning of full-length transcripts 
Amplification and cloning of full-length cDNAs were performed with the aim of generating 
overexpression constructs to functionally characterize the lncRNA candidates in prostate cancer cell 
lines. Candidate-specific primers were designed to amplify the complete transcript cDNA from a 
reference human prostate RNA template based on the outcome of RACE experiments. Successful 
amplification and sequencing of full-length LINC00920, LINC00844, and LINC01082 were achieved 
(Figure 4-5). On the other hand, despite exhaustive attempts to amplify SNHG18 and RP11-395L14.4, 
no PCR amplicons yielded fragments that matched the expected size, or aligned to the reference 
sequence (data not shown). 
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Figure 4-5. Amplification and sequencing of the full length (FL) cDNA of lncRNA targets.  
PCR products for (A) LINC00920 (1567 bp), (B) LINC00844 (407 bp), and (C) LINC01082 
(441 bp) were loaded in 2% agarose gels and stained with ethidium bromide. Alignment tracks 
are shown on the right of each agarose gel image. 
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The amplified cDNA fragments corresponding to LINC00920, LINC00844, and LINC01082 were 
initially cloned into pCR
TM
4Blunt-TOPO®, subcloned into the mammalian expression vector 
pcDNATM3.1(+), and sequence-verified by Sanger sequencing (Supplementary Table 9-1). Going 
forward, LINC00920 was selected for further investigation due to its overexpression in tumors which 
suggested an oncogenic function. Moreover, among the remaining candidates, only LINC00920 
demonstrated robust expression in the PCa cell lines tested (Section 4.2), enabling the possibility of 
performing functional analysis through gene silencing. Lastly, the high endogeous expression of 
LINC00920 would be advantageous for subsequent RNA pulldown assays. 
4.5. Multiple models validate the non-coding potential of LINC00920 
Three transcript assessment platforms—Coding-Potential Assessment Tool (CPAT) [200], Coding 
Potential Calculator (CPC) [201], and Phylogenetic Codon Substitution Frequencies (PhyloCSF) 
[229]—were utilized to confirm the non-coding potential of LINC00920 (Figure 4-6). Using the 
transcript sequence verified by RACE, the CPAT and CPC scores were computed for LINC00920 
alongside ACTB (ENST00000331789.5) and GAPDH (ENST00000396861.1) mRNAs as coding 
transcript controls and MALAT1 (ENST00000534336.1) and NEAT1 (ENST00000501122.2) as non-
coding controls. As expected, CPAT scores for ACTB and GAPDH mRNA were above the human 
coding threshold score of 0.364 [200] while values for MALAT1, NEAT1, and LINC00920 transcripts 
were diminishingly low (Figure 4-6A). Evaluation of the CPC coding potential also presented a 
similar trend wherein ACTB and GAPDH transcripts had positive scores while the control lncRNAs 
and LINC00920 produced negative values (Figure 4-6B). Positive PhyloCSF codon scores indicate 
increased likelihood of a particular region to be protein coding in a specified reading frame. 
Visualizing the LINC00920 transcript alongside PhyloCSF tracks for the three forward reading frames 
revealed negative codon scores for regions where evaluation is possible (green tracks) (Figure 4-6C). 
Altogether, these tests affirm that LINC00920 is a non-coding transcript. 
AC
TB
G
AP
D
H
M
AL
AT
1
N
E
AT
1
LI
N
C
00
92
0
0.0
0.5
1.0
1.5
CPAT
0.014
0.024
0.004
0.999 0.999
C
o
d
in
g
 p
ro
b
a
b
il
it
y
AC
TB
G
AP
D
H
M
AL
AT
1
N
E
AT
1
LI
N
C
00
92
0
-2
-1
0
1
2
3
CPC
2.833
2.436
-1.007
-0.836
-1.223
C
o
d
in
g
 p
o
te
n
ti
a
l
s
c
o
re
PhyloCSFA B C
 
Figure 4-6. Validation of the non-coding potential of the LINC00920 transcript. (A) 
Coding-Potential Assessment Tool (CPAT), (B) Coding Potential Calculator (CPC) and (C) 
Phylogenetic Codon Substitution Frequencies (PhyloCSF) were used to assess the non-coding 
potential of LINC00920. The dashed line in (A) indicates the human coding threshold score of 
0.364. ACTB and GAPDH were used as coding transcript controls while MALAT1 and NEAT1 
were used as non-coding transcript controls.   
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4.6. Silencing of LINC00920 results in decreased cellular proliferation, migration, and 
colony formation of PC-3 cells 
To query whether LINC00920 has a functional role in prostate cancer cells, knockdown experiments 
were performed in PC-3 cells wherein the lncRNA exhibits a relatively high expression as previously 
described (Section 4.2). Two independent siRNAs were able to efficiently silence the transcript by at 
least 80% (Figure 4-7A). The proliferative capacity of cells transfected with LINC00920-targeting 
siRNAs was significantly reduced at the 72- and 96-h post-transfection time points (Figure 4-7B). 
These cells also formed fewer colonies after 9 days of cultivation (Figure 4-7C-D). There was also a 
marked decrease in their migratory potential across a Boyden chamber (Figure 4-7E-F). However, the 
transfected cells did not show remarkable changes in invasive capacity through Matrigel (data not 
shown).  
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Figure 4-7. Functional assays performed on PC-3 cells upon LINC00920 siRNA 
knockdown. (A) SiRNAs targeting LINC00920 successfully reduced gene expression at the 
transcript level for subsequent cell assays.  (B) PC-3 cells transfected with LINC00920 siRNAs 
have decreased proliferative capacity beginning at 72-h post transfection. (C-D) Cells 
transfected with LINC00920 siRNAs formed fewer cell colonies. (E-F) Cells transfected with 
LINC00920 siRNAs had reduced migratory potential. (NTC: non-targeting control; **p≤0.01; 
***p≤0.001; white bars: 300 µm) 
   
 
 
 
 67 
To gain further insight on which cellular and biological processes LINC00920 could participate in that 
would lead to the observed phenotypes, gene expression arrays were performed upon lncRNA 
knockdown. The Human HT-12 v4 Expression Bead Chip from Illumina—consisting of 47000 probes 
corresponding to 31000 annotated genes—was the microarray platform used. Normalized expression 
values were processed in two ways. First, Gene Set Enrichment Analysis (GSEA) [203] was 
conducted on all annotated genes ranked according to fold-change values. Knockdown of LINC00920 
by two independent siRNAs resulted in common negatively enriched curated and gene ontology (GO) 
gene sets. The gene sets involved processes such as cell division, cell cycle, microtubule-based 
movement, and apoptosis, among others (Figure 4-8A). Such perturbed pathways could explain the 
observed phenotypes upon lncRNA knockdown. A second analysis was conducted on 315 genes 
shared among the top 1000 upregulated and downregulated genes upon knockdown by the two 
siRNAs (Figure 4-8B). Subsequent Ingenuity Pathway Analysis (IPA) performed on these genes 
showed “Cellular Development”, “Cellular Growth and Proliferation”, “Cell Death and Survival”, 
“Cellular Movement”, and “Gene Expression” as the top molecular and cellular functions deregulated 
upon LINC00920 knockdown (Figure 4-8C). Moreover, FOXO signaling activation was predicted in 
both microarray datasets particularly activation of FOXO3, FOXO1, and FOXO4 transcription factors 
(Figure 4-8D).  
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Figure 4-8. Microarray analysis upon LINC00920 knockdown in PC-3 cells. (A) Top 
negatively enriched curated and gene ontology gene sets based on Gene Set Enrichment 
Analysis (GSEA) for LINC00920 knockdown using 2 independent siRNAs. (B) Strategy in 
selecting analysis genes for Ingenuity Pathway Analysis (IPA). (C) Top deregulated molecular 
and cellular functions and (D) top activated transcriptions factors upon LINC00920 knockdown 
based on IPA. 
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4.7. LINC00920 knockdown increases expression of FOXO target genes in PC-3 
To first verify the effect of LINC00920 on FOXO activity, the expression of the canonical FOXO 
targets BCL2L11 [230, 231], GADD45A [232], and PMAIP1 [233] was assessed upon lncRNA 
knockdown or overexpression in PC-3 cells. In agreement with the predicted activation of FOXO 
signaling, a general trend of increased FOXO target expression was observed upon LINC00920 
knockdown using five independent siRNAs (Figure 4-9). Four siRNAs showed the same trend for 
BCL2L11 and GADD45a, and 2 siRNAs for PMAIP1. All expression values were normalized using a 
scrambled siRNA control. Furthermore, episomal overexpression of LINC00920 (pLINC00920) led to 
significant reduction of all FOXO targets in comparison with the empty vector control. The moderate 
upregulation of all FOXO targets upon LINC00920 knockdown most likely stemmed from 
hyperphosphorylation of AKT due to PC-3 cells harboring a homozygous PTEN deletion [234, 235]. 
Because of this increased AKT activity, and consequentially robust FOXO phosphorylation, 
LINC00920 knockdown would only be expected to have a marginal effect on the levels of FOXO 
targets. To test this rationale, AKT inhibition using the pan-AKT inhibitor ipatasertib [207] was 
performed in addition to lncRNA knockdown. 
Accordingly, a compounded increase in expression of all FOXO targets was observed in LINC00920-
knockdown cells treated with ipatasertib (Figure 4-9). With AKT signaling attenuated in PC-3 cells, 
the p-FOXO/FOXO ratio must have been within a window wherein the impact of LINC00920 is still 
observable. This is in contrast to untreated cells where further LINC00920 knockdown could not 
reactivate FOXO signaling due to an endogenously low FOXO activity level and an unchecked AKT 
pathway.  
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Figure 4-9. Perturbation of LINC00920 levels in ipatasertib-treated PC-3 cells influences 
expression of FOXO targets. Five independent siRNAs were used to silence LINC00920 and 
FOXO activity was evaluated by the expression of (A) BCL2L11, (B) GADD45A, and (C) 
PMAIP1, which are known targets of FOXO proteins. Minimal to no upregulation of FOXO 
targets were observed upon LINC00920 knockdown in the control (without ipatasertib 
treatment). In ipatasertib-treated cells, LINC00920 knockdown resulted in significant 
upregulation of all FOXO targets. Overexpressing LINC00920 on the other hand led to the 
downregulation of FOXO targets in both control and ipatasertib-treated cells. (D) Quantitation 
of LINC00920 levels upon siRNA-mediate knockdown and episomal overexpression. All 
expression values were normalized to the housekeeping gene HPRT1. Fold change values were 
calculated relative to a scrambled siRNA control. (*p≤0.05; **p≤0.01; ***p≤0.001)  
 
Similarly, in T2E-positive VCaP cells, LINC00920 knockdown using two independent siRNAs 
resulted in the increased expression of BCL2L11, GADD45A, and PMAIP1 (Figure 4-10). Taken 
together, these experiments provide evidence for the inverse correlation between LINC00920 
transcript levels and FOXO signaling activity in prostate cancer cells.  
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Figure 4-10. Perturbation of LINC00920 levels in VCaP cells also influences expression of 
FOXO targets. Two independent siRNAs were used to silence LINC00920 and FOXO activity 
was evaluated by the expression of (A) BCL2L11, (B) GADD45A, and (C) PMAIP1, which are 
known targets of FOXO proteins. Upregulation of  FOXO targets were observed upon 
LINC00920 knockdown using both siRNAs. (D) Quantitation of LINC00920 levels upon 
siRNA-mediate knockdown. All expression values were normalized to the housekeeping gene 
HPRT1. Fold change values were calculated relative to a scrambled siRNA control. (*p≤0.05; 
**p≤0.01; ***p≤0.001) 
4.8. The oncogenic transcription factor ERG drives LINC00920 transcription 
VCaP cells harbor a copy of the TMPRSS2:ERG gene fusion [236] commonly detected in 
TMPRSS2:ERG positive tumors (TMPRSS2:ERGa) [93, 94] which allows for androgen-dependent 
upregulation of ERG. ERG activity is the plausible cause for the relatively high LINC00920 
expression observed in this cell line. Indeed, expression analysis conducted for both genes in the 
ICGC-EOPC (n=135) and TCGA-PRAD (n=568) [75] cohorts revealed a positive correlation between 
ERG and LINC00920, with Pearson values of 0.57 and 0.45, respectively (Figure 4-11). To test the 
causality of this correlation, siRNA-mediated knockdown of ERG or LINC00920 in VCaP cells was 
performed, respectively, followed by expression quantification of the other gene. While an almost 
50% ERG knockdown resulted in a consequential downregulation of LINC00920 (Figure 4-12A), 
knockdown of the lncRNA did not have a significant effect on ERG expression (Figure 4-12B). 
Furthermore, in a tet-inducible ERG overexpression LNCaP model [97], a concomitant increase in 
LINC00920 expression was observed upon doxycycline induction in a temporal manner (Figure 
4-12C). 
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Figure 4-11. ERG and LINC00920 show positive gene expression correlation. Correlation 
analyses performed on the (A) ICGC-EOPC and (B) TCGA-PRAD RNA-seq data. A heatmap 
and a scatterplot are shown for both cohorts. The Pearson correlation value is indicated at the 
top right corner of each scatterplot.  
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Figure 4-12. ERG expression directly influences LINC00920 transcription. (A) ERG 
knockdown using two independent siRNAs significantly decreased LINC00920 levels in VCaP 
cells. (B) In contrast, LINC00920 knockdown did not perturb ERG expression. (C) In a tet-
inducible ERG overexpression LNCaP model, progressive LINC00920 upregulation was 
observed upon doxycyline induction. (**p≤0.01; ***p≤0.001)  
 
Chromatin immunoprecipitation (ChIP) and promoter luciferase assays were performed to query the 
underlying mechanism behind the positive influence of ERG on LINC00920 expression. These 
experiments were performed to clarify whether LINC00920 transcription is directly controlled by ERG 
through its function as a transcription factor, or by a secondary ERG-dependent mechanism. 
Chromatin marks from published PC-3 ChIP-seq datasets [210] were examined and overlayed 
upstream the lncRNA TSS to guide the identification of the bona fide promoter region of LINC00920. 
The -1000 bp window showed simultaneous positive enrichments for H3K27ac, H3K3me3, and RNA 
polymerase II, indicating promoter activity (Figure 4-13A) [237]. Within this region, two putative 
ETS binding domains harboring the core GGA(A/T) (Figure 4-13B) [99] motif were predicted using 
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JASPAR [218] at a stringent threshold score of 85% (Figure 4-13C). ChIP was performed in VCaP 
cells to determine whether the identified ETS domains are legitimate ERG binding sites. ChIP primers 
were designed to be in close proximity with the two binding domains (Figure 4-14A). In contrast to 
chromatin precipitated with IgG control, ERG precipitation resulted in significant enrichment of 
regions amplified by all three primer pairs (Figure 4-14B). The specificity of enrichments was also 
apparent upon comparison with negative control primers targeting a non-genic region.  
 
Figure 4-13. LINC00920 promoter region analysis reveals putative ERG binding sites.  
(A) Genomic region 1000 bp upstream of the LINC00920 TSS (highlighted in red) show 
occupancy of  active promoter marks H3K27ac, H3K4me3, and RNA polymerase II (RNAP 
II). (B) The GGA(A/T) ETS binding motif . (C) Sequence analysis of the LINC00920 promoter 
region using JASPAR  revealed two putative domains harboring the ETS binding motif.  
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Figure 4-14. ERG chromatin immunoprecipitation at the LINC00920 promoter in VCaP 
cells.  (A) The gene structure of LINC00920 with the inset showing the target regions of ChIP 
primers around the predicted ETS domains (gray). (B) Significant enrichment of LINC00920 
promoter fragments over a non-genic control (NC) was observed in ERG-precipitated DNA as 
quantified by qPCR using three primer pairs.  (***p≤0.001)  
 
Promoter luciferase assays were conducted to further characterize the ERG-mediated activation of 
LINC00920 transcription. The 1000 bp promoter fragment was initially amplified from PC-3 genomic 
DNA. Mutagenic primers were designed to introduce a double transversion (GG>CC) in the ETS 
GGA(A/T) motif [98]. While a single round of PCR was sufficient to introduce the mutations within 
ETS domain 1, overlap-extension PCR was performed to mutate the second ETS domain which is 
further upstream of the 3’-end of the promoter (Figure 4-15). These promoter fragments, together with 
a 1000-bp non-genic control DNA, were cloned upstream the luciferase reporter gene luc2 (Figure 
4-16). The promoter constructs were cotransfected with a Renilla luciferase containing vector into the 
tet-inducible LNCaP cells described previously [97]. Luminescence was measured as the readout of 
promoter activity upon doxycycline induction (Figure 4-17). Compared with empty vector and non-
genic controls, there is a significant increase in luminescence in cells transfected with the wild-type 
LINC00920 promoter construct. While mutation of the ETS domain immediately upstream of the TSS 
(ETS domain 1) did not significantly affect the luminescence signal compared with the wild-type 
(p=0.2627), a general trend of decrease was observed in replicate experiments. On the other hand, 
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mutation of the ETS domain 2 resulted in significantly diminished luciferase activity compared to the 
wild-type construct. It is noteworthy that despite abolishing the ETS domain 2, there was still residual 
signal of greater intensity approaching significance (p=0.0694) compared to the non-genic control that 
could be attributed to the intact ETS domain 1. Taken together, while ETS domain 2 appears to be the 
preferred ERG binding region, ETS domain 1 could potentially be a supplemental binding site. These 
results, together with the ChIP-qPCR data, clearly show that ERG regulates LINC00920 transcription 
by promoter binding, primarily at the ETS binding domain located -60 bp relative to the TSS. 
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Figure 4-15. Site-directed mutagenesis of the ETS domains within the LINC00920 
promoter.  (A) Overlap extension PCR was performed to mutate ETS domain 2. Briefly, a 
wild-type 5’-end forward primer (P1: F) and a mutant reverse primer targeting the span of the 
ETS domain (P1: R*) were used to generate the mutant 5’-end intermediate (PCR 1). 
Simultaneously, the 3’-end intermediate was generated (PCR 2) using a mutant forward primer 
overlapping the same region as P1: R* (P2: F*) and a wild-type 3’-end reverse primer (P2: R). 
The intermediate fragments were used as template in the final round of PCR (PCR 3) to 
generate the full-length mutant product. (B) The 982 bp, 5’-end intermediate fragment. (C) The 
84 bp, 3’-end intermediate fragment. (D) The full-length mutant LINC00920 promoter. (E) 
Sanger sequencing traces showing the GG>CC (highlighted) transversions introduced in the 
two ETS domains. 
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Figure 4-16. Generation of promoter constructs for luciferase assays. The wild-type and 
mutant LINC00920 promoter fragments, together with a non-genic negative control, were 
initially cloned into pCR®2.1-TOPO® and propagated. The pCR®2.1-TOPO® constructs 
were digested with SpeI and XhoI to generate promoter fragments with compatible ends for 
subcloning. The recipient pGL4.10[luc2] vector was linearized using NheI and XhoI to enable 
ligation of promoter fragments upstream the luciferase gene. *SpeI and NheI produce 
compatible cohesive ends.  
 
 
Figure 4-17. Normalized luciferase signals upon transfection of pGL4.10[luc2] constructs 
with wild-type or mutant LINC00920 promoter fragments into tet-inducible ERG 
overexpression LNCaP cells. Empty vector and non-genic DNA controls did not show 
increased luciferase activity upon transfection. In contrast, the wild-type promoter showed a 
marked increase of luciferase signal.  The ETS domain 1 (ETS 1) mutant tended to diminish 
promoter activity in comparison with the wild-type, but the shifts in signal did not reach 
significance. On the other hand, the ETS domain 2 (ETS 2) mutant significantly decreased 
promoter activation compared with the wild-type fragment, suggesting its greater relevance for 
ERG binding. (*p≤0.05) 
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4.9. The ETS family member ETV4 potentially regulates LINC00920 expression in PC-3 
cells 
Since PC-3 cells do not harbor the TMPRSS2:ERG allele, another ETS family member most likely 
mediates LINC00920 overexpression in this cell line. ETV4 has previously been described to be 
highly expressed in PC-3 compared to other prostatic cell lines [238]. This observation was 
recapitulated at the transcript level (Figure 4-18). SiRNA-mediated knockdown of ETV4 was 
performed in PC-3 cells to determine the regulatory effect of ETV4 on LINC00920. At least 90% 
ETV4 knockdown was achieved using two independent siRNAs (Figure 4-19). Interestingly, 
LINC00920 levels were reduced to about 50% upon ETV4 knockdown, suggesting promiscuity 
between ERG and ETV4 in regulating the lncRNA expression.   
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Figure 4-18. Normalized gene expression levels of ETS family members ETV4 and ERG 
in PCa cell lines relative to normal human prostatic tissue. While the prostate epithelial cell 
line RWPE-1 and the metastatic line DU-145 showed modest increase ETV4 expression, PC-3 
cells overexpress ETV4 approximately 10-fold higher compared with normal prostatic tissue 
(HuPros). Among the PCa cell lines tested, only VCaP, which harbors a TMPRSS2:ERG allele 
showed striking upregulation of ERG. 
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Figure 4-19. Dependence of LINC00920 transcription level on ETV4. ETV4 knockdown 
using two independent siRNAs significantly decreased LINC00920 levels in PC-3 cells. 
(*p≤0.05) 
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4.10. Mature LINC00920 transcripts are present in the nuclear and cytosolic compartments 
Similar to proteins, the function of lncRNAs is significantly tied to their subcellular localization. A 
selective lysis protocol which fractionates chromatin-bound, nucleoplasmic, and cytoplasmic RNA 
[208] was applied to PC-3, VCaP, and LNCaP cells. Quantitative PCR using primers spanning the 
intron of LINC00920 was carried out to determine whether mature and processed LINC00920 
transcripts are enriched in a specific compartment. Cytosolic HPRT1 and GAPDH transcripts as well 
as nuclear lncRNAs NEAT1 and MALAT1 were quantified in parallel for reference. As expected, 
NEAT1 and MALAT1 were overwhelmingly abundant in the nuclear fraction of all cell lines, with 
particularly high chromatin fraction enrichment in PC-3 and LNCaP cells (Figure 4-20). In contrast, 
HPRT1 and GAPDH had distribution profiles of higher cytoplasmic enrichment compared to the 
nuclear controls in PC-3 and LNCaP cells. For all cell lines tested, LINC00920 can be detected in all 
compartments, with higher nuclear distributions (nucleoplasm and chromatin) in PC-3 and VCaP. The 
presence of the lncRNA in the chromatin fraction, particularly in PC-3 cells, hints at potential 
functional interaction with chromosomal regions. The distribution of LINC00920 across all 
compartments also raises the possibility of dynamically shuttling between the nucleus and the 
cytoplasm which could be a cause or a consequence of a particular cellular process.  
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Figure 4-20. Subcellular distribution of LINC00920 in selected PCa cell lines. LINC00920 
levels were compared with cytoplasmic-enriched (i.e., HPRT1, GAPDH) and nuclear enriched 
(i.e., NEAT1, MALAT1) transcript controls.  
 
4.11. Putative role of LINC00920 at enhancer regions as revealed by chromatin isolation by 
RNA purification-high throughput sequencing (ChIRP-seq)  
Because a considerable fraction of mature LINC00920 transcripts were chromatin associated, it was 
reasonable to hypothesize that the lncRNA could have functional consequences on chromatin structure 
maintenance or on gene regulation. To address this, chromatin isolation by RNA isolation (ChIRP) 
[194] (Figure 4-21) was performed on PC-3 cells where endogenous LINC00920 expression was 
among the highest in the PCa cell lines tested. Chromatin shearing conditions were optimized using 
Bioruptor® Pico. For 6 x 10
6
 cells suspended in 300 µL lysis buffer, 35 sonication cycles were 
required to obtain the ideal uniform RNA length distribution between 100 to 1000 nt (Figure 4-22A) 
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[128, 194]. Simultaneously, this degree of shearing also led to chromatin solubilization. A 
considerable fraction of the chromatin was reduced down to 100 to 300 bp, peaking around the 
nucleosomal length of about 150 bp (Figure 4-22B). 
 
Figure 4-21. Chromatin isolation by RNA precipitation (ChIRP). Prior to pulldown, cells 
are crosslinked to preserve RNA interactions and then sonicated for chromatin solubilization.  
The resulting lysate is hybridized with a pool of tiling, biotinylated 20-mer DNA 
oligonucleotides antisense to the target transcript. Purification using streptavidin magnetic 
beads enriches target RNA complexes. For subsequent mass spectrometry, proteins are eluted 
by benzonase digestion. For DNA preparation, nucleic acids are eluted by proteinase K 
digestion, followed by DNA precipitation.  
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Figure 4-22. Optimization of sonication conditions for crosslinked PC-3 cells. Distribution 
of (A) RNA and (B) chromatin lengths were monitored at the indicated number of shearing 
cycles. Each shearing tube contains 6 million cells in 300 µL lysis buffer. The optimal cycle 
number was taken to be 35—the intermediary between 30 and 40 cycles—which would shear 
RNA and chromatin down to the ideal fragment range. 
 
Thirty 20-nt biotinylated single stranded DNA (ssDNA) oligos antisense to the target transcript 
(Figure 4-23A) were used to establish the RNA pulldown protocol. In small-scale experiments 
consisting of 2 x 10
6
 cells per pulldown, transcript enrichment was determined by quantitative PCR. 
Oligos targeting the lacZ transcript, which is normally absent in human cells, were used as negative 
control. The lacZ oligos did not enrich either MALAT1 or LINC00920 after RNA pulldown. In 
contrast, highly selective lncRNA enrichments were achieved for both LINC00920 (Figure 4-23B) 
and MALAT1 (Figure 4-23C) oligos.  
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Figure 4-23. Establishment of the ChIRP protocol by targeting LINC00920 and MALAT1 
lncRNAs.  (A) Pools of 30 biotinylated, antisense, 20-mer DNA oligos were used to ChIRP 
LINC00920 and MALAT1. Alignments of the oligos along the full transcript are shown for both 
lncRNAs. For sequences, see Table 2-12. Significant specific enrichments for LINC00920 (B) 
and MALAT1 (C) were achieved using the pooled oligos  in glutaraldehyde-fixed PC-3 cells. 
(D) Formaldehyde crosslinking did not result in enrichments for known MALAT1 chromatin 
targets. (E) Glutaraldehyde crosslinking showed considerable improvement in enriching the 
same MALAT1 targets. (*p≤0.05; **p≤0.01; ***p≤0.001) 
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All RNA methods aiming to map chromatin binding sites begin with a cross-linking step critical in 
preserving the chromosomal location of the target transcript [187]. Both formaldehyde and 
glutaraldehyde are chemical cross-linkers that have been used to capture in vivo RNA interactions 
[128, 192, 194]. Due to its small size, formaldehyde can preserve interactions within a 2 Å range, 
making it an ideal reagent for identifying molecules associating in close proximity [239]. Additionally, 
formaldehyde cross-links are reversible upon mild heating in an appropriate buffer, allowing retrieval 
of the interacting components. On the other hand, glutaraldehyde mediates irreversible cross-linking at 
longer distances owing to the carbon spacers present between the two aldehyde groups. To determine 
which chemical cross-linker would work best in capturing lncRNA-chromatin interactions, ChIRP 
using formaldehyde or glutaraldehyde was initially performed on MALAT1, a well-studied lncRNA 
with published chromatin targets [193]. Glutaraldehyde-ChIRP showed significant enrichment of 
MALAT1 targets HEXIM1, PS2, and PNN, with a similar trend of enrichment observed for another 
target, RNF40, compared with the lacZ control pulldown (Figure 4-23E). In contrast, formaldehyde-
ChIRP did not enrich any of the MALAT1 targets (Figure 4-23F). With these results, subsequent 
LINC00920-DNA capture experiments were performed using glutaraldehyde as the cross-linker. 
Upscaled glutaraldehyde-ChIRP experiments using 8 x 10
7
 cells per pulldown were performed to 
obtain sufficient input DNA material for library preparation using the NEBNext Ultra II DNA library 
preparation kit. Without prior DNA size selection, the resulting library size for all samples peaked 
between 300 and 400 bp (Figure 4-24). This can be rationalized by considering the addition of an 
adaptor, a linker, and index primers with a combined length of 184 bp to the approximately 150 bp-
fraction of sheared chromatin discussed previously. The resulting 6 libraries—a triplicate of lacZ-
precipitated DNA, and a triplicate of LINC00920-precipitated DNA—were pooled in equimolar 
amounts and sequenced on the HiSeq 2000 Illumina platform with a single-end 50-bp read length. 
Table 4-3 shows the read counts attributed to each demultiplexed library based on unique barcodes 
introduced by library-specific index primers. The raw sequencing data were processed and analyzed as 
outlined in Figure 4-25A. To assess the read coverage reproducibility among the replicates, signal 
correlation was made for each aligned BAM file (Figure 4-25B). The triplicates for both lacZ and 
LINC00920 showed very high correlation with each other, and the samples were distinctly clustered 
based on the precipitation condition (i.e., lacZ or LINC00920 capture). This correlation can also be 
visualized on the Integrative Genomics Viewer (IGV) [90] where peak profiles can be seen to be 
similar among the replicates (Figure 4-25C). 
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Figure 4-24. Bioanalyzer traces of sequencing libraries prepared from ChIRP DNA. 
NEBNext®Ultra™ II DNA Library Prep Kit was used to construct libraries from three 
biological replicates of LINC00920- and lacZ-precipitated DNA. Each library had a single peak 
centered between 300 to 400 bp corresponding to the combined lengths of the sequencing 
adapters, index primers, and ChIRP DNA insert. 
 
Table 4-3. Read count statistics of sequenced ChIRP-precipitated DNA libraries. 
FASTQ file Sample ID Base Count Read Count Barcode 
AS-207375-LR-31363_R1.fastq.gz  
P28 ChIRP: 
lacZ  
1519529190  29794690  ACAGTG  
AS-207377-LR-31363_R1.fastq.gz  
P28 ChIRP: 
LINC00920  
1279734738  25092838  GCCAAT  
AS-207381-LR-31363_R1.fastq.gz  
P29 ChIRP: 
lacZ  
1839903642  36076542  TAGCTT  
AS-207383-LR-31363_R1.fastq.gz  
P29 ChIRP: 
LINC00920  
2038382025  39968275  CTTGTA  
AS-207385-LR-31363_R1.fastq.gz  
P30 ChIRP: 
lacZ  
1632430491  32008441  CGATGT  
AS-207387-LR-31363_R1.fastq.gz  
P30 ChIRP: 
LINC00920  
1486910865  29155115  TGACCA  
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Figure 4-25. Initial processing and quality control assessment of ChIRP-seq data.  (A) The 
workflow adapted to prepare the raw ChIRP-seq data for occupancy analysis and peak calling. 
(B) The read coverage correlation among samples showed high reproducibility for each 
pulldown. (C) A representative view of aligned reads in the IGV browser revealing robust 
signal reproducibility among the triplicate samples. Red tracks correspond to LINC00920 
ChIRP while blue tracks correspond to lacZ ChIRP.    
   
 
To answer the question of whether LINC00920 binds directly to genic regions and consequently exert 
proximal gene regulatory function, normalized LINC00920 read coverage was overlapped with 
annotated genes (hg19). On average, LINC00920 traces were minimal across gene bodies with notable 
depletion around transcription start sites (TSSs) (Figure 4-26).  
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Figure 4-26. Normalized LINC00920 read coverage across genic regions in the human 
genome build hg19. Top: Average profiles of LINC00920 occupancy on genes normalized by 
length of 10 kbp with 2-kb extensions upstream the TSSs and downstream the TESs. Bottom: 
Heatmaps showing signals for individual genes (heatmap rows). Shown data was derived from 
a representative replicate. Blue: high read coverage, red: low read coverage. 
 
As histone modifications are tightly linked to chromatin state and transcriptional status, read densities 
of LINC00920 ChIRP-seq at TSSs were visualized vis-à-vis published PC-3 ChIP-seq datasets [210] 
for (i) H3K27ac, a marker of enhancers and promoters of active genes; (ii) H3K27me3, a repressive 
mark; (iii) H3K4me1, a marker found at transcriptional enhancers; (iv) H3K4me3, a marker of gene 
promoters; and (v) RNA polymerase II, a marker of active transcription (Figure 4-27). As expected, 
presumably active promoters enriched in RNA polymerase II showed positive H3K27ac and 
H3K4me3 occupancy without H3K27me3 enrichment. Interestingly, H3K4me1 marks showed 
comparably reduced signal profile resembling LINC00920 density around TSSs. 
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e1, H3K4me3, and RNA polymerase II (RNAP II) read coverages across promoter 
regions defined in the PC-3 genome. Top: Average profiles of LINC00920, H3K27ac, 
H3K27me3, H3K4me1, H3K4me3, and RNAP II occupancy on promoter centers (n=36,180) 
with 2-kb extensions upstream and downstream. Bottom: Heatmaps showing signals for 
individual genes (heatmap rows). Blue: high read coverage, red: low read coverage. 
In an effort to isolate LINC00920-enriched promoter regions for further investigation, all 36,180 
annotated TSSs were clustered based on read densities. Among the resulting four region clusters, 
cluster 1, corresponding to 5,287 loci, had the highest positive lncRNA association (Figure 4-28). 
Looking at the presence of RNA polymerase II and histone modifications in these regions, a number 
of interesting observations can be made (Figure 4-29). First, there is an overall decrease in RNA 
polymerase II occupancy indicating decreased transcription. Second, H3K4me3 peak density was 
narrower, possibly corroborating the diminished transcriptional activity in these regions. The final and 
most intriguing pattern was the coincident deposition of H3K4me1 in regions of high LINC00920 
occupancy. Moreover, since H3K27ac occupancy was invariantly high in this cluster, the emergence 
of H3K4me1 marks becomes predictive of enhancer activity [240, 241] in these LINC00920-
associated loci. 
 
Figure 4-28. ChIRP-seq density clustering reveals LINC00920 binding to a subset of 
promoters. Top: Average profiles of LINC00920 occupancy across clustered promoters. 
Bottom: Segmented heatmaps showing clustered promoters based on signal density. Promoter 
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regions in cluster 1 exhibit positive LINC00920 enrichment in all replicates. Cluster 2 
promoters show modest LINC00920 occupancy both upstream and downstream the promoter 
center. Clusters 3 and 4 promoters exhibit depletion of LINC00920 signal upstream and 
downstream the promoter center, respectively. Shown data was derived from a representative 
replicate. Blue: high read coverage, red: low read coverage. 
 
 
 
 
 
 
Figure 4-29. 
Normalized 
LINC00920, 
H3K27ac, 
H3K27me3, 
H3K4me1, 
H3K4me3, 
and RNA 
polymerase 
II (RNAP 
II) read 
coverages 
across 
cluster 1 
promoter 
regions. 
Top: 
Average 
profiles of 
LINC00920, 
H3K27ac, 
H3K27me3, 
H3K4me1, 
H3K4me3, 
and RNAP II 
occupancy 
across 5,287 
regions. 
Bottom: 
Heatmaps 
showing 
signals for 
individual 
promoter 
region 
(heatmap 
rows). Blue: 
high read 
coverage, 
red: low read 
coverage. 
 
The biological 
significance of 
LINC00920 interaction with these regions was queried using the Genomic Regions Enrichment of 
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Annotations Tool (GREAT) which assigns biological meaning to a set of genomic regions by 
analyzing the annotations of nearby genes [202]. The term “LKB1 signaling events” was the top-most 
hit among the molecular signatures included in the database (Figure 4-30A) [203, 221]. The LKB1 
gene (also known as STK11) encodes a serine/threonine kinase that phosphorylates and activates 5’ 
AMP-activated protein kinase (AMPK) [242]. The LKB1-AMPK axis is involved in a complex 
network of metabolic pathways that ultimately control cell growth in response to environmental 
nutrient changes. To specify the pathways most affected within the LKB1-AMPK network, Ingenuity 
Pathway Analysis was performed on the LKB1 gene set using the LINC00920 knockdown microarray 
data. This analysis revealed that upon LINC00920 silencing, PI3K/AKT and 14-3-3 signaling 
pathways were deactivated (Figure 4-30B). 
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Figure 4-30. Biological pathways predicted to be affected by the promoter-associated 
function of LINC00920. (A) LKB1 signaling is the most relevant result of the Genomic 
Regions Enrichment of Annotations Tool (GREAT) analysis performed on cluster 1 promoter 
regions. (B) Ingenuity pathway analysis predicted deactivation of PI3K/AKT and 14-3-3-
mediated signaling pathways from the expression profile of the LKB1 gene set in LINC00920-
knockdown cells.  
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Further evidence of a putative enhancer-associated function of LINC00920 is its enrichment in a 
subset of enhancer regions previously annotated in PC-3 cells [210]. Remarkably, about 29% of the 
70,496 predicted enhancer regions had traces of LINC00920 occupancy, with an almost equal 
distribution upstream and downstream of the enhancer center (Figure 4-31). 
 
Figure 4-31. Normalized LINC00920 read coverage across annotated enhancer regions in 
the PC-3 genome. Top: Average profiles of LINC00920 occupancy on enhancers 1-kb 
extensions upstream and downstream the annotated center. Bottom: Segmented heatmaps 
showing clustered enhancer regions based on signal intensity. Cluster 1 enhancer regions show 
enrichment of LINC00920 occupancy upstream the annotated center. Enhancer regions in 
cluster 2 show enrichment downstream of the center. The remaining cluster 3 enhancer regions 
do not show LINC00920 enrichment. Shown data was derived from a representative replicate. 
Dark blue: high read coverage, yellow: low read coverage. 
  
In addition to the coverage density-based analysis described above, bona fide RNA binding peaks 
were called using Model-based Analysis of ChIP-Seq 2 (MACS2). While this method was first 
developed to identify protein-bound chromatin regions [243], RNA-DNA capture by ChIRP is an 
analogous technology to ChIP making MACS2 an appropriate tool for RNA peak calling [193, 194]. 
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Genome-wide, 2,985 peaks were called using a cut-off fold-change value of 10 (over the lacZ signal) 
and a q-value of 0.001. Genomic feature annotation of peaks using a published chromatin 
segmentation dataset of the PC-3 genome [210] revealed that although the majority of the peaks was 
identified in heterochromatic regions, LINC00920 also associated with a variety of regulatory 
elements including enhancers (n=190, 6.4%) and promoters (n=64, 2.1%) (Figure 4-32). 
 
Figure 4-32. Analysis of  LINC00920 chromatin binding sites using MACS2.  (A) 
Distribution of LINC00920 ChIRP-seq peaks across annotated features in the PC-3 genome. 
(B) CT-rich homopyrimidine motif enriched in LINC00920 binding sites. 
4.12. Identification of proteins interacting with LINC00920 via ChIRP-mass spectrometry 
(ChIRP-MS)  
Due to the observation that LINC00920 is not restricted within either nuclear or cytosolic 
compartment, LINC00920-ChIRP in tandem with mass spectrometry (ChIRP-MS) was performed to 
query the functional role of LINC00920 beyond chromatin binding. The same set of biotinylated 
antisense oligos was used as in ChIRP-DNA with a few modified steps to tailor the protocol for 
protein retrieval. First, the number of cells was increased to 2 x 10
8 
per RNA precipitation to achieve 
high purification yields of the lncRNA complex since proteins cannot be amplified. Second, extensive 
formaldehyde crosslinking was performed (3% formaldehyde crosslinking for 30 minutes) to 
maximize protein capture. Finally, crosslinked proteins were eluted from streptavidin beads by 
benzonase digestion. These modifications were not detrimental to on-bead LINC00920 enrichment 
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upon pulldown (prior to elution) (Figure 4-33A). The eluted proteins were stained on a Coomassie gel 
prior to peptide digestion in preparation for mass spectrometry (Figure 4-33B). Three biological 
replicates were performed and a peptide signal intensity ratio cutoff of 1.2 between LINC00290 and 
lacZ precipitation was implemented to qualify protein enrichment. In total, 21 identified proteins were 
enriched in all replicates (Figure 4-33C, Supplementary Table 9-3). Unsurprisingly, gene ontology 
analysis of these proteins revealed RNA binding and transcript splicing functions (Figure 4-33D).  
Among the identified proteins are 14-3-3 protein isoforms: 14-3-3ε (YWHAE) and 14-3-3ζ (YWHAZ). 
14-3-3 proteins are small chaperone proteins that bind to phosphorylated ligands. Such binding 
provides steric hindrance or elicits a conformational change that alters the biochemical properties of 
the 14-3-3-bound protein [244]. The presence of these adaptor proteins was notable in light of the 
observation that FOXO signaling is activated upon LINC00920 knockdown. While 14-3-3ε 
enrichment did not reach the 1.2 cutoff in one MS replicate (Figure 4-33E), it was deemed worthwhile 
to investigate the appearance of both isoforms in the LINC00920 pulldown due to their implicated role 
in FOXO signaling. One of the many functions of 14-3-3 proteins is the regulation of FOXO 
transcription factors by cytoplasmic sequestration [245]. AKT-mediated phosphorylation of FOXO 
induces 14-3-3 binding, preventing reentry of FOXO into the nucleus. FOXO transcriptionally 
activates genes involved in cell cycle arrest, apoptosis, and reactive oxygen species detoxification, 
among others. Altogether, the microarray and mass spectrometry results led to the hypothesis that 
LINC00920/14-3-3 association enhances nuclear FOXO exclusion and subsequently reduce the 
expression of FOXO targets.  
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Figure 4-33. Identification of the LINC00920 protein interactome through ChIRP-MS.  
(A) Significant specific enrichment for LINC00920 using pooled antisense oligos was similarly 
achieved in formaldehyde-fixed PC-3 cells as in glutaraldehyde-fixed cells. (B) Eluted proteins 
from respective LINC00920- and lacZ-precipitations were loaded into a polyacrylamide gel 
and stained with Coomassie dye. Brackets indicate stained proteins that were cut from the gel 
and eventually processed for mass spectrometry. (C) Proteins enriched in the LINC00920 
pulldown were identified using a signal ratio cutoff of 1.2 (LINC00920:lacZ).  Considerable 
overlap of putative lncRNA binding proteins among the three biological replicates of ChIRP-
MS was observed with 21 proteins common to all replicates. (D) Gene ontology analysis of the 
21 proteins revealed predominantly RNA-associated processes. (E) Relative enrichment values 
of 14-3-3 proteins in the LINC00920 pulldown for all replicates.  
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4.13. Validation of LINC00920 transcript/14-3-3 protein interaction 
RNA immunoprecipitation (RIP) using 14-3-3-specific antibodies was performed in VCaP cells to 
validate the association of LINC00920 and the 14-3-3 proteins as identified from the ChIRP-MS data. 
Primers tiling the span of the spliced LINC00920 transcript were designed in the attempt to map the 
protein-interacting portion of the lncRNA (Figure 4-34A). Significant LINC00920 enrichment over 
the IgG control was observed for the primer pair amplifying the intronic junction of the transcript upon 
14-3-3ε precipitation (Figure 4-34B). On the other hand, 14-3-3ζ precipitation did not enrich for any 
fragment of the lncRNA. These results point to the specific interaction of LINC00920 with the 14-3-3ε 
protein isoform. 
 
Figure 4-34. RNA immunoprecipitation (RIP) of 14-3-3 proteins.  (A) RIP primers were 
designed to tile across the full LINC00920 transcript. (B) RIP was performed for the 14-3-3ε 
and 14-3-3ζ isoforms in VCaP cells. RNA precipitated by 14-3-3ε showed significant 
enrichment, relative to the IgG control, for the LINC00920 fragment amplified by the intron-
spanning primer pair (RIP4). In contrast, no significant enrichment for any  amplified 
LINC00920 fragment was observed in the 14-3-3ζ  pulldown, indicating a 14-3-3ε-specific 
binding of the lncRNA. The small nucleolar RNA SNORA55 was used as negative control. 
(**p≤0.01) 
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Complementary to RNA immunoprecipitation, affinity purification on streptavidin beads using in vitro 
transcribed biotinylated LINC00920 (bi-LINC00920) was performed to pull down recombinant 14-3-
3ε from solution (Figure 4-35A). Because the pcDNA3.1(+) mammalian expression vector harbors 
the T7 promoter upstream of its multiple cloning site, the pcDNA3.1(+)-LINC00920 construct was 
used to generate the DNA template to be transcribed in vitro. The construct was linearized at the 
unique XbaI restriction site downstream the cloned full-length LINC00920 cDNA (Figure 4-35B). 
Together with a linearized plasmid harboring the firefly luciferase (Fluc) gene under the 
transcriptional control of the T7 promoter to serve as control template, LINC00920 was transcribed 
using T7 RNA polymerase and a ribonucleotide mix with and without biotin-16-UTP. Non-
biotinylated transcription reactions yielded the expected RNA lengths for Fluc (1800 nt) and 
LINC00920 (1567 nt) (Figure 4-35C). Biotinylated reactions generated RNA products slightly heavier 
than the expected size due to the incorporation of biotinylated uracil. In some reactions, template DNA 
contamination was present seen as high molecular weight bands in the RNA gel. In such cases, 
DNase-I digestion was performed prior to use of the biotinylated products (Figure 4-35D). 
 
Figure 4-35. Generation of biotin-tagged LINC00920 through in vitro transcription. (A) In 
vitro transcription using T7 RNA polymerase. (B) Vector map of pcDNA3.1(+) wherein the 
full-length LINC00920 cDNA was cloned upstream of the XbaI restriction site. (C) In vitro 
transcription was performed for the firefly luciferase (Fluc; 1800 nt) and LINC00920 (1567 nt) 
without and with biotinylation. RNA product lengths were estimated by running the samples 
though 1% formaldehyde/MOPS/agarose denaturing gel. The red asterisk (*) indicates a DNA 
template band that was removed upon additional DNase-I digestion (D). 
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Next, direct interaction of lncRNA and protein was investigated in vitro by precipitating recombinant 
14-3-3ε (r14-3-3ε) with the biotinylated transcript on magnetic streptavidin beads. On a silver-stained 
polyacrylamide gel, r14-3-3ε had an estimated molecular weight of 35 kDa (Figure 4-36A). RNase A 
treatment was performed to verify that the precipitation of the protein is dependent on the presence of 
LINC00920. After incubation, the precipitated protein was eluted by boiling the beads in Laemmli 
buffer. Without RNase A treatment, r14-3-3ε could be probed via western blot while RNA digestion 
abrogated the band signal (Figure 4-36B). These observations indicate that intact LINC00920 is 
required to pulldown r14-3-3ε and furthermore imply a direct interaction between the RNA and 
protein in solution. 
 
Figure 4-36. Affinity purification of recombinant 14-3-3ε (r14-3-3ε) using biotinylated 
LINC00920 (bi-LINC00920).  (A) R14-3-3ε was estimated to be approximately 35 kDa on a 
silver-stained 4-20% polyacrylamide gel. (B) After hybridization with r14-3-3ε, affinity 
purification was performed on bi-LINC00920 using streptavidin beads without or with RNase 
A treatment to determine the RNA dependence of r14-3-3ε binding. Immunoblot of the eluted 
proteins showed a direct interaction of r14-3-3ε and bi-LINC00920 that was abolished upon 
RNA digestion.  
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5. Discussion 
5.1. Identification and selection strategy of prostate cancer-associated lncRNAs 
Participation of lncRNAs in cancer hallmark processes such as cell proliferation, apoptosis, invasion, 
and metastasis through various molecular modalities has emerged in the past decade. Nonetheless, the 
numbers of differentially expressed transcripts and well-characterized lncRNAs remain severely 
disproportionate in all cancer entities. In the context of the low mutational burden in PCa, looking into 
the dysregulation of the non-coding genome can potentially yield novel insights into the molecular 
biology of the tumor. 
Differential expression analysis performed on the ICGC-EOPC cohort revealed multiple deregulated 
lncRNAs in the prostate transcriptome. Transcripts selected for further investigation were limited to 
the multi-exonic lincRNA biotype. This criterion minimizes the possibility of selecting false-positive 
candidates that could have arisen from poor mapping of sequencing reads. In addition, the majority of 
functionally annotated lincRNAs was excluded from the short-list of candidates—despite considerable 
differences in expression between normal and tumor tissues—due to low read counts (<500 mean 
counts), which would translate to technical difficulties in cellular functional analysis. The proximity of 
regulatory elements around the chromosomal locus of the target was also inspected to assess whether 
the candidate might be actively transcribed. Lastly, the expression profile of a potential candidate was 
confirmed to be robust in the TCGA-PRAD [75] and TANRIC [246] datasets. Following these 
selection guidelines, seven PCa-associated lncRNAs were nominated for further study. RP11-
867G23.3, RP11-3P17.5, and LINC00920 were found to be significantly upregulated in prostate 
tumors while LINC00844, LINC01082, RP11-395L14.4, and SNHG18 were significantly repressed. 
The well-documented cell-type specificity of lncRNAs became apparent upon expression level 
validation of the seven candidates by qPCR in PCa cell lines. Although RWPE-1, LNCaP, VCaP, DU-
145, and PC-3 are all prostatic-derived cell lines, each exhibits a unique genetic background with a 
specific transcriptional program. RWPE-1 is a model for non-tumorigenic human prostatic epithelium. 
LNCaP and VCaP cells are derived from metastatic prostate adenocarcinomas and are androgen-
responsive. Furthermore, VCaP cells harbor an allele of the TMPRSS2:ERG gene fusion which results 
in ERG overexpression. DU-145 and PC-3 are metastatic cell lines but do not express AR nor PSA, 
and are consequently hormone insensitive. PC-3 cells are also PTEN deficient and highly aneuploidal 
[247]. These distinct genetic contexts would explain the inconsistent trend of lncRNA expression 
between the transcriptome data and normalized qPCR measurements for some cell lines. At the same 
time, this observation highlights the potential of lncRNAs in defining specific tumor subtypes.        
RACE was performed using a standard human prostate RNA in order to characterize the predominant 
and most likely functional transcript isoform in prostate cells. The 5’- and 3’- ends were successfully 
cloned and sequenced for all lncRNA candidates except for RP11-867G23.3 and RP11-3P17.5. For 
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LINC00920, LINC00844, and SNHG18, the sequenced 3’-ends revealed shorter transcript isoforms 
compared to the lengths annotated by RefSeq or GENCODE. Alternative polyadenylation (APA) is 
the most likely cause of this discrepancy. APA entails RNA processing yielding distinct 3’ termini on 
RNA polymerase II transcripts, including lncRNAs [248]. APA is tissue-specific, and is recognized to 
be a mechanism of gene regulation widespread in eukaryotes. Endonucleolytic cleavage and 
subsequent polyadenylation occurs  downstream of canonical hexameric polyadenylation signals 
[249]. Accordingly, these polyadenylation motifs were present immediately upstream the cloned 3’-
ends of LINC00920, LINC00844, and SNHG18, implying prostate cell-specific RNA processing of 
these transcripts. For lncRNAs with multiple annotated isoforms (i.e., RP11-395L14.4 and SNHG18), 
RACE results also demonstrated the utility of this technology in identifying predominant transcript 
isoforms.  
From the remaining lncRNA candidates, only the full-length cDNAs of LINC00920, LINC00844, and 
LINC01082 were successfully cloned and amplified, further narrowing down the selection list. Due to 
its overexpressed nature in tumors—suggestive of an oncogenic function—and its robust expression in 
PCa cell lines—in contrast to the limited detectability of LINC00844 and LINC01082—LINC00920 
was ultimately selected for further investigation.  
5.2. The non-coding potential of LINC00920 RNA 
Although lncRNAs and mRNAs share post-transcriptional features such as 5’- m
7
Gpppn capping and 
polyadenylation, and the capacity to undergo splicing, non-coding transcripts can be distinguished 
from their coding counterparts upon evaluation of ORF size and coverage, nucleotide or codon 
frequencies and composition, evolutionary substitution patterns, similarity to known protein-coding 
transcripts, and presence of known functional domains [250]. Coding regions have the tendency to 
harbor ORF lengths longer than expected by chance [251]. The ORF coverage, which is the length of 
the longest ORF normalized to the transcript size, may also be considered as the probability of 
determining a long ORF increases with transcript length [200]. Moreover, nucleotide frequencies 
within protein coding ORFs are defined by non-random codon usage and thus are partly indicative of 
coding potential [250]. Protein coding-, in contrast to non-coding genes, evolve under selective 
pressure to maintain intact ORFs and to preserve specific amino acid residues or amino acid types at 
defined positions [252]. This selective pressure can be evaluated by performing multiple sequence 
alignments, comparing nucleotide substitution frequencies, and assessing the integrity of the ORF 
upon introduction of insertions and deletions (indels). Sequence similarities to known mRNAs may 
also be inspected to evaluate the coding potential of a transcript. Finally, encoded protein domains are 
commonly present in protein-coding sequences but absent in non-coding transcripts [250]. 
In this study, three computational tools were applied to confirm the non-coding potential of 
LINC00920. This approach enabled an evaluation of the (non-)coding potential using multiple criteria 
that would not have been achieved by a single tool. The CPAT coding probability score is based on a 
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logistic regression model built on open reading frame (ORF) size, ORF coverage, combinatorial effect 
of nucleotide composition and codon usage bias (Fickett score) and hexamer usage score [200], which 
is related to the differential usage of nucleotide hexamers observed in exons and introns [253]. The 
CPC relies on the ORF length and quality of the transcript. In addition, this tool considers the 
BLASTX output quality of the RNA query and compares the resulting information with bona fide 
protein-coding transcripts [201]. Finally, PhyloCSF utilizes evolutionary signatures derived from 
alignments of conserved coding regions to score the likelihood of a transcript to be protein-coding 
[229]. All three tools corroborated the non-coding capacity of LINC00920, yielding non-coding 
potential scores comparable to well-established lncRNAs NEAT1 and MALAT1, and in contrast to 
mRNAs such as GAPDH and ACTB1. 
5.3. In vitro functional characterization of LINC00920 
The functional role of LINC00920 was interrogated in PC-3 cells, wherein the transcript was found to 
be upregulated compared to the immortalized prostate epithelial cell line RWPE-1. Cells depleted of 
LINC00920 showed decreased proliferative, migratory, and colony forming capacities. Together with 
the high expression observed in tumors, these results assert the oncogenic properties of LINC00920. 
Furthermore, microarray profiling of cells depleted of LINC00920 revealed perturbed cellular 
pathways highly relevant to the observed cellular phenotypes. Interestingly, focused analysis of the top 
LINC00920-deregulated genes predicted enhanced FOXO signaling activity upon lncRNA 
knockdown.   
In humans, the FOXO family of transcription factors is comprised of four members: FOXO1, FOXO3, 
FOXO4, and FOXO6 [254]. FOXO proteins share redundant functions as they bind the cognate 
(G/C)(T/A)AA(C/T)AA Forkhead response element (FRE) [255]. FOXO protein specific functions 
can be mediated by interaction with various coregulators [254]. Depending on the cellular context, 
FOXO transcriptional programs affect a variety of processes by regulating genes involved in cell cycle 
arrest (e.g., GADD45A, CDKN1B), apoptosis (e.g., BCL2L11, PMAIP1), differentiation (e.g., 
PDGFRA, PRDM1) and metabolic response (e.g., CAT, SOD2) [230-233, 256, 257]. In cancer entities 
such as leukemia, breast cancer, and prostate cancer [258, 259], FOXO transcription factors are 
considered tumor suppressors as they act as downstream effectors of PTEN [260]. Upon PTEN loss or 
somatic mutations in pathway-involved genes, PI3K signaling activation leads to elevated AKT 
survival pathway activity. Among the direct AKT substrates in the nucleus are FOXO proteins whose 
subsequent phosphorylation leads to deactivation and eventual nuclear exclusion (Figure 5-1) [261-
263]. 
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Figure 5-1. Simplified illustration of FOXO signaling regulation by the PTEN/PI3K 
pathway. Receptor tyrosine kinase (RTK) activates phosphoinositide 3-kinase (PI3K) which in 
turn phosphorylates phosphatidylinositol 4,5-bisphosphate (PIP2) [264]. If active, PTEN 
antagonizes PI3K function by dephosphorylating phosphatidylinositol (3,4,5)-trisphosphate 
(PIP3) [265]. PIP3 triggers the phosphorylation and concomitant activation of AKT. Active 
AKT phosphorylates FOXO proteins at specific sites resulting in FOXO deactivation and 
subsequent downregulation of target genes related to the indicated physiological processes.  
 
The antagonistic effect of LINC00920 expression on FOXO signaling was further confirmed by the 
increased transcription of canonical FOXO target genes upon LINC00920 knockdown in ipatasertib-
treated PC-3 cells. For experimental rigor, five independent siRNAs were used to validate the effect of 
LINC00920 on the canonical FOXO target genes BCL2L11, GADD45A, and PMAIP1. While silencing 
LINC00920 alone led to minor changes in the expression of FOXO targets, simultaneous LINC00920 
knockdown and AKT inhibition through ipatasertib treatment significantly upregulated all genes in 
comparison with the scrambled siRNA control. These observations can be rationalized by a 
hyperactive AKT brought about by PTEN deletion inherent in PC-3 cells. Without ipatasertib, FOXO 
proteins are consistently phosphorylated and inactive, presumably masking the effect of LINC00920 in 
FOXO target activation. On the other hand, limiting AKT activity uncoupled the influence of the 
hyperactive PI3K pathway on FOXO signaling. In this context, the isolated activating effect of 
LINC00920 knockdown on FOXO signaling was evident. Complementing these results, LINC00920 
overexpression led to significant downregulation of GADD45A and PMAIP1. BCL2L11 expression 
was similarly affected, albeit not statistically significant. The opposing effect of LINC00920 
expression to FOXO activity was also demonstrated in VCaP, a PTEN-intact cell line with high 
endogenous LINC00920 expression.  
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Growth arrest and DNA damage inducible 45 alpha (GADD45A) encodes a tumor suppressive protein 
implicated in DNA repair, maintenance of genomic stability, cell cycle control, and apoptosis [266]. 
GADD45A facilitates cell cycle arrest in response to genotoxic stress by inhibiting CDK1/CYCLIN 
B1 complex formation required for G2-M transition during cell cycle progression [267]. GADD45A 
has been shown to be downregulated in primary prostate tumors compared to nonmalignant tissue 
[268]. The gene products of BCL2-Like 11 (BCL2L11 or BIM) and Phorbol-12-Myristate-13-Acetate-
Induced Protein 1 (PMAIP1 or NOXA) are essential pro-apoptotic proteins belonging to the BH3-only 
protein family. BH3-only proteins initiate the mitochondrial apoptotic pathway by activating Bax-like 
proteins or by binding and sequestering anti-apoptotic Bcl-2 proteins [269]. It is also important to note 
that other FOXO established targets such as TNFSF10, CCNG2, and CDKN1B were similarly 
evaluated for expression activation upon LINC00920 perturbation. However, no remarkable alteration 
in expression was observed for these genes upon lncRNA knockdown in the absence or presence of 
ipatasertib (Supplementary Figure 9-2). This suggests that inactivation of FOXO signaling in this 
context is limited to the downregulation of select genes. Interestingly, a previous report has asserted 
that FOXO target genes can be classified as responsive to FOXO levels alone (class I genes) or in 
combination with other transcriptional activators (class II genes) depending on the multiplicity of 
FREs in the promoter region [270]. This classification might explain the non-responsiveness of those 
FOXO target genes to LINC00920 knockdown. Taken together, LINC00920 plays a role in modulating 
a subset of FOXO targets associated with cell cycle control and apoptosis in prostate cancer cells. 
5.4. LINC00920 transcription is regulated by ERG 
The hypothesis that ERG drives LINC00920 transcription stemmed from the initial observation that 
the lncRNA is upregulated in the T2E-positive VCaP cells. In support of this, correlations between 
LINC00920 and ERG were determined in the TCGA-PRAD and ICGC-EOPC datasets. Lentiviral 
transduction of ERG in LNCaP cells also recently showed concomitant upregulation of LINC00920 
[95]. Indeed, ERG perturbation in VCaP and tet-inducible ERG-overexpressing LNCaP cells 
demonstrated the dependence of LINC00920 expression on the transcription factor. Furthermore, 
direct interaction of ERG with identified ETS domains within the LINC00920 promoter was 
established through promoter luciferase and ChIP assays. These experiments further suggest a 
hierarchical multi-site binding of ERG within a single regulatory region, which has previously also 
been observed in the YAP1 promoter [271].   
In androgen independent and T2E-negative PC-3 cells, LINC00920 transcription can be attributed to 
the overexpression of another ETS family member ETV4, which binds to the same ETS domain as 
ERG. ETV4 gene fusions and the consequent overexpression of the ETV4 protein are detected in 4% 
of primary prostate tumors [75]. The metastasis promoting effect of ETV4, in collaboration with 
activated PI3K and RAS signaling pathways, has been reported in an advanced PCa mouse model 
[272]. Moreover, ETV4 has been established to be required for the anchorage-independent growth of 
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PC-3 cells [273]. Since LINC00920 acts downstream of ERG and ETV4, it is tempting to speculate 
that the tumorigenic effects of the two ETS transcription factors could partly be mediated by 
LINC00920 through its crosstalk with FOXO signaling. To date, LINC00920 is only the second 
lncRNA reported to be regulated by ERG [82, 274], and the first lncRNA gene to be described as a 
direct ERG target in prostate cancer cells. 
5.5. The LINC00920 interactome 
The presence of mature LINC00920 transcripts in the chromatin, nucleoplasmic, and cytoplasmic 
fractions implies a number of possibilities as to how the lncRNA can negatively affect FOXO 
signaling/elicit the observed cellular phenotype in prostate cancer cells. Since lncRNAs do not 
function in isolation and instead work in complement with proteins or other nucleic acids, lncRNA 
interactome identification is central to understanding its modality. In this study, ChIRP, in tandem 
with high throughput sequencing (ChIRP-seq) and mass spectrometry (ChIRP-MS), was applied to 
interrogate the role of LINC00920 in the context of both the chromatin and RNA binding proteins 
(RBPs). ChIRP experiments were performed with endogenous levels of LINC00920 in PC-3 cells, 
minimizing potential interacting artifacts that would most likely be detected if the transcript was 
otherwise overexpressed.  
5.5.1. The chromatin binding map of LINC00920 
Due to the notable presence of LINC00920 in the chromatin fraction, ChIRP-seq was performed to 
map its putative chromatin binding sites. Previously, ChIRP-seq experiments targeting Drosophila 
roX2, human TERC and HOTAIR lncRNAs have revealed important insights regarding interactions 
between non-coding transcripts and the chromatin [194]. ChIRP can be performed using either 
formaldehyde or glutaraldehyde as chemical crosslinkers as the chemistry of both reagents in theory 
enables sufficient preservation of RNA:DNA contacts [192, 239, 275]. However, it has been 
empirically determined that formaldehyde is not effective in crosslinking some lncRNA:DNA 
interactions, such as those mediated by TERC [194, 276]. Ultimately, LINC00920 ChIRP-seq 
experiments were optimized using glutaraldehyde instead of formaldehyde as the fixing agent due to 
its superior DNA capture efficiency as revealed by MALAT1 validation pulldowns. 
ChIRP-seq displayed a low genome-wide mean coverage signal of LINC00920 which likely reflects 
the limited number of transcript copies available for chromatin interaction within the cell. 
Nonetheless, enrichment of the lncRNA across subsets of regulatory regions, particularly of promoters 
and enhancers, suggests potential functionalities at the level of gene regulation. Interestingly, 
LINC00920-occupied promoters were found to be implicated in biological functions related to LKB1 
signaling, and further converging on the PI3K/AKT and 14-3-3 signaling pathways. Intriguingly, 
perturbation of these pathways has been redundant in the context of LINC00920 function in prostate 
cancer cells. Nonetheless, additional functional interrogation of these chromatin regions is required to 
complement and validate such predictions.  
 105 
Another notable observation from the genomic mapping of LINC00920 occupancy is its enrichment in 
a subset of enhancer regions. Adding to this is the apparent colocalization of LINC00920 and the 
histone mark H3K4me1 signals in the same cluster of promoter regions. H3K4me1 is typically found 
at enhancers and large 5’ segments of actively transcribed genes [277]. Enhancers are cis-regulatory 
elements defined as 100-1000 bp non-coding DNA regions that activate gene transcription regardless 
of their distance, location, or orientation relative to specific cognate promoters [278]. Specifically, 
primed enhancers are marked with H3K4me1 with simultaneous depletion of H3K4me3. On the other 
hand, active enhancers are enriched for H3K4me1, H3K27ac, and other histone modifications such as 
H4K16ac and H3K122ac [240, 241, 279]. It is currently unclear whether this histone deposition 
overlap has biological relevance, but the complete reversal from H3K4me1 depletion in the genome-
wide context to enrichment at LINC00920-occupied regions is striking.  
Although LINC00920 ChIRP-MS failed to identify H3K4me1 associated proteins (such as chromatin 
remodelers BAZ1A/B and chromatin associated factors belonging to the SWI/SNF complex [280]), 
this does not rule out the colocalization of H3K4me1 and LINC00920. This only demonstrates the 
non-association of the lncRNA with the chromatin regulators. Considering that only around 15% of 
annotated promoters were co-occupied, it is also possible that the amount of H3K4me1-associated 
proteins precipitated by the LINC00920-antisense oligos did not reach detection sensitivity. It has been 
demonstrated that H3K4me1 has a role in recruiting the SWI/SNF complex to enhancers, but how 
enhancers are pre-marked by H3K4me1 remains an open question [280]. Histone methyltransferases 
such as KMT2C and KMT2D (MLL3/4) have been reported to interact with cell-type specific and 
signaling-dependent factors that possibly earmark regions for histone methylation [281-283]. 
Interestingly, the lncRNA HOTTIP has been reported to recruit WDR5-MLL5 complexes to the 5’ 
HOXA locus, which results in the deposition of H3K4me3 mark along a broad chromatin domain, 
triggering gene activation [284]. It should be noted however that recruitment of WDR5-MLL5 is 
brought about through the nascent transcription of HOTTIP, which acts to tether the protein complex 
to the target locus in cis. On the other hand, the mouse lncRNA Fendrr has been demonstrated to 
recruit the chromatin regulatory Polycomb complex PRC2 both in cis and in trans, mediating 
trimethylation at H3K27 at target gene promoters [112].  These examples could be taken into account 
upon generating a hypothesis for LINC00920 function at enhancer regions.  
In parallel, corroborating evidence implicating LINC00920 with enhancer-related function was 
revealed by MACS2-based peak calling and subsequent genomic feature annotation. Second only to 
heterochromatic regions, LINC00920 was found most enriched at annotated enhancers in the PC-3 
genome. Remarkably, DNA motif discovery revealed lncRNA binding tendency to stretches of CT-
rich homopyrimidines, which are known to form triple-helical nucleic acid interactions through 
Hoogsteen hydrogen bonding [285, 286]. This suggests the possibility of a LINC00920:DNA:DNA 
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triplex formation at the identified chromatin sites. However, validation of this hypothesis requires 
further investigation. 
5.5.2. The protein interaction partners of LINC00920 
The majority of the captured proteins identified by MS upon LINC00920 ChIRP are well known RNA 
binding proteins involved in RNA splicing and maturation (i.e., heterogeneous ribonucleoprotein 
particles, hnRNPs). This result does not come as a surprise since lacZ-targeting oligos were used for 
the negative control pulldown. Hence, proteins related to RNA biogenesis are likely to be enriched in 
the experimental condition as the lacZ mRNA is not endogenously transcribed in human cells. Lest a 
false-positive target is identified, these RNA processing proteins were excluded from candidate 
selection. Nonetheless, the possibility that among these is a bona fide LINC00920-interacting protein 
with functional implication beyond RNA biogenesis and maturation cannot be fully discounted and 
remains a limitation of this study.  
Given the intersection of LINC00920 with FOXO signaling in the microarray data, the consistent 
enrichment of 14-3-3 proteins in LINC00920 ChIRP-MS experiments was a relevant observation. 
While little is known about the RNA-binding capacity of 14-3-3 proteins, RNA-binding activities 
within the 14-3-3 domain have recently been reported through a global RNA proteomics approach 
[287].  
Canonically, 14-3-3s are chaperone proteins that bind to phosphorylated ligands, among them FOXO 
proteins [244]. In total, there are seven 14-3-3 isoforms expressed in mammals: β (identical to α upon 
phosphorylation), γ, ε, η, ζ (identical to δ upon phosphorylation), θ, and σ. Although encoded by 
different genes, all isoforms exhibit highly similar primary sequences [288]. Each protein is 
approximately 30 kDa in size. Typically functioning as homo- or heterodimers partnered with other 
family members, a 14-3-3 monomer consists of nine α-helices that form a conserved amphipathic 
region that acts as the phosphorylation-binding pocket [289]. Binding of the 14-3-3 dimer provides 
steric hindrance or elicits a conformational change that alters the biochemical properties of host 
proteins [244]. For FOXO proteins in particular, 14-3-3 binding licenses FOXO for nuclear exclusion.  
FOXO proteins harbor both a nuclear export signal (NES) at the C-terminus and a nuclear localization 
signal (NLS) proximal to the FH domain, which permit nucleocytoplasmic shuttling [262, 290]. This 
shuttling mechanism is directly influenced by FOXO phosphorylation—primarily by AKT—resulting 
in a regulatory mechanism involving subcellular FOXO sequestration. All mammalian FOXO proteins 
harbor three highly conserved putative AKT recognition motifs with the consensus sequence 
RXRXXS/T [291]. The recognition motifs are found, one each, at the N-terminal, C-terminal, and FH 
domains. Phosphorylation at the N-terminal and FH domains are required for protein translocation. 
The phosphorylated residues act as docking points for 14-3-3 proteins whose binding initiates the 
formation of the nuclear export complex [261]. Upon PI3K pathway activation, dual phosphorylation 
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of FOXO by AKT at the C-terminal and FH domains triggers 14-3-3 binding (Figure 5-2) [292]. This 
results in DNA displacement from the FOXO FH domain. Dimer binding at the same time masks the 
FOXO NLS. Other kinases (i.e., CK1, DYRK1A) phosphorylate multiple residues at the C-terminus, 
priming the complex for association with export factors [263]. The FOXO NES is then recognized and 
bound by the exportin protein CRM1, followed by RAN-GTP attachment. The assembled complex is 
then shuttled from the nucleus through the nuclear pore complex [293]. Once in the cytoplasm, 
phosphorylated FOXO proteins are ubiquitinated, leading to proteasomal degradation which provides 
another layer of FOXO regulation [294, 295].  
 
Figure 5-2. Subcellular shuttling of FOXO proteins. 1, Active nuclear FOXO proteins bind 
to Forkhead response elements (FREs) at gene regulatory regions, driving the transcription of 
FOXO responsive genes. 2, In the presence of growth factors, the PI3K pathway activates 
AKT, which translocates into the nucleus and phosphorylates FOXO. 3, 14-3-3 proteins 
recognize the phosphorylated residues, and as a dimer, bind at the N-terminal and Forkhead 
AKT sites of FOXO. 4, Multiple residues are subsequently phosphorylated by other kinases 
and nuclear export proteins CRM1 and RAN-GTP interact with the nuclear export signal of 
FOXO. 5, Finally, the assembled complex is transported to the cytoplasm through the nuclear 
pore complex. 
 
Although both 14-3-3ε and 14-3-3ζ isoforms were identified by ChIRP-MS, only the direct association 
between LINC00920 and 14-3-3ε was validated by RIP, which was further corroborated by subsequent 
in vitro affinity purification experiments. Due to the high sequence and structural similarities among 
14-3-3 isoforms, it is possible that 14-3-3ε peptides were misidentified as 14-3-3ζ. This would account 
for the apparent specificity of LINC00920 interaction with 14-3-3ε. Indeed, in one experimental 
replicate, peptide signals attributed to 14-3-3 proteins were not isoform-specific. On the other hand, it 
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is also likely that both isoforms were accurately identified by MS but only 14-3-3ε is capable of 
directly associating with the lncRNA, and 14-3-3ζ was simultaneously captured as the dimeric partner 
of 14-3-3ε. In support of this, 14-3-3ε/14-3-3ζ heterodimers have been reported to form in mammalian 
cells [296].  
LINC00920 knockdown increases FOXO function while maintaining the expression of the most 
abundant FOXO isoform in PC-3 cells (Supplementary Figure 9-1). Consequently, the most rational 
implication of LINC00920 binding to 14-3-3ε appears to be increasing the stability of the 14-3-
3/FOXO complex, triggering the nuclear export of FOXO. With respect to FOXO signaling, 
LINC00920 upregulation mimics a cellular context with an activated PI3K pathway, resulting in 
increased nuclear exclusion of FOXO and subsequent repression of its gene targets (Figure 5-3). The 
observed activation of FOXO target genes upon LINC00920 silencing can then be rationalized within 
this molecular framework. In addition, the non-exclusive localization of LINC00920 transcripts in the 
nuclear and cytoplasmic compartments is also in line with the proposed role of LINC00920 within the 
nucleocytoplasmic shuttling model of FOXO.  
 
Figure 5-3. The proposed role of LINC00920 in FOXO/14-3-3 complex assembly in PCa 
cells. In cells depleted of LINC00920, FOXO signaling is basally active. In a cellular context of 
LINC00920 enrichment and AKT activation, 14-3-3 dimerization and binding to FOXO is 
enhanced, resulting in promoted shuttling of FOXO to the cytoplasm. This depletes nuclear 
FOXO levels, leading to diminished transcription of a subset of FOXO gene targets.   
 
5.6. Bridging ERG, PTEN, and FOXO signaling through LINC00920 
Despite the molecular functions attributed to ERG, gene fusion occurrence is considered to be an early 
event in carcinogenesis, and ERG overexpression alone is not sufficient to trigger cellular 
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transformation [297, 298]. Concomitant tumor suppressor gene (i.e., PTEN, TP53) inactivation or 
additional oncogene (i.e., PI3K/AKT) activation must take place to initiate tumorigenesis [299].  
Hyperactivation of PI3K signaling is a common event in PCa, typically facilitated by PTEN loss or 
somatic mutations in pathway-involved genes. Consequently, diminished FOXO signaling is 
frequently observed in the clinical setting and PCa models. In 640 radical prostatectomy samples, 
nuclear FOXO1 expression was higher in normal prostate than in benign prostatic hyperplasia and 
prostate cancer [300], suggesting decreased FOXO1 activity in the diseased state. In a transgenic 
adenocarcinoma of the mouse prostate (TRAMP) mouse model, suppression of FOXO3 activity led to 
increased PCa progression [301]. FOXO3 function was similarly attenuated, as measured by CDKN1B 
promoter activity, in an androgen-independent PCa model derived from in vivo selection of LNCaP 
tumors in castrated mice [302]. In PTEN-null PC-3 cells, overexpression of a phosphorylation-
resistant mutant form of FOXO1 negatively regulates the oncogenic RUNX2 transcription factor, 
leading to reduced migration and invasion [303]. Adenoviral overexpression of FOXO1 and FOXO3 
in LAPC4 prostate carcinoma cells induced the expresssion of pro-apoptotic and tumor suppressive 
genes such as TNFSF10, BNIP3L, DAPK1, and SMAD4 [304]. More recently, it has been reported that 
loss of FOXO1 cooperates with TMPRSS2:ERG overexpression to drive tumor formation and cell 
invasion in prostate cancer [305]. Taken together, these reports illustrate the apparent red line 
interweaving between processes involving ERG, PTEN/PI3K/AKT, and FOXO signaling in the 
context of prostate cancer progression. However, a complete understanding of the diverse molecular 
mechanisms underpinning these complex associations remains elusive. 
The functional model of LINC00920 proposed in this study provides a novel insight on how ERG 
mediates its downstream effects through a lncRNA-mediated attenuation of FOXO signaling. ERG 
drives the transcription of LINC00920 which, upon binding to 14-3-3ε, promotes FOXO sequestration 
and nuclear export of the complex. This mechanism partly rationalizes the decline of FOXO signaling 
through the clinical course of PCa, particularly in ERG-overexpressing cancer cells [305]. Expanding 
this model to an early time point of the disease, during which ETS gene fusions have just been 
established, LINC00920 expression could be a way for pre-cancerous cells to circumvent the tumor 
suppressive influence of PTEN. In this context, ERG- or ETV4-overexpressing cells most likely obtain 
survival advantage by downregulating a subset of tumor suppressive FOXO targets. Subsequently, 
upon PTEN deactivation or PI3K hyperactivation in an ERG overexpressing background, the cell 
experiences concerted oncogenic pressure which initiates downstream transcriptional programs that 
trigger cellular transformation, and eventually maintenance of the neoplastic phenotype. 
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5.7. Outlook 
5.7.1. Further exploration of LINC00920 function in the chromatin 
As LINC00920 coverage was found to colocalize with the enhancer-associated histone mark 
H3K4me1 in a subset of promoter regions in the PC-3 genome, it would be worthwhile to investigate 
the causality between LINC00920 binding and H3K4me1 deposition at these sites. If LINC00920 is 
found to be required for the establishment of H3K4me1 marks, an interesting query would be whether 
LINC00920 licenses these regions as substrates for histone methyltransferases. This can be evaluated 
through H3K4me1 ChIP-seq upon LINC00920 expression perturbation. If corroborating evidence is 
found, it can be inferred that the lncRNA impacts the activity of a number enhancer elements. 
However, given that enhancers can function at great distances, a perceivable challenge that must 
eventually be confronted is the identification of cognate target genes of these putative enhancer 
regions. Ultimately, querying the role of LINC00920 would entail measurements of transcription 
activation of target genes regulated by the enhancer under consideration. 
5.7.2. Assessment of FOXO/14-3-3ε binding affinity 
In support of the proposed role of LINC00920 in FOXO/14-3-3 complex assembly in PCa cells, 
further investigations should include evaluations of the binding affinity between FOXO and 14-3-3ε, 
in the absence or supplementation of LINC00920 RNA. Although the FOXO1 isoform has been 
observed to be the most abundant FOXO protein in PC-3 cells (Supplementary Figure 9-1A) and 
presumably the most important effector of FOXO signaling in this cell line, it would of interest to 
query whether 14-3-3ε exhibits degenerate or preferential binding to a particular FOXO isoform. To 
date, different 14-3-3 isoforms have been shown to bind and regulate FOXO proteins, including 14-3-
3σ [306], 14-3-3ε [307], 14-3-3θ [308] and 14-3-3ζ [261]. However, nuanced combinations and 
binding preferences among family members remain unclear [309] but are likely to be context- and cell 
type-dependent. Technologies that can be applied to assess and compare 14-3-3ε/FOXO interaction 
include reciprocal co-immunoprecipitation, proximity ligation assay, colocalization assay through 
fluorescence imaging, and immunoblotting of nuclear and cytoplasmic FOXO. 
5.7.3. Expanding the in vitro-generated model to ex- and in vivo systems 
Future efforts to dissect the function of LINC00920 using preclinical models would extend the 
relevance of the results presented in this thesis. Genetically engineered mouse models [310, 311], 
xenografted human cell lines [312, 313], patient-derived xenograft models [314, 315], and patient-
derived tumor organoids [316, 317] have been used to characterize cancer-associated lncRNAs in cells 
within intact tumor microenvironments. While each approach has inherent strengths and weaknesses, 
these models in general recapitulate the dynamics of multiple tumor components—such as tumor 
vasculature, immune cells, stromal cells, signaling molecules, and the extracellular matrix—that 
contribute to tumor development and evolution [318]. 
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5.7.4. Considerations for clinical translation 
LncRNAs in general could offer multiple opportunities for clinical translation. Many lncRNAs 
demonstrate tissue-restricted and cancer-specific expression signatures [81].  Indeed, based on tissue-
wide GTEx RNA-seq analysis, the prostate and the testis are among the tissue types with the highest 
LINC00920 expression (Supplementary Figure 9-3) [319].  Moreover, its upregulation in ERG-
positive PCa tumors potentially makes LINC00920 a suitable biomarker for both tissue-of-origin 
assays and tumor molecular subtyping. However, it remains to be explored whether the overall 
expression level of LINC00920 would be sufficient, in the practical sense, for diagnostic applications.  
In recent years, nucleic acid-based therapies have emerged to post-transcriptionally target lncRNAs. 
These include the application of RNA-mediated interference (RNAi), single-stranded antisense 
oligonucleotides (ASOs), and morpholino oligonucleotides [320]. On the basis of its oncogenicity and 
expression pattern, LINC00920 could be a potential therapeutic target in ERG-positive PCa. However, 
despite clinical approvals for ASO drugs as treatment for spinal muscular atrophy [321] and familial 
hypercholesterolemia [322], and a morpholino-based splicing modulator for patients with Duchenne 
muscular dystrophy [323], most lncRNA-targeting therapeutics are in the very early stages of 
development and are still far from clinical use [320].   
 
 
 
 
 
 
 
 
 
 
 
 112 
6. Attributions 
LINC00920 promoter luciferase assays, including promoter construct generation, were performed with 
supervision by Niclas Flosdorf as part of a bachelor’s thesis. Gene expression profiling was performed 
by the Microarray Unit of the Genomics and Proteomics Core Facility (GPCF), DKFZ. Similarly, 
high-throughput DNA sequencing was performed by the High-Throughput Sequencing Unit while 
mass spectrometry experiments and subsequent analyses were performed by the Mass Spectrometry-
based Protein Analysis Unit of the GPCF. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 113 
7. Acknowledgements 
This work came to fruition through the efforts of a number of talented and hard-working individuals. 
A lot of credit goes to my supervisor—Prof. Dr. Holger Sültmann—for supporting and mentoring me 
through this stage of my academic career, for the guidance and constant encouragement, and for 
teaching me how to ask the important questions. I would like to thank my thesis advisory committee 
members—PD Dr. Odilia Popanda and Prof. Dr. med. Stefan Dünsing—for sharing their expertise and 
for providing constructive comments that made the project balanced and more coherent.  
Special thanks to Prof. Dr. Sven Diederichs and Minakshi Gandhi for their invaluable support during 
the establishment of the ChIRP protocol. I am deeply grateful to Dr. Angela Schulz, Dr. Bernd 
Heßling, and Martin Schneider from the Genomics and Proteomics Core Facility of the DKFZ for 
generously sharing their expertise on DNA sequencing (Angela), and mass spectrometry (Bernd and 
Martin). I am grateful to Dr. Doreen Heckmann-Nötzel for the shared experience of exploring the 
complex world of lncRNAs and for being an excellent sounding board for ideas. I am indebted to PD 
Dr. Sabine Klauck for her support in and out of the laboratory, and for always taking the extra step in 
providing assistance—administrative or otherwise. Many thanks for the critical reading of the 
manuscript.  
I would like to show my greatest appreciation to Sabrina Gerhardt for her endless patience and 
exceptional technical assistance. My deepest thanks go to Niclas Flosdorf for the stimulating 
discussions and for completing a portion of the project. The biggest and warmest thank you to the 
members of the B063 group: Leonie, Steffen, Anja, Sabrina M., Sebastian, Mone, Anka, Florian, Lisa, 
Louise, and Saskia. If not for the insightful scientific chats, easygoing company, delicious cakes, and 
oftentimes random and silly pop-culture conversations, completing this thesis would have been a 
thousand-fold more daunting. 
To my family in Heidelberg: Karol, Luis, Simon, Gretchen, Jagoda, Ate Ina, Friedhelm, and Tita 
Yolly. Thank you for providing me the comforts of home thousands of miles away from home. To my 
Heidelberg/Mannheim/Wuppertal Filipino core group: Paulo, Angel, Josh, Fidel, Aeiou, Paul, Joseph, 
and David. Thank you for the company, the laughs, and the lounging sessions. 
I owe a very important debt to Prof. Dr. Rey Garcia for letting my scientific interests flourish and for 
encouraging me to pursue advanced studies abroad. Likewise, I would like to extend my heartfelt 
thanks to Lorenz and Joanne: I am truly blessed by your friendships.  
And to my family, thank you. I dedicate this achievement to you. I love you 3000. 
 
 
 114 
8. References 
1. Zhang, D., et al., Prostate Luminal Progenitor Cells in Development and Cancer. Trends 
Cancer, 2018. 4(11): p. 769-783. 
2. Wang, G., et al., Genetics and biology of prostate cancer. Genes Dev, 2018. 32(17-18): p. 
1105-1140. 
3. Wang, Y., et al., Cell differentiation lineage in the prostate. Differentiation, 2001. 68(4-5): p. 
270-9. 
4. Szczyrba, J., et al., Neuroendocrine Cells of the Prostate Derive from the Neural Crest. J Biol 
Chem, 2017. 292(5): p. 2021-2031. 
5. Abrahamsson, P.A., et al., The course of neuroendocrine differentiation in prostatic 
carcinomas. An immunohistochemical study testing chromogranin A as an "endocrine 
marker". Pathol Res Pract, 1989. 185(3): p. 373-80. 
6. Wang, Z.A., et al., Lineage analysis of basal epithelial cells reveals their unexpected plasticity 
and supports a cell-of-origin model for prostate cancer heterogeneity. Nat Cell Biol, 2013. 
15(3): p. 274-83. 
7. Zhao, S.G., et al., Associations of Luminal and Basal Subtyping of Prostate Cancer With 
Prognosis and Response to Androgen Deprivation Therapy. JAMA Oncol, 2017. 3(12): p. 
1663-1672. 
8. Smith, B.A., et al., A basal stem cell signature identifies aggressive prostate cancer 
phenotypes. Proc Natl Acad Sci U S A, 2015. 112(47): p. E6544-52. 
9. Ferlay, J., et al., Cancer incidence and mortality worldwide: sources, methods and major 
patterns in GLOBOCAN 2012. Int J Cancer, 2015. 136(5): p. E359-86. 
10. Leitzmann, M.F. and S. Rohrmann, Risk factors for the onset of prostatic cancer: age, 
location, and behavioral correlates. Clin Epidemiol, 2012. 4: p. 1-11. 
11. Noone AM, H.N., Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, 
Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2015, 
National Cancer Institute. April 2018 [cited 2018; Available from: 
https://seer.cancer.gov/csr/1975_2015/. 
12. Gronberg, H., Prostate cancer epidemiology. Lancet, 2003. 361(9360): p. 859-64. 
13. Torre, L.A., et al., Global Cancer Incidence and Mortality Rates and Trends--An Update. 
Cancer Epidemiol Biomarkers Prev, 2016. 25(1): p. 16-27. 
14. Jalloh, M., et al., Evaluation of 4,672 routine prostate biopsies performed in six African 
countries. Journal Africain du Cancer / African Journal of Cancer, 2013. 5(3): p. 144-154. 
15. Hsing, A.W., et al., High prevalence of screen detected prostate cancer in West Africans: 
implications for racial disparity of prostate cancer. J Urol, 2014. 192(3): p. 730-5. 
16. Rebbeck, T.R. and G.P. Haas, Temporal trends and racial disparities in global prostate 
cancer prevalence. Can J Urol, 2014. 21(5): p. 7496-506. 
17. Lichtenstein, P., et al., Environmental and heritable factors in the causation of cancer--
analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med, 2000. 
343(2): p. 78-85. 
18. Verhage, B.A., et al., Site-specific familial aggregation of prostate cancer. Int J Cancer, 2004. 
109(4): p. 611-7. 
19. Hjelmborg, J.B., et al., The heritability of prostate cancer in the Nordic Twin Study of Cancer. 
Cancer Epidemiol Biomarkers Prev, 2014. 23(11): p. 2303-10. 
20. Mucci, L.A., et al., Familial Risk and Heritability of Cancer Among Twins in Nordic 
Countries. JAMA, 2016. 315(1): p. 68-76. 
21. Berry, R., et al., Linkage analyses at the chromosome 1 loci 1q24-25 (HPC1), 1q42.2-43 
(PCAP), and 1p36 (CAPB) in families with hereditary prostate cancer. Am J Hum Genet, 
2000. 66(2): p. 539-46. 
22. Schleutker, J., et al., A genetic epidemiological study of hereditary prostate cancer (HPC) in 
Finland: frequent HPCX linkage in families with late-onset disease. Clin Cancer Res, 2000. 
6(12): p. 4810-5. 
 115 
23. Xu, J., et al., HOXB13 is a susceptibility gene for prostate cancer: results from the 
International Consortium for Prostate Cancer Genetics (ICPCG). Hum Genet, 2013. 132(1): 
p. 5-14. 
24. Ledet, E.M., et al., Suggestive evidence of linkage identified at chromosomes 12q24 and 2p16 
in African American prostate cancer families from Louisiana. Prostate, 2012. 72(9): p. 938-
47. 
25. Brown, W.M., et al., Hereditary prostate cancer in African American families: linkage 
analysis using markers that map to five candidate susceptibility loci. Br J Cancer, 2004. 90(2): 
p. 510-4. 
26. Matsui, H., et al., Genomewide linkage analysis of familial prostate cancer in the Japanese 
population. J Hum Genet, 2004. 49(1): p. 9-15. 
27. Eeles, R.A., et al., Identification of seven new prostate cancer susceptibility loci through a 
genome-wide association study. Nat Genet, 2009. 41(10): p. 1116-21. 
28. Schumacher, F.R., et al., Genome-wide association study identifies new prostate cancer 
susceptibility loci. Hum Mol Genet, 2011. 20(19): p. 3867-75. 
29. Haiman, C.A., et al., Genome-wide association study of prostate cancer in men of African 
ancestry identifies a susceptibility locus at 17q21. Nat Genet, 2011. 43(6): p. 570-3. 
30. Kote-Jarai, Z., et al., Seven prostate cancer susceptibility loci identified by a multi-stage 
genome-wide association study. Nat Genet, 2011. 43(8): p. 785-91. 
31. Schumacher, F.R., et al., Association analyses of more than 140,000 men identify 63 new 
prostate cancer susceptibility loci. Nat Genet, 2018. 50(7): p. 928-936. 
32. Mateo, J., et al., DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. N Engl J 
Med, 2015. 373(18): p. 1697-708. 
33. TOPARP: A Phase II Trial of Olaparib in Patients With Advanced Castration Resistant 
Prostate Cancer. Available from: https://ClinicalTrials.gov/show/NCT01682772. 
34. Datta, K., et al., Mechanism of lymph node metastasis in prostate cancer. Future Oncol, 2010. 
6(5): p. 823-36. 
35. Sartor, O. and J.S. de Bono, Metastatic Prostate Cancer. N Engl J Med, 2018. 378(17): p. 
1653-1654. 
36. Force, U.S.P.S.T., et al., Screening for Prostate Cancer: US Preventive Services Task Force 
Recommendation Statement. JAMA, 2018. 319(18): p. 1901-1913. 
37. Mottet, N., et al., EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, 
Diagnosis, and Local Treatment with Curative Intent. Eur Urol, 2017. 71(4): p. 618-629. 
38. Vickers, A.J., et al., Strategy for detection of prostate cancer based on relation between 
prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study. 
BMJ, 2013. 346: p. f2023. 
39. Litwin, M.S. and H.J. Tan, The Diagnosis and Treatment of Prostate Cancer: A Review. 
JAMA, 2017. 317(24): p. 2532-2542. 
40. Gordetsky, J. and J. Epstein, Grading of prostatic adenocarcinoma: current state and 
prognostic implications. Diagn Pathol, 2016. 11: p. 25. 
41. Sun F, O.O., Fontanarosa J, et al. Therapies for Clinically Localized Prostate Cancer: Update 
of a 2008 Systematic Review [Internet]. 2014 Dec. (Comparative Effectiveness Reviews, No. 
146) Introduction:[Available from: https://www.ncbi.nlm.nih.gov/books/NBK269309/. 
42. Fakhrejahani, F., R.A. Madan, and W.L. Dahut, Management Options for Biochemically 
Recurrent Prostate Cancer. Curr Treat Options Oncol, 2017. 18(5): p. 26. 
43. Siegel, R.L., K.D. Miller, and A. Jemal, Cancer statistics, 2018. CA Cancer J Clin, 2018. 
68(1): p. 7-30. 
44. Dai, C., H. Heemers, and N. Sharifi, Androgen Signaling in Prostate Cancer. Cold Spring 
Harb Perspect Med, 2017. 7(9). 
45. Mahon, K.L., et al., Pathways of chemotherapy resistance in castration-resistant prostate 
cancer. Endocr Relat Cancer, 2011. 18(4): p. R103-23. 
46. Galazi, M., et al., Precision medicine for prostate cancer. Expert Rev Anticancer Ther, 2014. 
14(11): p. 1305-15. 
 116 
47. Network, N.C.C. NCCN Guidelines Version 2.2018 Prostate Cancer. 2018  [cited 2018 27 
July 2018]; Available from: 
https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf. 
48. Briganti, A., et al., Active Surveillance for Low-risk Prostate Cancer: The European 
Association of Urology Position in 2018. Eur Urol, 2018. 74(3): p. 357-368. 
49. Attard, G., et al., Prostate cancer. The Lancet, 2016. 387(10013): p. 70-82. 
50. Salari, K., et al., Active Surveillance of Prostate Cancer is a Viable Option in Men Younger 
Than 60 Years. J Urol, 2019. 
51. Bill-Axelson, A., et al., Radical prostatectomy versus watchful waiting in localized prostate 
cancer: the Scandinavian prostate cancer group-4 randomized trial. J Natl Cancer Inst, 2008. 
100(16): p. 1144-54. 
52. Bill-Axelson, A., et al., Radical prostatectomy or watchful waiting in early prostate cancer. N 
Engl J Med, 2014. 370(10): p. 932-42. 
53. Theodorescu, D., Cancer cryotherapy: evolution and biology. Rev Urol, 2004. 6 Suppl 4: p. 
S9-S19. 
54. Ahmed, H.U., et al., Focal therapy for localised unifocal and multifocal prostate cancer: a 
prospective development study. Lancet Oncol, 2012. 13(6): p. 622-32. 
55. Azzouzi, A.R., et al., TOOKAD(R) Soluble focal therapy: pooled analysis of three phase II 
studies assessing the minimally invasive ablation of localized prostate cancer. World J Urol, 
2015. 33(7): p. 945-53. 
56. Montero, A., et al., Docetaxel for treatment of solid tumours: a systematic review of clinical 
data. Lancet Oncol, 2005. 6(4): p. 229-39. 
57. Parker, C., et al., Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl 
J Med, 2013. 369(3): p. 213-23. 
58. Kantoff, P.W., et al., Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N 
Engl J Med, 2010. 363(5): p. 411-22. 
59. Saad, F., J. McKiernan, and J. Eastham, Rationale for zoledronic acid therapy in men with 
hormone-sensitive prostate cancer with or without bone metastasis. Urol Oncol, 2006. 24(1): 
p. 4-12. 
60. Fizazi, K., et al., Denosumab versus zoledronic acid for treatment of bone metastases in men 
with castration-resistant prostate cancer: a randomised, double-blind study. Lancet, 2011. 
377(9768): p. 813-22. 
61. Humeniuk, M.S., et al., Platinum sensitivity in metastatic prostate cancer: does histology 
matter? Prostate Cancer Prostatic Dis, 2018. 21(1): p. 92-99. 
62. Matsumoto, T., et al., The androgen receptor in health and disease. Annu Rev Physiol, 2013. 
75: p. 201-24. 
63. Tan, M.H., et al., Androgen receptor: structure, role in prostate cancer and drug discovery. 
Acta Pharmacol Sin, 2015. 36(1): p. 3-23. 
64. Carroll, P.H. and J.L. Mohler, NCCN Guidelines Updates: Prostate Cancer and Prostate 
Cancer Early Detection. J Natl Compr Canc Netw, 2018. 16(5S): p. 620-623. 
65. Koshkin, V.S. and E.J. Small, Apalutamide in the treatment of castrate-resistant prostate 
cancer: evidence from clinical trials. Ther Adv Urol, 2018. 10(12): p. 445-454. 
66. Chandrasekar, T., et al., Mechanisms of resistance in castration-resistant prostate cancer 
(CRPC). Transl Androl Urol, 2015. 4(3): p. 365-80. 
67. Scott, L.J., Abiraterone Acetate: A Review in Metastatic Castration-Resistant Prostrate 
Cancer. Drugs, 2017. 77(14): p. 1565-1576. 
68. de Bono, J.S., et al., Abiraterone and increased survival in metastatic prostate cancer. N Engl 
J Med, 2011. 364(21): p. 1995-2005. 
69. Ryan, C.J., et al., Abiraterone in metastatic prostate cancer without previous chemotherapy. N 
Engl J Med, 2013. 368(2): p. 138-48. 
70. Scher, H.I., et al., Increased survival with enzalutamide in prostate cancer after 
chemotherapy. N Engl J Med, 2012. 367(13): p. 1187-97. 
71. Beer, T.M., et al., Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J 
Med, 2014. 371(5): p. 424-33. 
 117 
72. Smith, M.R., M.K. Yu, and E.J. Small, Apalutamide and Metastasis-free Survival in Prostate 
Cancer. N Engl J Med, 2018. 378(26): p. 2542. 
73. Angeles, A.K., et al., Genome-Based Classification and Therapy of Prostate Cancer. 
Diagnostics (Basel), 2018. 8(3). 
74. Fraser, M., et al., Genomic hallmarks of localized, non-indolent prostate cancer. Nature, 2017. 
541(7637): p. 359-364. 
75. Cancer Genome Atlas Research, N., The Molecular Taxonomy of Primary Prostate Cancer. 
Cell, 2015. 163(4): p. 1011-25. 
76. Robinson, D., et al., Integrative clinical genomics of advanced prostate cancer. Cell, 2015. 
161(5): p. 1215-1228. 
77. Weischenfeldt, J., et al., Integrative genomic analyses reveal an androgen-driven somatic 
alteration landscape in early-onset prostate cancer. Cancer Cell, 2013. 23(2): p. 159-70. 
78. Ren, S., et al., Whole-genome and Transcriptome Sequencing of Prostate Cancer Identify New 
Genetic Alterations Driving Disease Progression. Eur Urol, 2017. 
79. Quigley, D.A., et al., Genomic Hallmarks and Structural Variation in Metastatic Prostate 
Cancer. Cell, 2018. 175(3): p. 889. 
80. Gerhauser, C., et al., Molecular Evolution of Early-Onset Prostate Cancer Identifies 
Molecular Risk Markers and Clinical Trajectories. Cancer Cell, 2018. 34(6): p. 996-1011 e8. 
81. Prensner, J.R., et al., Transcriptome sequencing across a prostate cancer cohort identifies 
PCAT-1, an unannotated lincRNA implicated in disease progression. Nat Biotechnol, 2011. 
29(8): p. 742-9. 
82. Ylipaa, A., et al., Transcriptome Sequencing Reveals PCAT5 as a Novel ERG-Regulated Long 
Noncoding RNA in Prostate Cancer. Cancer Res, 2015. 75(19): p. 4026-31. 
83. Bhasin, J.M., et al., Methylome-wide Sequencing Detects DNA Hypermethylation 
Distinguishing Indolent from Aggressive Prostate Cancer. Cell Rep, 2015. 13(10): p. 2135-46. 
84. Kim, J.H., et al., Deep sequencing reveals distinct patterns of DNA methylation in prostate 
cancer. Genome Res, 2011. 21(7): p. 1028-41. 
85. Brocks, D., et al., Intratumor DNA methylation heterogeneity reflects clonal evolution in 
aggressive prostate cancer. Cell Rep, 2014. 8(3): p. 798-806. 
86. Kron, K.J., et al., TMPRSS2-ERG fusion co-opts master transcription factors and activates 
NOTCH signaling in primary prostate cancer. Nat Genet, 2017. 49(9): p. 1336-1345. 
87. Latonen, L., et al., Integrative proteomics in prostate cancer uncovers robustness against 
genomic and transcriptomic aberrations during disease progression. Nat Commun, 2018. 
9(1): p. 1176. 
88. Muller, A.K., et al., Proteomic Characterization of Prostate Cancer to Distinguish 
Nonmetastasizing and Metastasizing Primary Tumors and Lymph Node Metastases. 
Neoplasia, 2018. 20(2): p. 140-151. 
89. Sinha, A., et al., The Proteogenomic Landscape of Curable Prostate Cancer. Cancer Cell, 
2019. 35(3): p. 414-427 e6. 
90. Robinson, J.T., et al., Integrative genomics viewer. Nat Biotechnol, 2011. 29(1): p. 24-6. 
91. Rubin, M.A. and F. Demichelis, The Genomics of Prostate Cancer: emerging understanding 
with technologic advances. Mod Pathol, 2018. 31(S1): p. S1-11. 
92. Hieronymus, H., et al., Copy number alteration burden predicts prostate cancer relapse. Proc 
Natl Acad Sci U S A, 2014. 111(30): p. 11139-44. 
93. Tomlins, S.A., et al., Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia, 
2008. 10(2): p. 177-88. 
94. Tomlins, S.A., et al., Recurrent fusion of TMPRSS2 and ETS transcription factor genes in 
prostate cancer. Science, 2005. 310(5748): p. 644-8. 
95. Sandoval, G.J., et al., Binding of TMPRSS2-ERG to BAF Chromatin Remodeling Complexes 
Mediates Prostate Oncogenesis. Mol Cell, 2018. 71(4): p. 554-566 e7. 
96. Yu, J., et al., An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG 
gene fusions in prostate cancer progression. Cancer Cell, 2010. 17(5): p. 443-54. 
97. Ratz, L., et al., TMPRSS2:ERG gene fusion variants induce TGF-beta signaling and epithelial 
to mesenchymal transition in human prostate cancer cells. Oncotarget, 2017. 8(15): p. 25115-
25130. 
 118 
98. Dryden, N.H., et al., The transcription factor Erg controls endothelial cell quiescence by 
repressing activity of nuclear factor (NF)-kappaB p65. J Biol Chem, 2012. 287(15): p. 12331-
42. 
99. Adamo, P. and M.R. Ladomery, The oncogene ERG: a key factor in prostate cancer. 
Oncogene, 2016. 35(4): p. 403-14. 
100. Beltran, H., et al., Molecular characterization of neuroendocrine prostate cancer and 
identification of new drug targets. Cancer Discov, 2011. 1(6): p. 487-95. 
101. Terry, S. and H. Beltran, The many faces of neuroendocrine differentiation in prostate cancer 
progression. Front Oncol, 2014. 4: p. 60. 
102. Beltran, H., et al., Divergent clonal evolution of castration-resistant neuroendocrine prostate 
cancer. Nat Med, 2016. 22(3): p. 298-305. 
103. Aparicio, A.M., et al., Combined Tumor Suppressor Defects Characterize Clinically Defined 
Aggressive Variant Prostate Cancers. Clin Cancer Res, 2016. 22(6): p. 1520-30. 
104. Dardenne, E., et al., N-Myc Induces an EZH2-Mediated Transcriptional Program Driving 
Neuroendocrine Prostate Cancer. Cancer Cell, 2016. 30(4): p. 563-577. 
105. Svensson, C., et al., REST mediates androgen receptor actions on gene repression and 
predicts early recurrence of prostate cancer. Nucleic Acids Res, 2014. 42(2): p. 999-1015. 
106. Eddy, S.R., Non-coding RNA genes and the modern RNA world. Nat Rev Genet, 2001. 2(12): 
p. 919-29. 
107. Lander, E.S., et al., Initial sequencing and analysis of the human genome. Nature, 2001. 
409(6822): p. 860-921. 
108. Lee, R.C., R.L. Feinbaum, and V. Ambros, The C. elegans heterochronic gene lin-4 encodes 
small RNAs with antisense complementarity to lin-14. Cell, 1993. 75(5): p. 843-54. 
109. Reinhart, B.J., et al., The 21-nucleotide let-7 RNA regulates developmental timing in 
Caenorhabditis elegans. Nature, 2000. 403(6772): p. 901-6. 
110. Brown, C.J., et al., A gene from the region of the human X inactivation centre is expressed 
exclusively from the inactive X chromosome. Nature, 1991. 349(6304): p. 38-44. 
111. Ulitsky, I., et al., Conserved function of lincRNAs in vertebrate embryonic development 
despite rapid sequence evolution. Cell, 2011. 147(7): p. 1537-50. 
112. Grote, P., et al., The tissue-specific lncRNA Fendrr is an essential regulator of heart and body 
wall development in the mouse. Dev Cell, 2013. 24(2): p. 206-14. 
113. Sauvageau, M., et al., Multiple knockout mouse models reveal lincRNAs are required for life 
and brain development. Elife, 2013. 2: p. e01749. 
114. Lin, C.-P. and L. He, Noncoding RNAs in Cancer Development. Annual Review of Cancer 
Biology, 2017. 1(1): p. 163-184. 
115. Schmitt, A.M. and H.Y. Chang, Long Noncoding RNAs in Cancer Pathways. Cancer Cell, 
2016. 29(4): p. 452-463. 
116. Pickl, J.M., et al., Novel RNA markers in prostate cancer: functional considerations and 
clinical translation. Biomed Res Int, 2014. 2014: p. 765207. 
117. Pickl, J.M., et al., Ago-RIP-Seq identifies Polycomb repressive complex I member CBX7 as a 
major target of miR-375 in prostate cancer progression. Oncotarget, 2016. 7(37): p. 59589-
59603. 
118. Pichler, M. and G.A. Calin, MicroRNAs in cancer: from developmental genes in worms to 
their clinical application in patients. Br J Cancer, 2015. 113(4): p. 569-73. 
119. Ng, K.W., et al., Piwi-interacting RNAs in cancer: emerging functions and clinical utility. Mol 
Cancer, 2016. 15: p. 5. 
120. Moyano, M. and G. Stefani, piRNA involvement in genome stability and human cancer. J 
Hematol Oncol, 2015. 8: p. 38. 
121. Appaiah, H.N., et al., Persistent upregulation of U6:SNORD44 small RNA ratio in the serum 
of breast cancer patients. Breast Cancer Res, 2011. 13(5): p. R86. 
122. Mannoor, K., J. Liao, and F. Jiang, Small nucleolar RNAs in cancer. Biochim Biophys Acta, 
2012. 1826(1): p. 121-8. 
123. Chen, L., et al., SNORD76, a box C/D snoRNA, acts as a tumor suppressor in glioblastoma. 
Sci Rep, 2015. 5: p. 8588. 
 119 
124. Siprashvili, Z., et al., The noncoding RNAs SNORD50A and SNORD50B bind K-Ras and are 
recurrently deleted in human cancer. Nat Genet, 2016. 48(1): p. 53-8. 
125. Goodarzi, H., et al., Endogenous tRNA-Derived Fragments Suppress Breast Cancer 
Progression via YBX1 Displacement. Cell, 2015. 161(4): p. 790-802. 
126. Green, D., W.D. Fraser, and T. Dalmay, Transfer RNA-derived small RNAs in the cancer 
transcriptome. Pflugers Arch, 2016. 468(6): p. 1041-7. 
127. McHugh, C.A., et al., The Xist lncRNA interacts directly with SHARP to silence transcription 
through HDAC3. Nature, 2015. 521(7551): p. 232-6. 
128. Engreitz, J.M., et al., The Xist lncRNA exploits three-dimensional genome architecture to 
spread across the X chromosome. Science, 2013. 341(6147): p. 1237973. 
129. Lee, S., et al., Noncoding RNA NORAD Regulates Genomic Stability by Sequestering 
PUMILIO Proteins. Cell, 2016. 164(1-2): p. 69-80. 
130. Zhang, Y., et al., Analysis of the androgen receptor-regulated lncRNA landscape identifies a 
role for ARLNC1 in prostate cancer progression. Nat Genet, 2018. 50(6): p. 814-824. 
131. Pasmant, E., et al., Characterization of a germ-line deletion, including the entire INK4/ARF 
locus, in a melanoma-neural system tumor family: identification of ANRIL, an antisense 
noncoding RNA whose expression coclusters with ARF. Cancer Res, 2007. 67(8): p. 3963-9. 
132. Askarian-Amiri, M.E., et al., SNORD-host RNA Zfas1 is a regulator of mammary development 
and a potential marker for breast cancer. RNA, 2011. 17(5): p. 878-91. 
133. Latge, G., et al., Natural Antisense Transcripts: Molecular Mechanisms and Implications in 
Breast Cancers. Int J Mol Sci, 2018. 19(1). 
134. Yu, G., et al., Pseudogene PTENP1 functions as a competing endogenous RNA to suppress 
clear-cell renal cell carcinoma progression. Mol Cancer Ther, 2014. 13(12): p. 3086-97. 
135. Karreth, F.A., et al., The BRAF pseudogene functions as a competitive endogenous RNA and 
induces lymphoma in vivo. Cell, 2015. 161(2): p. 319-32. 
136. Poliseno, L., et al., A coding-independent function of gene and pseudogene mRNAs regulates 
tumour biology. Nature, 2010. 465(7301): p. 1033-8. 
137. Liu, Y., et al., Current Advances on the Important Roles of Enhancer RNAs in Gene 
Regulation and Cancer. Biomed Res Int, 2018. 2018: p. 2405351. 
138. McCleland, M.L., et al., CCAT1 is an enhancer-templated RNA that predicts BET sensitivity 
in colorectal cancer. J Clin Invest, 2016. 126(2): p. 639-52. 
139. Zhao, Y., et al., Activation of P-TEFb by Androgen Receptor-Regulated Enhancer RNAs in 
Castration-Resistant Prostate Cancer. Cell Rep, 2016. 15(3): p. 599-610. 
140. Terracciano, D., et al., The role of a new class of long noncoding RNAs transcribed from 
ultraconserved regions in cancer. Biochim Biophys Acta Rev Cancer, 2017. 1868(2): p. 449-
455. 
141. Olivieri, M., et al., Long non-coding RNA containing ultraconserved genomic region 8 
promotes bladder cancer tumorigenesis. Oncotarget, 2016. 7(15): p. 20636-54. 
142. Mestdagh, P., et al., An integrative genomics screen uncovers ncRNA T-UCR functions in 
neuroblastoma tumours. Oncogene, 2010. 29(24): p. 3583-92. 
143. Dragomir, M. and G.A. Calin, Circular RNAs in Cancer - Lessons Learned From microRNAs. 
Front Oncol, 2018. 8: p. 179. 
144. Li, X., L. Yang, and L.L. Chen, The Biogenesis, Functions, and Challenges of Circular RNAs. 
Mol Cell, 2018. 71(3): p. 428-442. 
145. Bachmayr-Heyda, A., et al., Correlation of circular RNA abundance with proliferation--
exemplified with colorectal and ovarian cancer, idiopathic lung fibrosis, and normal human 
tissues. Sci Rep, 2015. 5: p. 8057. 
146. Guo, H., et al., Mammalian microRNAs predominantly act to decrease target mRNA levels. 
Nature, 2010. 466(7308): p. 835-40. 
147. Roberts, T.C., The MicroRNA Biology of the Mammalian Nucleus. Mol Ther Nucleic Acids, 
2014. 3: p. e188. 
148. Liu, J., et al., Argonaute2 is the catalytic engine of mammalian RNAi. Science, 2004. 
305(5689): p. 1437-41. 
 120 
149. Lewis, B.P., C.B. Burge, and D.P. Bartel, Conserved seed pairing, often flanked by 
adenosines, indicates that thousands of human genes are microRNA targets. Cell, 2005. 
120(1): p. 15-20. 
150. Lu, J., et al., MicroRNA expression profiles classify human cancers. Nature, 2005. 435(7043): 
p. 834-8. 
151. Wach, S., et al., MicroRNA profiles of prostate carcinoma detected by multiplatform 
microRNA screening. Int J Cancer, 2012. 130(3): p. 611-21. 
152. Tong, A.W., et al., MicroRNA profile analysis of human prostate cancers. Cancer Gene Ther, 
2009. 16(3): p. 206-16. 
153. Szczyrba, J., et al., The microRNA profile of prostate carcinoma obtained by deep sequencing. 
Mol Cancer Res, 2010. 8(4): p. 529-38. 
154. Brase, J.C., et al., Circulating miRNAs are correlated with tumor progression in prostate 
cancer. Int J Cancer, 2011. 128(3): p. 608-16. 
155. Majid, S., et al., miRNA-34b inhibits prostate cancer through demethylation, active chromatin 
modifications, and AKT pathways. Clin Cancer Res, 2013. 19(1): p. 73-84. 
156. Vanacore, D., et al., Micrornas in prostate cancer: an overview. Oncotarget, 2017. 8(30): p. 
50240-50251. 
157. Derrien, T., et al., The GENCODE v7 catalog of human long noncoding RNAs: analysis of 
their gene structure, evolution, and expression. Genome Res, 2012. 22(9): p. 1775-89. 
158. Church, D.M., et al., Lineage-specific biology revealed by a finished genome assembly of the 
mouse. PLoS Biol, 2009. 7(5): p. e1000112. 
159. Cabili, M.N., et al., Integrative annotation of human large intergenic noncoding RNAs reveals 
global properties and specific subclasses. Genes Dev, 2011. 25(18): p. 1915-27. 
160. Ulitsky, I. and D.P. Bartel, lincRNAs: genomics, evolution, and mechanisms. Cell, 2013. 
154(1): p. 26-46. 
161. Zhao, Y., et al., NONCODE 2016: an informative and valuable data source of long non-
coding RNAs. Nucleic Acids Res, 2016. 44(D1): p. D203-8. 
162. Huarte, M., et al., A large intergenic noncoding RNA induced by p53 mediates global gene 
repression in the p53 response. Cell, 2010. 142(3): p. 409-19. 
163. Ji, P., et al., MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and 
survival in early-stage non-small cell lung cancer. Oncogene, 2003. 22(39): p. 8031-41. 
164. Prensner, J.R., et al., The long noncoding RNA SChLAP1 promotes aggressive prostate cancer 
and antagonizes the SWI/SNF complex. Nat Genet, 2013. 45(11): p. 1392-8. 
165. Yap, K.L., et al., Molecular interplay of the noncoding RNA ANRIL and methylated histone 
H3 lysine 27 by polycomb CBX7 in transcriptional silencing of INK4a. Mol Cell, 2010. 38(5): 
p. 662-74. 
166. Rinn, J.L., et al., Functional demarcation of active and silent chromatin domains in human 
HOX loci by noncoding RNAs. Cell, 2007. 129(7): p. 1311-23. 
167. Zhao, J., et al., Polycomb proteins targeted by a short repeat RNA to the mouse X 
chromosome. Science, 2008. 322(5902): p. 750-6. 
168. Pandey, R.R., et al., Kcnq1ot1 antisense noncoding RNA mediates lineage-specific 
transcriptional silencing through chromatin-level regulation. Mol Cell, 2008. 32(2): p. 232-
46. 
169. Tsuiji, H., et al., Competition between a noncoding exon and introns: Gomafu contains 
tandem UACUAAC repeats and associates with splicing factor-1. Genes Cells, 2011. 16(5): p. 
479-90. 
170. Tsai, M.C., et al., Long noncoding RNA as modular scaffold of histone modification 
complexes. Science, 2010. 329(5992): p. 689-93. 
171. Hung, T., et al., Extensive and coordinated transcription of noncoding RNAs within cell-cycle 
promoters. Nat Genet, 2011. 43(7): p. 621-9. 
172. Wang, J., et al., CREB up-regulates long non-coding RNA, HULC expression through 
interaction with microRNA-372 in liver cancer. Nucleic Acids Res, 2010. 38(16): p. 5366-83. 
173. Cesana, M., et al., A long noncoding RNA controls muscle differentiation by functioning as a 
competing endogenous RNA. Cell, 2011. 147(2): p. 358-69. 
 121 
174. Matsui, K., et al., Natural antisense transcript stabilizes inducible nitric oxide synthase 
messenger RNA in rat hepatocytes. Hepatology, 2008. 47(2): p. 686-97. 
175. Aird, J., et al., Carcinogenesis in prostate cancer: The role of long non-coding RNAs. 
Noncoding RNA Res, 2018. 3(1): p. 29-38. 
176. Walsh, A.L., et al., Long noncoding RNAs and prostate carcinogenesis: the missing 'linc'? 
Trends Mol Med, 2014. 20(8): p. 428-36. 
177. Bussemakers, M.J., et al., DD3: a new prostate-specific gene, highly overexpressed in 
prostate cancer. Cancer Res, 1999. 59(23): p. 5975-9. 
178. Lemos, A.E., et al., PCA3 long noncoding RNA modulates the expression of key cancer-
related genes in LNCaP prostate cancer cells. Tumour Biol, 2016. 37(8): p. 11339-48. 
179. Ozgur, E., et al., PCA3 Silencing Sensitizes Prostate Cancer Cells to Enzalutamide-mediated 
Androgen Receptor Blockade. Anticancer Res, 2017. 37(7): p. 3631-3637. 
180. Takayama, K., et al., Androgen-responsive long noncoding RNA CTBP1-AS promotes prostate 
cancer. EMBO J, 2013. 32(12): p. 1665-80. 
181. Prensner, J.R., et al., PCAT-1, a long noncoding RNA, regulates BRCA2 and controls 
homologous recombination in cancer. Cancer Res, 2014. 74(6): p. 1651-60. 
182. Petrovics, G., et al., Elevated expression of PCGEM1, a prostate-specific gene with cell 
growth-promoting function, is associated with high-risk prostate cancer patients. Oncogene, 
2004. 23(2): p. 605-11. 
183. Chung, S., et al., Association of a novel long non-coding RNA in 8q24 with prostate cancer 
susceptibility. Cancer Sci, 2011. 102(1): p. 245-52. 
184. Yang, L., et al., lncRNA-dependent mechanisms of androgen-receptor-regulated gene 
activation programs. Nature, 2013. 500(7464): p. 598-602. 
185. Barra, J. and E. Leucci, Probing Long Non-coding RNA-Protein Interactions. Front Mol 
Biosci, 2017. 4: p. 45. 
186. McHugh, C.A., P. Russell, and M. Guttman, Methods for comprehensive experimental 
identification of RNA-protein interactions. Genome Biol, 2014. 15(1): p. 203. 
187. Nainar, S., C. Feng, and R.C. Spitale, Chemical Tools for Dissecting the Role of lncRNAs in 
Epigenetic Regulation. ACS Chem Biol, 2016. 11(8): p. 2091-100. 
188. Ule, J., et al., CLIP identifies Nova-regulated RNA networks in the brain. Science, 2003. 
302(5648): p. 1212-5. 
189. Chi, S.W., et al., Argonaute HITS-CLIP decodes microRNA-mRNA interaction maps. Nature, 
2009. 460(7254): p. 479-86. 
190. Garzia, A., et al., Optimization of PAR-CLIP for transcriptome-wide identification of binding 
sites of RNA-binding proteins. Methods, 2017. 118-119: p. 24-40. 
191. Konig, J., et al., iCLIP--transcriptome-wide mapping of protein-RNA interactions with 
individual nucleotide resolution. J Vis Exp, 2011(50). 
192. Simon, M.D., et al., The genomic binding sites of a noncoding RNA. Proc Natl Acad Sci U S 
A, 2011. 108(51): p. 20497-502. 
193. West, J.A., et al., The long noncoding RNAs NEAT1 and MALAT1 bind active chromatin sites. 
Mol Cell, 2014. 55(5): p. 791-802. 
194. Chu, C., et al., Genomic maps of long noncoding RNA occupancy reveal principles of RNA-
chromatin interactions. Mol Cell, 2011. 44(4): p. 667-78. 
195. Chu, C., et al., Systematic discovery of Xist RNA binding proteins. Cell, 2015. 161(2): p. 404-
16. 
196. Engreitz, J., E.S. Lander, and M. Guttman, RNA antisense purification (RAP) for mapping 
RNA interactions with chromatin. Methods Mol Biol, 2015. 1262: p. 183-97. 
197. Engreitz, J.M., et al., RNA-RNA interactions enable specific targeting of noncoding RNAs to 
nascent Pre-mRNAs and chromatin sites. Cell, 2014. 159(1): p. 188-199. 
198. Hacisuleyman, E., et al., Topological organization of multichromosomal regions by the long 
intergenic noncoding RNA Firre. Nat Struct Mol Biol, 2014. 21(2): p. 198-206. 
199. Borner, K., et al., Robust RNAi enhancement via human Argonaute-2 overexpression from 
plasmids, viral vectors and cell lines. Nucleic Acids Res, 2013. 41(21): p. e199. 
200. Wang, L., et al., CPAT: Coding-Potential Assessment Tool using an alignment-free logistic 
regression model. Nucleic Acids Res, 2013. 41(6): p. e74. 
 122 
201. Kong, L., et al., CPC: assess the protein-coding potential of transcripts using sequence 
features and support vector machine. Nucleic Acids Res, 2007. 35(Web Server issue): p. 
W345-9. 
202. McLean, C.Y., et al., GREAT improves functional interpretation of cis-regulatory regions. Nat 
Biotechnol, 2010. 28(5): p. 495-501. 
203. Subramanian, A., et al., Gene set enrichment analysis: a knowledge-based approach for 
interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A, 2005. 102(43): p. 
15545-50. 
204. Schindelin, J., et al., Fiji: an open-source platform for biological-image analysis. Nat 
Methods, 2012. 9(7): p. 676-82. 
205. Geissmann, Q., OpenCFU, a new free and open-source software to count cell colonies and 
other circular objects. PLoS One, 2013. 8(2): p. e54072. 
206. Team, R., RStudio: Integrated Development for R. 2015, RStudio Inc.: Boston, MA, USA. 
207. Lin, J., et al., Targeting activated Akt with GDC-0068, a novel selective Akt inhibitor that is 
efficacious in multiple tumor models. Clin Cancer Res, 2013. 19(7): p. 1760-72. 
208. Lai, F., E. Blumenthal, and R. Shiekhattar, Detection and Analysis of Long Noncoding RNAs. 
Methods Enzymol, 2016. 573: p. 421-44. 
209. Goldman, M., et al., The UCSC Xena platform for public and private cancer genomics data 
visualization and interpretation. bioRxiv, 2019: p. 326470. 
210. Taberlay, P.C., et al., Reconfiguration of nucleosome-depleted regions at distal regulatory 
elements accompanies DNA methylation of enhancers and insulators in cancer. Genome Res, 
2014. 24(9): p. 1421-32. 
211. Afgan, E., et al., The Galaxy platform for accessible, reproducible and collaborative 
biomedical analyses: 2016 update. Nucleic Acids Res, 2016. 44(W1): p. W3-W10. 
212. Andrews, S. FastQC: A quality control tool for high throughput sequence data. 2018; 
Available from: http://www.bioinformatics.babraham.ac.uk/projects/fastqc. 
213. Blankenberg, D., et al., Manipulation of FASTQ data with Galaxy. Bioinformatics, 2010. 
26(14): p. 1783-5. 
214. Langmead, B. and S.L. Salzberg, Fast gapped-read alignment with Bowtie 2. Nat Methods, 
2012. 9(4): p. 357-9. 
215. Li, H., et al., The Sequence Alignment/Map format and SAMtools. Bioinformatics, 2009. 
25(16): p. 2078-9. 
216. Ramirez, F., et al., deepTools2: a next generation web server for deep-sequencing data 
analysis. Nucleic Acids Res, 2016. 44(W1): p. W160-5. 
217. Haeussler, M., et al., The UCSC Genome Browser database: 2019 update. Nucleic Acids Res, 
2019. 47(D1): p. D853-D858. 
218. Khan, A., et al., JASPAR 2018: update of the open-access database of transcription factor 
binding profiles and its web framework. Nucleic Acids Res, 2018. 46(D1): p. D1284. 
219. Taberlay, P.C., et al., Three-dimensional disorganization of the cancer genome occurs 
coincident with long-range genetic and epigenetic alterations. Genome Res, 2016. 26(6): p. 
719-31. 
220. Bailey, T.L. and C. Elkan, Fitting a mixture model by expectation maximization to discover 
motifs in biopolymers. Proc Int Conf Intell Syst Mol Biol, 1994. 2: p. 28-36. 
221. Liberzon, A., et al., Molecular signatures database (MSigDB) 3.0. Bioinformatics, 2011. 
27(12): p. 1739-40. 
222. Iyer, M.K., et al., The landscape of long noncoding RNAs in the human transcriptome. Nat 
Genet, 2015. 47(3): p. 199-208. 
223. Werner, M.S., et al., Chromatin-enriched lncRNAs can act as cell-type specific activators of 
proximal gene transcription. Nat Struct Mol Biol, 2017. 24(7): p. 596-603. 
224. Ransohoff, J.D., Y. Wei, and P.A. Khavari, The functions and unique features of long 
intergenic non-coding RNA. Nat Rev Mol Cell Biol, 2018. 19(3): p. 143-157. 
225. Washietl, S., M. Kellis, and M. Garber, Evolutionary dynamics and tissue specificity of human 
long noncoding RNAs in six mammals. Genome Res, 2014. 24(4): p. 616-28. 
226. Harrow, J., et al., GENCODE: the reference human genome annotation for The ENCODE 
Project. Genome Res, 2012. 22(9): p. 1760-74. 
 123 
227. Xu, J., et al., A comprehensive overview of lncRNA annotation resources. Brief Bioinform, 
2017. 18(2): p. 236-249. 
228. Frohman, M.A., M.K. Dush, and G.R. Martin, Rapid production of full-length cDNAs from 
rare transcripts: amplification using a single gene-specific oligonucleotide primer. Proc Natl 
Acad Sci U S A, 1988. 85(23): p. 8998-9002. 
229. Lin, M.F., I. Jungreis, and M. Kellis, PhyloCSF: a comparative genomics method to 
distinguish protein coding and non-coding regions. Bioinformatics, 2011. 27(13): p. i275-82. 
230. Dijkers, P.F., et al., Expression of the pro-apoptotic Bcl-2 family member Bim is regulated by 
the forkhead transcription factor FKHR-L1. Curr Biol, 2000. 10(19): p. 1201-4. 
231. Dijkers, P.F., et al., Forkhead transcription factor FKHR-L1 modulates cytokine-dependent 
transcriptional regulation of p27(KIP1). Mol Cell Biol, 2000. 20(24): p. 9138-48. 
232. Tran, H., et al., DNA repair pathway stimulated by the forkhead transcription factor FOXO3a 
through the Gadd45 protein. Science, 2002. 296(5567): p. 530-4. 
233. Valis, K., et al., Hippo/Mst1 stimulates transcription of the proapoptotic mediator NOXA in a 
FoxO1-dependent manner. Cancer Res, 2011. 71(3): p. 946-54. 
234. Vlietstra, R.J., et al., Frequent inactivation of PTEN in prostate cancer cell lines and 
xenografts. Cancer Res, 1998. 58(13): p. 2720-3. 
235. McMenamin, M.E., et al., Loss of PTEN expression in paraffin-embedded primary prostate 
cancer correlates with high Gleason score and advanced stage. Cancer Res, 1999. 59(17): p. 
4291-6. 
236. Mertz, K.D., et al., Molecular characterization of TMPRSS2-ERG gene fusion in the NCI-
H660 prostate cancer cell line: a new perspective for an old model. Neoplasia, 2007. 9(3): p. 
200-6. 
237. Negre, N., et al., A cis-regulatory map of the Drosophila genome. Nature, 2011. 471(7339): p. 
527-31. 
238. Hollenhorst, P.C., et al., The ETS gene ETV4 is required for anchorage-independent growth 
and a cell proliferation gene expression program in PC3 prostate cells. Genes & cancer, 
2010. 1(10): p. 1044-1052. 
239. Machyna, M. and M.D. Simon, Catching RNAs on chromatin using hybridization capture 
methods. Brief Funct Genomics, 2018. 17(2): p. 96-103. 
240. Heintzman, N.D., et al., Distinct and predictive chromatin signatures of transcriptional 
promoters and enhancers in the human genome. Nat Genet, 2007. 39(3): p. 311-8. 
241. Heintzman, N.D., et al., Histone modifications at human enhancers reflect global cell-type-
specific gene expression. Nature, 2009. 459(7243): p. 108-12. 
242. Shackelford, D.B. and R.J. Shaw, The LKB1-AMPK pathway: metabolism and growth control 
in tumour suppression. Nat Rev Cancer, 2009. 9(8): p. 563-75. 
243. Zhang, Y., et al., Model-based analysis of ChIP-Seq (MACS). Genome Biol, 2008. 9(9): p. 
R137. 
244. Hermeking, H., The 14-3-3 cancer connection. Nat Rev Cancer, 2003. 3(12): p. 931-43. 
245. Zhang, X., et al., Akt, FoxO and regulation of apoptosis. Biochim Biophys Acta, 2011. 
1813(11): p. 1978-86. 
246. Li, J., et al., TANRIC: An Interactive Open Platform to Explore the Function of lncRNAs in 
Cancer. Cancer Res, 2015. 75(18): p. 3728-37. 
247. Cunningham, D. and Z. You, In vitro and in vivo model systems used in prostate cancer 
research. J Biol Methods, 2015. 2(1). 
248. Tian, B. and J.L. Manley, Alternative polyadenylation of mRNA precursors. Nat Rev Mol Cell 
Biol, 2017. 18(1): p. 18-30. 
249. Hu, J., et al., Bioinformatic identification of candidate cis-regulatory elements involved in 
human mRNA polyadenylation. RNA, 2005. 11(10): p. 1485-93. 
250. Housman, G. and I. Ulitsky, Methods for distinguishing between protein-coding and long 
noncoding RNAs and the elusive biological purpose of translation of long noncoding RNAs. 
Biochim Biophys Acta, 2016. 1859(1): p. 31-40. 
251. Dinger, M.E., et al., Differentiating protein-coding and noncoding RNA: challenges and 
ambiguities. PLoS Comput Biol, 2008. 4(11): p. e1000176. 
 124 
252. Clamp, M., et al., Distinguishing protein-coding and noncoding genes in the human genome. 
Proc Natl Acad Sci U S A, 2007. 104(49): p. 19428-33. 
253. Claverie, J.M., I. Sauvaget, and L. Bougueleret, K-tuple frequency analysis: from intron/exon 
discrimination to T-cell epitope mapping. Methods Enzymol, 1990. 183: p. 237-52. 
254. van der Vos, K.E. and P.J. Coffer, FOXO-binding partners: it takes two to tango. Oncogene, 
2008. 27(16): p. 2289-99. 
255. Furuyama, T., et al., Identification of the differential distribution patterns of mRNAs and 
consensus binding sequences for mouse DAF-16 homologues. Biochem J, 2000. 349(Pt 2): p. 
629-34. 
256. Vogel, M.J., et al., FOXO1 repression contributes to block of plasma cell differentiation in 
classical Hodgkin lymphoma. Blood, 2014. 124(20): p. 3118-29. 
257. Mei, Y., et al., Regulation of neuroblastoma differentiation by forkhead transcription factors 
FOXO1/3/4 through the receptor tyrosine kinase PDGFRA. Proc Natl Acad Sci U S A, 2012. 
109(13): p. 4898-903. 
258. Paik, J.H., et al., FoxOs are lineage-restricted redundant tumor suppressors and regulate 
endothelial cell homeostasis. Cell, 2007. 128(2): p. 309-23. 
259. Dansen, T.B. and B.M. Burgering, Unravelling the tumor-suppressive functions of FOXO 
proteins. Trends Cell Biol, 2008. 18(9): p. 421-9. 
260. Ghaffari, S., et al., Cytokines and BCR-ABL mediate suppression of TRAIL-induced apoptosis 
through inhibition of forkhead FOXO3a transcription factor. Proc Natl Acad Sci U S A, 2003. 
100(11): p. 6523-8. 
261. Brunet, A., et al., Akt promotes cell survival by phosphorylating and inhibiting a Forkhead 
transcription factor. Cell, 1999. 96(6): p. 857-68. 
262. Brownawell, A.M., et al., Inhibition of nuclear import by protein kinase B (Akt) regulates the 
subcellular distribution and activity of the forkhead transcription factor AFX. Mol Cell Biol, 
2001. 21(10): p. 3534-46. 
263. Rena, G., et al., Two novel phosphorylation sites on FKHR that are critical for its nuclear 
exclusion. EMBO J, 2002. 21(9): p. 2263-71. 
264. Carracedo, A. and P.P. Pandolfi, The PTEN-PI3K pathway: of feedbacks and cross-talks. 
Oncogene, 2008. 27(41): p. 5527-41. 
265. Maehama, T. and J.E. Dixon, The tumor suppressor, PTEN/MMAC1, dephosphorylates the 
lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem, 1998. 
273(22): p. 13375-8. 
266. Zhan, Q., Gadd45a, a p53- and BRCA1-regulated stress protein, in cellular response to DNA 
damage. Mutat Res, 2005. 569(1-2): p. 133-43. 
267. Jin, S., et al., The GADD45 inhibition of Cdc2 kinase correlates with GADD45-mediated 
growth suppression. J Biol Chem, 2000. 275(22): p. 16602-8. 
268. Schulz, W.A., et al., Factor interaction analysis for chromosome 8 and DNA methylation 
alterations highlights innate immune response suppression and cytoskeletal changes in 
prostate cancer. Mol Cancer, 2007. 6: p. 14. 
269. Doerflinger, M., J.A. Glab, and H. Puthalakath, BH3-only proteins: a 20-year stock-take. 
FEBS J, 2015. 282(6): p. 1006-16. 
270. Wang, F., et al., Structures of KIX domain of CBP in complex with two FOXO3a 
transactivation domains reveal promiscuity and plasticity in coactivator recruitment. Proc 
Natl Acad Sci U S A, 2012. 109(16): p. 6078-83. 
271. Kim, T.D., S. Shin, and R. Janknecht, ETS transcription factor ERG cooperates with histone 
demethylase KDM4A. Oncol Rep, 2016. 35(6): p. 3679-88. 
272. Aytes, A., et al., ETV4 promotes metastasis in response to activation of PI3-kinase and Ras 
signaling in a mouse model of advanced prostate cancer. Proc Natl Acad Sci U S A, 2013. 
110(37): p. E3506-15. 
273. Hollenhorst, P.C., et al., The ETS gene ETV4 is required for anchorage-independent growth 
and a cell proliferation gene expression program in PC3 prostate cells. Genes Cancer, 2011. 
1(10): p. 1044-1052. 
274. Smolle, M.A., et al., Current Insights into Long Non-Coding RNAs (LncRNAs) in Prostate 
Cancer. Int J Mol Sci, 2017. 18(2). 
 125 
275. Quinn, J.J., et al., Revealing long noncoding RNA architecture and functions using domain-
specific chromatin isolation by RNA purification. Nat Biotechnol, 2014. 32(9): p. 933-940. 
276. Chu, C., R.C. Spitale, and H.Y. Chang, Technologies to probe functions and mechanisms of 
long noncoding RNAs. Nat Struct Mol Biol, 2015. 22(1): p. 29-35. 
277. Calo, E. and J. Wysocka, Modification of enhancer chromatin: what, how, and why? Mol 
Cell, 2013. 49(5): p. 825-37. 
278. Long, H.K., S.L. Prescott, and J. Wysocka, Ever-Changing Landscapes: Transcriptional 
Enhancers in Development and Evolution. Cell, 2016. 167(5): p. 1170-1187. 
279. Pradeepa, M.M., et al., Histone H3 globular domain acetylation identifies a new class of 
enhancers. Nat Genet, 2016. 48(6): p. 681-6. 
280. Local, A., et al., Identification of H3K4me1-associated proteins at mammalian enhancers. Nat 
Genet, 2018. 50(1): p. 73-82. 
281. Kawabe, Y., et al., Carm1 regulates Pax7 transcriptional activity through MLL1/2 
recruitment during asymmetric satellite stem cell divisions. Cell Stem Cell, 2012. 11(3): p. 
333-45. 
282. Lee, S., et al., Coactivator as a target gene specificity determinant for histone H3 lysine 4 
methyltransferases. Proc Natl Acad Sci U S A, 2006. 103(42): p. 15392-7. 
283. Mo, R., S.M. Rao, and Y.J. Zhu, Identification of the MLL2 complex as a coactivator for 
estrogen receptor alpha. J Biol Chem, 2006. 281(23): p. 15714-20. 
284. Wang, K.C., et al., A long noncoding RNA maintains active chromatin to coordinate homeotic 
gene expression. Nature, 2011. 472(7341): p. 120-4. 
285. Bacolla, A., G. Wang, and K.M. Vasquez, New Perspectives on DNA and RNA Triplexes As 
Effectors of Biological Activity. PLoS Genet, 2015. 11(12): p. e1005696. 
286. Szabat, M., E. Kierzek, and R. Kierzek, Modified RNA triplexes: Thermodynamics, structure 
and biological potential. Sci Rep, 2018. 8(1): p. 13023. 
287. Castello, A., et al., Comprehensive Identification of RNA-Binding Domains in Human Cells. 
Mol Cell, 2016. 63(4): p. 696-710. 
288. Babula, J.J. and J.Y. Liu, Integrate Omics Data and Molecular Dynamics Simulations toward 
Better Understanding of Human 14-3-3 Interactomes and Better Drugs for Cancer Therapy. J 
Genet Genomics, 2015. 42(10): p. 531-547. 
289. Pennington, K.L., et al., The dynamic and stress-adaptive signaling hub of 14-3-3: emerging 
mechanisms of regulation and context-dependent protein-protein interactions. Oncogene, 
2018. 37(42): p. 5587-5604. 
290. Biggs, W.H., 3rd, et al., Protein kinase B/Akt-mediated phosphorylation promotes nuclear 
exclusion of the winged helix transcription factor FKHR1. Proc Natl Acad Sci U S A, 1999. 
96(13): p. 7421-6. 
291. Alessi, D.R., et al., Molecular basis for the substrate specificity of protein kinase B; 
comparison with MAPKAP kinase-1 and p70 S6 kinase. FEBS Lett, 1996. 399(3): p. 333-8. 
292. Obsil, T. and V. Obsilova, Structural basis for DNA recognition by FOXO proteins. Biochim 
Biophys Acta, 2011. 1813(11): p. 1946-53. 
293. Van Der Heide, L.P., M.F. Hoekman, and M.P. Smidt, The ins and outs of FoxO shuttling: 
mechanisms of FoxO translocation and transcriptional regulation. Biochem J, 2004. 380(Pt 
2): p. 297-309. 
294. Plas, D.R. and C.B. Thompson, Akt activation promotes degradation of tuberin and FOXO3a 
via the proteasome. J Biol Chem, 2003. 278(14): p. 12361-6. 
295. Matsuzaki, H., et al., Insulin-induced phosphorylation of FKHR (Foxo1) targets to 
proteasomal degradation. Proc Natl Acad Sci U S A, 2003. 100(20): p. 11285-90. 
296. Chaudhri, M., M. Scarabel, and A. Aitken, Mammalian and yeast 14-3-3 isoforms form 
distinct patterns of dimers in vivo. Biochem Biophys Res Commun, 2003. 300(3): p. 679-85. 
297. Carver, B.S., et al., Aberrant ERG expression cooperates with loss of PTEN to promote cancer 
progression in the prostate. Nat Genet, 2009. 41(5): p. 619-24. 
298. King, J.C., et al., Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in 
prostate oncogenesis. Nat Genet, 2009. 41(5): p. 524-6. 
 126 
299. Zong, Y., et al., ETS family transcription factors collaborate with alternative signaling 
pathways to induce carcinoma from adult murine prostate cells. Proc Natl Acad Sci U S A, 
2009. 106(30): p. 12465-70. 
300. Li, R., et al., Forkhead protein FKHR and its phosphorylated form p-FKHR in human prostate 
cancer. Hum Pathol, 2007. 38(10): p. 1501-7. 
301. Shukla, S., et al., Deregulation of FoxO3a accelerates prostate cancer progression in TRAMP 
mice. Prostate, 2013. 73(14): p. 1507-17. 
302. Lynch, R.L., et al., The progression of LNCaP human prostate cancer cells to androgen 
independence involves decreased FOXO3a expression and reduced p27KIP1 promoter 
transactivation. Mol Cancer Res, 2005. 3(3): p. 163-9. 
303. Zhang, H., et al., FOXO1 inhibits Runx2 transcriptional activity and prostate cancer cell 
migration and invasion. Cancer Res, 2011. 71(9): p. 3257-67. 
304. Modur, V., et al., FOXO proteins regulate tumor necrosis factor-related apoptosis inducing 
ligand expression. Implications for PTEN mutation in prostate cancer. J Biol Chem, 2002. 
277(49): p. 47928-37. 
305. Yang, Y., et al., Loss of FOXO1 Cooperates with TMPRSS2-ERG Overexpression to Promote 
Prostate Tumorigenesis and Cell Invasion. Cancer Res, 2017. 77(23): p. 6524-6537. 
306. Su, Y.W., et al., 14-3-3sigma regulates B-cell homeostasis through stabilization of FOXO1. 
Proc Natl Acad Sci U S A, 2011. 108(4): p. 1555-60. 
307. Shen, Y., et al., FoxO1 inhibits transcription and membrane trafficking of epithelial Na+ 
channel. J Cell Sci, 2015. 128(19): p. 3621-30. 
308. Arimoto-Ishida, E., et al., Inhibition of phosphorylation of a forkhead transcription factor 
sensitizes human ovarian cancer cells to cisplatin. Endocrinology, 2004. 145(4): p. 2014-22. 
309. Tzivion, G., M. Dobson, and G. Ramakrishnan, FoxO transcription factors; Regulation by 
AKT and 14-3-3 proteins. Biochim Biophys Acta, 2011. 1813(11): p. 1938-45. 
310. Zhang, B., et al., The lncRNA Malat1 is dispensable for mouse development but its 
transcription plays a cis-regulatory role in the adult. Cell Rep, 2012. 2(1): p. 111-23. 
311. Mello, S.S., et al., Neat1 is a p53-inducible lincRNA essential for transformation suppression. 
Genes Dev, 2017. 31(11): p. 1095-1108. 
312. Trimarchi, T., et al., Genome-wide mapping and characterization of Notch-regulated long 
noncoding RNAs in acute leukemia. Cell, 2014. 158(3): p. 593-606. 
313. Gutschner, T., et al., The noncoding RNA MALAT1 is a critical regulator of the metastasis 
phenotype of lung cancer cells. Cancer Res, 2013. 73(3): p. 1180-9. 
314. Gupta, R.A., et al., Long non-coding RNA HOTAIR reprograms chromatin state to promote 
cancer metastasis. Nature, 2010. 464(7291): p. 1071-6. 
315. Leucci, E., et al., Melanoma addiction to the long non-coding RNA SAMMSON. Nature, 2016. 
531(7595): p. 518-22. 
316. Arun, G., et al., Differentiation of mammary tumors and reduction in metastasis upon Malat1 
lncRNA loss. Genes Dev, 2016. 30(1): p. 34-51. 
317. Diermeier, S.D., et al., Mammary Tumor-Associated RNAs Impact Tumor Cell Proliferation, 
Invasion, and Migration. Cell Rep, 2016. 17(1): p. 261-274. 
318. Balkwill, F.R., M. Capasso, and T. Hagemann, The tumor microenvironment at a glance. J 
Cell Sci, 2012. 125(Pt 23): p. 5591-6. 
319. Consortium, G.T., The Genotype-Tissue Expression (GTEx) project. Nat Genet, 2013. 45(6): 
p. 580-5. 
320. Arun, G., S.D. Diermeier, and D.L. Spector, Therapeutic Targeting of Long Non-Coding 
RNAs in Cancer. Trends Mol Med, 2018. 24(3): p. 257-277. 
321. Finkel, R.S., et al., Treatment of infantile-onset spinal muscular atrophy with nusinersen: a 
phase 2, open-label, dose-escalation study. Lancet, 2016. 388(10063): p. 3017-3026. 
322. Geary, R.S., B.F. Baker, and S.T. Crooke, Clinical and preclinical pharmacokinetics and 
pharmacodynamics of mipomersen (kynamro((R))): a second-generation antisense 
oligonucleotide inhibitor of apolipoprotein B. Clin Pharmacokinet, 2015. 54(2): p. 133-46. 
323. Goemans, N.M., et al., Systemic administration of PRO051 in Duchenne's muscular 
dystrophy. N Engl J Med, 2011. 364(16): p. 1513-22. 
 
 127 
9. Appendix 
9.1. Full-length sequences of cloned lncRNAs 
Supplementary Table 9-1. Sequences of lncRNAs as verified by Sanger sequencing. 
Full-length LINC00844 cDNA sequence (405 bp) 
Source: Normal human prostate  
AGAGACAAAGGAAACACAGAGACATAGACATGGATCTGGGAAATACACCTTTTGCTACTCGTTCA
GTTTTAGCAAGGAGGTTTCTTGCATGGCTAAGCAAAACTTAAACTTCCTCTGAGAATTACAGGAAT
TACAGGACCTGACAAAGCTATGAAGATTAAAACCTATAGGAAGAAAATCTGAACCAGAAACAGTA
TGGCAGAATTGGGATCTGACTCACAGAGGGAAGAACTTATAATTCTTCACAGGTCACATAGAAGCA
TGAGAATTTGGGTTCAAGCAAGTAAATTCTAAATCAGAATCCATACATAAAGTGTTTGCAATGTCC
AGTTATATCTCCATGATATTTTCTTTGTGGAAGTTGATTGTTCTTCCTTACAATAAATTGCTTGAATT
GTCTGTCTA 
Full-length LINC01082 cDNA sequence (441 bp) 
Source: Normal human prostate 
GGTTTAGATTAGCCGTGGCCTAGGCCGTTTGACGGGGTGACACGAGCCTGCAGGGCCGAGTCCAAG
GCCCGGAGATAGGACCAACCGTCAGGAATGCGAGGAATGTTTTTCTTCGGACTCTATCGAGGCACA
CAGACAGACCATGGGGATTCTGTCTACAGTGACAGCCTTAACATTTGCCAGAGCCCTGGACGGCTG
CAGAAATGGCATTGCCCACCCTGCAAGTGAGAAGCACAGACTCGAGAAATGTAGGGAACTCGAGA
GCAGCCACTCGGCCCCAGGATCAACCCAGCACCGAAGAAAAACAACCAGAAGAAATTATTCTTCA
GCCTGAAATGAAGCCGGGATCAAATGGTTGCTGATCAGAGCCCATATTTAAATTGGAAAAGTCAA
ATTGAGCATTATTAAATAAAGCTTGTTTAATATGTCTCAAACAGAAAA 
Full-length LINC00920 cDNA sequence (1567 bp) 
Source: Normal human prostate 
ATCTTCACAGGGAAGGAAGCAACAAAACTCTGCCTTTGGCTTTTGCTGGCTGAGCAGGGAAAGGCC
TATAGACACAGGGCATTGGGCAGGAGCTAGAACAGCCCTCCCTAGAGCACTACATAAAGCAGCCA
ATATTTTGCAAAGCATAGGGAAGAGTGAAAGTCATCCGGGGCATTTGCAGACACAGCACTAAGAA
CTTGGTGACAACAGCCCTGAAGCAAAACAGCAGCATGTACTGGGCAGGGCTTGGGAGATAAGACA
GGACATCTGAAGCTAAACATGGATCCCCTCTGAAAGCTACAATCAAAGTGTCATCCACAAAATCTT
ATCTCAAGCCTTGACTAGAGAAGGACCCACTTCCAAGACCACAGAGTTGAATGAATTCAGTCCTTG
CAGCCCGTTGAACTGAGGGCCTCCCCAACATGCTCACCTGCTTCATCAAAGCCTGCGAGAGAGAGA
GTCCACTAGCAAGAGGACATTGCAGTCTTATCTAATGCAATCACTGAAGTGACATCCTGTCACCTT
GGTCACCTTTTCTATTCTATTCATTATAAATGAGTCCCAAGTCCTGCCACACTCAAGTGGAGGGGAT
TACACAGGGCTGGAGTACCAGCGGTGGGGATAATTTGGGGTCATCTTAGAGTTCTTCCATCACACG
GGAATTCTCAGCTCACCAAATCTGGGATTCCGCATCTGGCCATTCCTTAAGCTGAAGGCCTGGCAT
ATTTTTGAGTGTCCATTTGGATCAGCTAATAAACCCAGGGTTTGTCTACTGGCTGGAGGAGTAAGA
ACTATAAGGCTAATTGAAATGAATCTACTTAAAATAGTGACCTGATTTTTCTAATAATTACTGGAA
GGTAAGGGTTGATTGAGACTTTAAAATAAAACCAAAAATTATTCTAAATTTTTCATATTTTATATAA
GAAAGTTTTGATTTTTACTGCAACCATTTTCTAACTCTTAAAATAAAGAAAGGATAATTCAAGTGTT
GATATTTTCCCAACATAAATATACAGGAACATAATGTAGCTTACTTGTATTTTATCTTTGATTTACA
CAAGAGAATTTTTATACAAATATTCCAGGCTCATTAGTTTTCCCAAAGGCTTCTCATAATCCTTTGA
TATTTAAATCATTCCCTCTTTCAAGTCATTTTTTATCTGCCTTGTCGATACTCTTTTTGTTAATTTGCC
CAACTCATCTGGATCTTCCTTTGTCACTGGCTCTGTAAATTTGAGTATTTCTCCAATAATGCTCCTGT
CAACTTTATGAAACCCTTTGTCTTTTGCAAGATTTAAAAATTCCCTTTATAATAAGCATTCTACAGT
AAGTGAAGACTCACTAGCAAATATATGAGTGATGGATCAAGAGAGACAAAGTGTTAAAAATTGAC
AGATGCAACTTTTAAAAATGAAATTCTTGGTTACCATCTAACAAAGTAAGTACAGGACCTGTATGC
TGAAAACTACAAAACACTAATGAAGGAATCAAAGAAAGTGTAAATAAATGGAGAGATATACCATG
TTCATGAATTGGAAGTCTCAGAATTATTAAAATGTAAATTCTA 
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9.2. Top deregulated genes upon LINC00920 knockdown in PC-3 cells 
Supplementary Table 9-2. LINC00920-deregulated genes (n=315) analyzed with Ingenuity 
Pathway Analysis (IPA) 
Expr Fold 
Change 
ID Entrez Gene Name Location Type(s) 
5.696 IL8 C-X-C motif chemokine ligand 8 
Extracellular 
Space 
cytokine 
4.399 PDLIM7 PDZ and LIM domain 7 Cytoplasm other 
3.911 RDH10 retinol dehydrogenase 10 Nucleus enzyme 
3.699 PI3 peptidase inhibitor 3 
Extracellular 
Space 
other 
3.2 CXCL1 C-X-C motif chemokine ligand 1 
Extracellular 
Space 
cytokine 
3.077 GEM 
GTP binding protein overexpressed in skeletal 
muscle 
Plasma 
Membrane 
enzyme 
2.954 SOD2 superoxide dismutase 2 Cytoplasm enzyme 
2.924 DSC2 desmocollin 2 
Plasma 
Membrane 
other 
2.913 DUSP1 dual specificity phosphatase 1 Nucleus phosphatase 
2.892 DHRS9 dehydrogenase/reductase 9 Cytoplasm enzyme 
2.683 CLDN11 claudin 11 
Plasma 
Membrane 
other 
2.659 CFDP1 craniofacial development protein 1 
Extracellular 
Space 
other 
2.625 TACSTD1 epithelial cell adhesion molecule 
Plasma 
Membrane 
other 
2.445 RASD1 ras related dexamethasone induced 1 Cytoplasm enzyme 
2.315 P4HA2 prolyl 4-hydroxylase subunit alpha 2 Cytoplasm transporter 
2.256 CRABP2 cellular retinoic acid binding protein 2 Cytoplasm transporter 
2.231 FAM91A1 family with sequence similarity 91 member A1 Cytoplasm other 
2.165 ZNF385D zinc finger protein 385D Nucleus other 
2.109 FGFBP1 fibroblast growth factor binding protein 1 
Extracellular 
Space 
other 
2.081 LAMB3 laminin subunit beta 3 
Extracellular 
Space 
transporter 
2.069 PLOD2 procollagen-lysine,2-oxoglutarate 5-dioxygenase 2 Cytoplasm enzyme 
2.055 TFF2 trefoil factor 2 
Extracellular 
Space 
other 
2.044 FTHL2 ferritin heavy chain 1 pseudogene 2 Other other 
2.02 BAIAP2L1 BAI1 associated protein 2 like 1 Cytoplasm other 
1.97 HERC5 
HECT and RLD domain containing E3 ubiquitin 
protein ligase 5 
Cytoplasm enzyme 
1.961 FTHL16 ferritin heavy chain 1 pseudogene 16 Other other 
1.953 ID1 inhibitor of DNA binding 1, HLH protein Nucleus 
transcription 
regulator 
1.953 OAS1 2'-5'-oligoadenylate synthetase 1 Cytoplasm enzyme 
1.948 VPS4B vacuolar protein sorting 4 homolog B Cytoplasm transporter 
1.91 FUT11 fucosyltransferase 11 Cytoplasm enzyme 
1.901 EGFR epidermal growth factor receptor 
Plasma 
Membrane 
kinase 
1.894 SGK serum/glucocorticoid regulated kinase 1 Cytoplasm kinase 
1.869 PTGER2 prostaglandin E receptor 2 
Plasma 
Membrane 
G-protein coupled 
receptor 
1.838 FTHL11 ferritin heavy chain 1 pseudogene 11 Other other 
1.826 ATP1B1 ATPase Na+/K+ transporting subunit beta 1 
Plasma 
Membrane 
transporter 
1.803 AIF1L allograft inflammatory factor 1 like 
Plasma 
Membrane 
other 
1.787 PABPC4 poly(A) binding protein cytoplasmic 4 Cytoplasm 
translation 
regulator 
1.785 GSK3B glycogen synthase kinase 3 beta Nucleus kinase 
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1.784 EIF2AK2 
eukaryotic translation initiation factor 2 alpha 
kinase 2 
Cytoplasm kinase 
1.774 MOXD1 monooxygenase DBH like 1 Cytoplasm enzyme 
1.773 AP3S1 adaptor related protein complex 3 subunit sigma 1 Cytoplasm transporter 
1.769 GNG5 G protein subunit gamma 5 
Plasma 
Membrane 
other 
1.764 CYR61 cysteine rich angiogenic inducer 61 
Extracellular 
Space 
other 
1.758 TMEM167A transmembrane protein 167A Other other 
1.754 IFIT1 
interferon induced protein with tetratricopeptide 
repeats 1 
Cytoplasm other 
1.752 FAIM3 Fc fragment of IgM receptor 
Plasma 
Membrane 
other 
1.731 SH3BP4 SH3 domain binding protein 4 Cytoplasm other 
1.728 IFNGR1 interferon gamma receptor 1 
Plasma 
Membrane 
transmembrane 
receptor 
1.728 MATN2 matrilin 2 
Extracellular 
Space 
other 
1.723 TMEM27 collectrin, amino acid transport regulator 
Plasma 
Membrane 
other 
1.722 IL13RA1 interleukin 13 receptor subunit alpha 1 
Plasma 
Membrane 
transmembrane 
receptor 
1.717 FBXL20 F-box and leucine rich repeat protein 20 Cytoplasm enzyme 
1.716 RIOK3 RIO kinase 3 Cytoplasm kinase 
1.709 MAP4K5 
mitogen-activated protein kinase kinase kinase 
kinase 5 
Cytoplasm kinase 
1.705 HLTF helicase like transcription factor Nucleus 
transcription 
regulator 
1.7 PLCL2 phospholipase C like 2 Cytoplasm enzyme 
1.693 FTHL3 ferritin heavy chain 1 pseudogene 3 Other other 
1.681 GRB7 growth factor receptor bound protein 7 
Plasma 
Membrane 
other 
1.677 IER3 immediate early response 3 Cytoplasm other 
1.671 PPPDE1 desumoylating isopeptidase 2 Cytoplasm enzyme 
1.671 ERN1 endoplasmic reticulum to nucleus signaling 1 Cytoplasm kinase 
1.667 WWP2 
WW domain containing E3 ubiquitin protein 
ligase 2 
Cytoplasm enzyme 
1.664 ELF3 E74 like ETS transcription factor 3 Nucleus 
transcription 
regulator 
1.66 STK38 serine/threonine kinase 38 Nucleus kinase 
1.646 CAV2 caveolin 2 
Plasma 
Membrane 
other 
1.643 USP36 ubiquitin specific peptidase 36 Nucleus peptidase 
1.642 LIPA lipase A, lysosomal acid type Cytoplasm enzyme 
1.638 C1orf86 FA core complex associated protein 20 Nucleus other 
1.629 ADAMTS1 
ADAM metallopeptidase with thrombospondin 
type 1 motif 1 
Extracellular 
Space 
peptidase 
1.623 GBE1 1,4-alpha-glucan branching enzyme 1 Cytoplasm enzyme 
1.618 CLGN calmegin Cytoplasm peptidase 
1.618 GLT25D1 collagen beta(1-O)galactosyltransferase 1 Cytoplasm enzyme 
1.608 PEG10 paternally expressed 10 Nucleus other 
1.608 TFF1 trefoil factor 1 
Extracellular 
Space 
other 
1.605 CTSC cathepsin C Cytoplasm peptidase 
1.598 NAT13 
N(alpha)-acetyltransferase 50, NatE catalytic 
subunit 
Cytoplasm enzyme 
1.596 DOCK10 dedicator of cytokinesis 10 Cytoplasm other 
1.595 CENTG2 
ArfGAP with GTPase domain, ankyrin repeat and 
PH domain 1 
Cytoplasm enzyme 
1.594 FAM83H family with sequence similarity 83 member H Other other 
1.593 RNF149 ring finger protein 149 Cytoplasm enzyme 
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1.59 AXUD1 cysteine and serine rich nuclear protein 1 Nucleus 
transcription 
regulator 
1.582 PIP4K2A 
phosphatidylinositol-5-phosphate 4-kinase type 2 
alpha 
Cytoplasm kinase 
1.581 L2HGDH L-2-hydroxyglutarate dehydrogenase Cytoplasm enzyme 
1.575 SUMO2 small ubiquitin-like modifier 2 Nucleus enzyme 
1.562 CD24 CD24 molecule 
Plasma 
Membrane 
other 
1.559 IDS iduronate 2-sulfatase Cytoplasm enzyme 
1.548 SPRY2 sprouty RTK signaling antagonist 2 
Plasma 
Membrane 
other 
1.545 TIMP2 TIMP metallopeptidase inhibitor 2 
Extracellular 
Space 
other 
1.539 HEATR1 HEAT repeat containing 1 Nucleus other 
1.534 FAM102A family with sequence similarity 102 member A Other other 
1.531 RPS15A ribosomal protein S15a Cytoplasm other 
1.524 SEPN1 selenoprotein N Cytoplasm other 
1.521 SAT1 spermidine/spermine N1-acetyltransferase 1 Cytoplasm enzyme 
1.52 SUV420H1 lysine methyltransferase 5B Nucleus enzyme 
1.518 ACP1 acid phosphatase 1 Cytoplasm phosphatase 
1.518 EPHX1 epoxide hydrolase 1 Cytoplasm peptidase 
1.509 TUBB tubulin beta class I Cytoplasm other 
1.496 FTH1 ferritin heavy chain 1 Cytoplasm enzyme 
1.496 KIAA1143 KIAA1143 Other other 
1.495 GJC2 gap junction protein gamma 2 
Plasma 
Membrane 
transporter 
1.495 PTK2 protein tyrosine kinase 2 Cytoplasm kinase 
1.492 GPR180 G protein-coupled receptor 180 Cytoplasm other 
1.491 CLDN1 claudin 1 
Plasma 
Membrane 
other 
1.488 LAPTM4B lysosomal protein transmembrane 4 beta Cytoplasm other 
1.486 AVPI1 arginine vasopressin induced 1 Other other 
1.486 GADD45A growth arrest and DNA damage inducible alpha Nucleus other 
1.484 FKBP1A FK506 binding protein 1A Cytoplasm enzyme 
1.481 TMEM185A transmembrane protein 185A Nucleus other 
1.48 LHFP LHFPL tetraspan subfamily member 6 Other other 
1.476 ADAM19 ADAM metallopeptidase domain 19 
Plasma 
Membrane 
peptidase 
1.476 HPRT1 hypoxanthine phosphoribosyltransferase 1 Cytoplasm enzyme 
1.476 NCRNA00161 long intergenic non-protein coding RNA 161 Other other 
1.474 COL5A1 collagen type V alpha 1 chain 
Extracellular 
Space 
other 
1.472 GMDS GDP-mannose 4,6-dehydratase Cytoplasm enzyme 
1.467 CDA cytidine deaminase Nucleus enzyme 
1.466 ASPH aspartate beta-hydroxylase Cytoplasm enzyme 
1.461 ELMOD2 ELMO domain containing 2 Other other 
1.46 TMEM87A transmembrane protein 87A Cytoplasm other 
1.46 VAPA VAMP associated protein A 
Plasma 
Membrane 
other 
1.452 LHPP 
phospholysine phosphohistidine inorganic 
pyrophosphate phosphatase 
Cytoplasm phosphatase 
1.445 CTSH cathepsin H Cytoplasm peptidase 
1.443 CTGF connective tissue growth factor 
Extracellular 
Space 
growth factor 
1.44 MAX MYC associated factor X Nucleus 
transcription 
regulator 
1.438 EBPL EBP like Cytoplasm enzyme 
1.438 ZC3HAV1 zinc finger CCCH-type containing, antiviral 1 
Plasma 
Membrane 
other 
1.435 MOSC1 mitochondrial amidoxime reducing component 1 Cytoplasm enzyme 
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1.43 RGMB repulsive guidance molecule BMP co-receptor b 
Plasma 
Membrane 
other 
1.428 PRPS2 phosphoribosyl pyrophosphate synthetase 2 Cytoplasm kinase 
1.425 TGM2 transglutaminase 2 Cytoplasm enzyme 
1.424 ABLIM1 actin binding LIM protein 1 Cytoplasm other 
1.415 SLC22A5 solute carrier family 22 member 5 
Plasma 
Membrane 
transporter 
1.406 DENND1A DENN domain containing 1A 
Plasma 
Membrane 
other 
1.406 MYO19 myosin XIX Cytoplasm enzyme 
1.406 NAPG NSF attachment protein gamma Cytoplasm transporter 
1.404 ARL14 ADP ribosylation factor like GTPase 14 Other other 
1.403 CLDND1 claudin domain containing 1 
Plasma 
Membrane 
other 
1.403 DNAJB6 
DnaJ heat shock protein family (Hsp40) member 
B6 
Nucleus 
transcription 
regulator 
1.4 LTBP3 
latent transforming growth factor beta binding 
protein 3 
Extracellular 
Space 
other 
1.395 PSPC1 paraspeckle component 1 Nucleus 
transcription 
regulator 
1.394 IRF7 interferon regulatory factor 7 Nucleus 
transcription 
regulator 
1.394 C16orf13 methyltransferase like 26 Other other 
1.393 FTHL8 ferritin heavy chain 1 pseudogene 8 Other other 
1.392 C7orf42 transmembrane protein 248 Other other 
1.392 UGDH UDP-glucose 6-dehydrogenase Nucleus enzyme 
1.39 CCDC85B coiled-coil domain containing 85B Cytoplasm other 
1.39 DNER delta/notch like EGF repeat containing 
Plasma 
Membrane 
transmembrane 
receptor 
1.387 IL1RL1 interleukin 1 receptor like 1 
Plasma 
Membrane 
transmembrane 
receptor 
1.387 SPINT2 serine peptidase inhibitor, Kunitz type 2 
Extracellular 
Space 
other 
1.38 MID2 midline 2 Cytoplasm other 
1.377 HAS3 hyaluronan synthase 3 
Plasma 
Membrane 
enzyme 
1.376 SAMD9 sterile alpha motif domain containing 9 Cytoplasm other 
1.371 DENND5B DENN domain containing 5B Cytoplasm other 
1.367 MOSC2 mitochondrial amidoxime reducing component 2 Cytoplasm enzyme 
1.366 HIST1H3D histone cluster 1 H3 family member d Nucleus other 
1.366 MAGED4B MAGE family member D4B Other other 
1.357 HPCAL1 hippocalcin like 1 Cytoplasm other 
1.357 IGFBP4 insulin like growth factor binding protein 4 
Extracellular 
Space 
other 
1.354 ATP6V1A ATPase H+ transporting V1 subunit A 
Plasma 
Membrane 
transporter 
1.354 CCDC47 coiled-coil domain containing 47 
Extracellular 
Space 
other 
1.353 ARFGEF2 
ADP ribosylation factor guanine nucleotide 
exchange factor 2 
Cytoplasm other 
1.351 SERF1B small EDRK-rich factor 1A Other other 
1.35 MMP23A matrix metallopeptidase 23A (pseudogene) 
Extracellular 
Space 
other 
-1.367 ARHGEF19 Rho guanine nucleotide exchange factor 19 Cytoplasm other 
-1.368 ENC1 ectodermal-neural cortex 1 Nucleus peptidase 
-1.371 MAP4K4 
mitogen-activated protein kinase kinase kinase 
kinase 4 
Cytoplasm kinase 
-1.376 CRIP2 cysteine rich protein 2 Nucleus other 
-1.377 SKP2 S-phase kinase associated protein 2 Nucleus enzyme 
-1.377 STXBP5 syntaxin binding protein 5 
Plasma 
Membrane 
other 
-1.378 SLC37A4 solute carrier family 37 member 4 Cytoplasm transporter 
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-1.38 SFRS6 serine and arginine rich splicing factor 6 Nucleus other 
-1.386 CCND1 cyclin D1 Nucleus 
transcription 
regulator 
-1.387 F2R coagulation factor II thrombin receptor 
Plasma 
Membrane 
G-protein coupled 
receptor 
-1.39 COL13A1 collagen type XIII alpha 1 chain 
Plasma 
Membrane 
other 
-1.392 MIPOL1 mirror-image polydactyly 1 Nucleus other 
-1.393 PTGFR prostaglandin F receptor 
Plasma 
Membrane 
G-protein coupled 
receptor 
-1.396 TMEM45B transmembrane protein 45B 
Extracellular 
Space 
other 
-1.405 COL18A1 collagen type XVIII alpha 1 chain 
Extracellular 
Space 
other 
-1.407 RXRB retinoid X receptor beta Nucleus 
ligand-dependent 
nuclear receptor 
-1.408 ROBO3 roundabout guidance receptor 3 
Plasma 
Membrane 
transmembrane 
receptor 
-1.409 LEPROTL1 leptin receptor overlapping transcript like 1 
Plasma 
Membrane 
other 
-1.41 PDDC1 
glutamine amidotransferase like class 1 domain 
containing 1 
Cytoplasm other 
-1.41 KCTD5 
potassium channel tetramerization domain 
containing 5 
Cytoplasm other 
-1.411 RBBP9 RB binding protein 9, serine hydrolase Nucleus other 
-1.411 ZNF837 zinc finger protein 837 Other other 
-1.413 NIPA1 NIPA magnesium transporter 1 
Plasma 
Membrane 
transporter 
-1.421 TM7SF2 transmembrane 7 superfamily member 2 Cytoplasm enzyme 
-1.422 TMEM30A transmembrane protein 30A Cytoplasm transporter 
-1.423 NSMCE4A 
NSE4 homolog A, SMC5-SMC6 complex 
component 
Nucleus other 
-1.425 ACTN4 actinin alpha 4 Cytoplasm 
transcription 
regulator 
-1.43 POLR3G RNA polymerase III subunit G Nucleus enzyme 
-1.435 ADK adenosine kinase Nucleus kinase 
-1.437 PFTK1 cyclin dependent kinase 14 Nucleus kinase 
-1.438 MAPK3 mitogen-activated protein kinase 3 Cytoplasm kinase 
-1.444 SDSL serine dehydratase like Cytoplasm enzyme 
-1.445 ARSB arylsulfatase B Cytoplasm enzyme 
-1.449 ACCS 
1-aminocyclopropane-1-carboxylate synthase 
homolog (inactive) 
Other enzyme 
-1.449 RPL23A ribosomal protein L23a Cytoplasm other 
-1.45 CECR7 cat eye syndrome chromosome region, candidate 7 Other other 
-1.457 ABCA13 ATP binding cassette subfamily A member 13 
Extracellular 
Space 
transporter 
-1.457 C20orf177 family with sequence similarity 217 member B Other other 
-1.462 NDRG3 NDRG family member 3 Cytoplasm other 
-1.467 TRPM4 
transient receptor potential cation channel 
subfamily M member 4 
Plasma 
Membrane 
ion channel 
-1.472 EIF2S2 
eukaryotic translation initiation factor 2 subunit 
beta 
Cytoplasm 
translation 
regulator 
-1.474 CTDSP2 CTD small phosphatase 2 Nucleus phosphatase 
-1.474 HIBADH 3-hydroxyisobutyrate dehydrogenase Cytoplasm enzyme 
-1.477 NUDT1 nudix hydrolase 1 
Extracellular 
Space 
phosphatase 
-1.478 ZFYVE20 rabenosyn, RAB effector Cytoplasm other 
-1.479 NPEPL1 aminopeptidase like 1 Nucleus peptidase 
-1.487 APOBEC3G 
apolipoprotein B mRNA editing enzyme catalytic 
subunit 3G 
Nucleus enzyme 
-1.487 COPS7B COP9 signalosome subunit 7B Cytoplasm other 
-1.49 C20orf56 long intergenic non-protein coding RNA 261 Other other 
 133 
-1.49 NBPF20 NBPF member 11 Other other 
-1.491 ARL5A ADP ribosylation factor like GTPase 5A Other enzyme 
-1.494 ANKFY1 ankyrin repeat and FYVE domain containing 1 Cytoplasm 
transcription 
regulator 
-1.494 HCP5 HLA complex P5 Other other 
-1.498 PHF14 PHD finger protein 14 Nucleus other 
-1.508 CDC2L6 cyclin dependent kinase 19 Nucleus kinase 
-1.508 CXADR CXADR, Ig-like cell adhesion molecule 
Plasma 
Membrane 
transmembrane 
receptor 
-1.511 PNRC2 proline rich nuclear receptor coactivator 2 Nucleus other 
-1.518 TMX1 thioredoxin related transmembrane protein 1 Cytoplasm enzyme 
-1.525 SDC1 syndecan 1 
Plasma 
Membrane 
enzyme 
-1.529 TCEA2 transcription elongation factor A2 Nucleus 
transcription 
regulator 
-1.53 WDR42A DDB1 and CUL4 associated factor 8 Nucleus other 
-1.531 CAST calpastatin Cytoplasm peptidase 
-1.532 SKP1 S-phase kinase associated protein 1 Nucleus 
transcription 
regulator 
-1.571 ETV5 ETS variant 5 Nucleus 
transcription 
regulator 
-1.572 ITPRIPL2 ITPRIP like 2 Other other 
-1.575 IL17RC interleukin 17 receptor C 
Plasma 
Membrane 
transmembrane 
receptor 
-1.576 GPR4 G protein-coupled receptor 4 
Plasma 
Membrane 
G-protein coupled 
receptor 
-1.582 SCD stearoyl-CoA desaturase Cytoplasm enzyme 
-1.586 MUC1 mucin 1, cell surface associated 
Plasma 
Membrane 
other 
-1.587 KIAA1641 ankyrin repeat domain 36B 
Extracellular 
Space 
other 
-1.588 SLC35F2 solute carrier family 35 member F2 Other other 
-1.59 SMARCD1 
SWI/SNF related, matrix associated, actin 
dependent regulator of chromatin, subfamily d, 
member 1 
Nucleus 
transcription 
regulator 
-1.593 PLCXD3 
phosphatidylinositol specific phospholipase C X 
domain containing 3 
Plasma 
Membrane 
other 
-1.598 CALM3 calmodulin 1 Cytoplasm other 
-1.599 LANCL1 LanC like 1 
Plasma 
Membrane 
other 
-1.611 ICK intestinal cell kinase Cytoplasm kinase 
-1.612 KCNT2 
potassium sodium-activated channel subfamily T 
member 2 
Plasma 
Membrane 
ion channel 
-1.628 ACLY ATP citrate lyase Cytoplasm enzyme 
-1.628 GSTZ1 glutathione S-transferase zeta 1 Cytoplasm enzyme 
-1.633 FAR1 fatty acyl-CoA reductase 1 Cytoplasm enzyme 
-1.637 HNRNPUL2 heterogeneous nuclear ribonucleoprotein U like 2 Nucleus other 
-1.64 OSBP oxysterol binding protein Cytoplasm transporter 
-1.648 IFRD2 interferon related developmental regulator 2 Nucleus other 
-1.657 AES amino-terminal enhancer of split Nucleus 
transcription 
regulator 
-1.661 CNPY4 canopy FGF signaling regulator 4 Other other 
-1.661 RNASEH1 ribonuclease H1 Nucleus enzyme 
-1.664 ATG5 autophagy related 5 Cytoplasm other 
-1.664 CYB561D1 cytochrome b561 family member D1 Other other 
-1.669 HMGCL 3-hydroxy-3-methylglutaryl-CoA lyase Cytoplasm enzyme 
-1.669 RYBP RING1 and YY1 binding protein Nucleus 
transcription 
regulator 
-1.673 PDCD6IP programmed cell death 6 interacting protein Cytoplasm other 
-1.679 SOCS2 suppressor of cytokine signaling 2 Cytoplasm other 
-1.681 DDX17 DEAD-box helicase 17 Nucleus enzyme 
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-1.685 UBE2Z ubiquitin conjugating enzyme E2 Z Nucleus enzyme 
-1.695 ARL6IP5 
ADP ribosylation factor like GTPase 6 interacting 
protein 5 
Cytoplasm other 
-1.707 C7orf55 
formation of mitochondrial complex V assembly 
factor 1 homolog 
Cytoplasm other 
-1.708 GBA2 glucosylceramidase beta 2 Cytoplasm enzyme 
-1.709 HINT2 histidine triad nucleotide binding protein 2 Cytoplasm other 
-1.71 CTTN cortactin 
Plasma 
Membrane 
other 
-1.714 ZNF827 zinc finger protein 827 Other other 
-1.716 PHB2 prohibitin 2 Cytoplasm 
transcription 
regulator 
-1.723 MRPL52 mitochondrial ribosomal protein L52 Cytoplasm other 
-1.735 SERF2 small EDRK-rich factor 2 Other other 
-1.739 TRIB3 tribbles pseudokinase 3 Nucleus kinase 
-1.743 CBX6 chromobox 6 Nucleus other 
-1.756 SLC35B4 solute carrier family 35 member B4 Cytoplasm transporter 
-1.758 CDC25B cell division cycle 25B Nucleus phosphatase 
-1.772 HOXB13 homeobox B13 Nucleus 
transcription 
regulator 
-1.774 PTP4A2 protein tyrosine phosphatase type IVA, member 2 Cytoplasm phosphatase 
-1.79 BAG3 BCL2 associated athanogene 3 Cytoplasm other 
-1.791 TCTEX1D2 Tctex1 domain containing 2 Cytoplasm other 
-1.807 BMPR2 bone morphogenetic protein receptor type 2 
Plasma 
Membrane 
kinase 
-1.812 PHACTR3 phosphatase and actin regulator 3 Nucleus other 
-1.814 RBM3 RNA binding motif protein 3 Cytoplasm other 
-1.819 ACP6 acid phosphatase 6, lysophosphatidic Cytoplasm phosphatase 
-1.82 C19orf60 required for excision 1-B domain containing Other other 
-1.834 DYNC1LI2 dynein cytoplasmic 1 light intermediate chain 2 Cytoplasm other 
-1.875 ADM2 adrenomedullin 2 
Extracellular 
Space 
other 
-1.887 ABCC3 ATP binding cassette subfamily C member 3 
Plasma 
Membrane 
transporter 
-1.895 TAGLN3 transgelin 3 
Extracellular 
Space 
other 
-1.899 PGD phosphogluconate dehydrogenase Cytoplasm enzyme 
-1.947 ENSA endosulfine alpha Cytoplasm transporter 
-1.95 USP4 ubiquitin specific peptidase 4 Nucleus peptidase 
-1.955 RAB8B RAB8B, member RAS oncogene family Cytoplasm enzyme 
-1.957 HSBP1 heat shock factor binding protein 1 Nucleus other 
-1.961 WARS tryptophanyl-tRNA synthetase Cytoplasm enzyme 
-1.986 EPRS glutamyl-prolyl-tRNA synthetase Cytoplasm enzyme 
-1.987 FBLN1 fibulin 1 
Extracellular 
Space 
other 
-1.998 PRKCA protein kinase C alpha Cytoplasm kinase 
-2.01 KIAA1310 KAT8 regulatory NSL complex subunit 3 Nucleus other 
-2.023 RAG1AP1 solute carrier family 50 member 1 
Plasma 
Membrane 
transporter 
-2.076 VRK3 vaccinia related kinase 3 Nucleus kinase 
-2.128 HAPLN1 hyaluronan and proteoglycan link protein 1 
Extracellular 
Space 
other 
-2.149 KLC1 kinesin light chain 1 Cytoplasm other 
-2.151 ZNF664 zinc finger protein 664 Nucleus 
transcription 
regulator 
-2.188 RPS23 ribosomal protein S23 Cytoplasm 
translation 
regulator 
-2.233 IDH1 isocitrate dehydrogenase (NADP(+)) 1, cytosolic Cytoplasm enzyme 
-2.253 NFATC2IP 
nuclear factor of activated T cells 2 interacting 
protein 
Nucleus other 
-2.264 UBE3C ubiquitin protein ligase E3C Nucleus enzyme 
 135 
-2.276 FIBP FGF1 intracellular binding protein Nucleus other 
-2.282 MED20 mediator complex subunit 20 Nucleus 
transcription 
regulator 
-2.362 ASNS asparagine synthetase (glutamine-hydrolyzing) Cytoplasm enzyme 
-2.413 FZD4 frizzled class receptor 4 
Plasma 
Membrane 
G-protein coupled 
receptor 
-2.428 TTC19 tetratricopeptide repeat domain 19 Cytoplasm other 
-2.492 PHGDH phosphoglycerate dehydrogenase Cytoplasm enzyme 
-2.503 GPX8 glutathione peroxidase 8 (putative) Cytoplasm enzyme 
-2.509 URM1 ubiquitin related modifier 1 Cytoplasm other 
-2.573 ZNF598 zinc finger protein 598 
Extracellular 
Space 
enzyme 
-2.706 CCNY cyclin Y Nucleus other 
-3.158 CD59 CD59 molecule (CD59 blood group) 
Plasma 
Membrane 
other 
-3.249 PPP1CB protein phosphatase 1 catalytic subunit beta Cytoplasm phosphatase 
-3.662 FAM62B extended synaptotagmin 2 
Plasma 
Membrane 
other 
-4.242 TSPO translocator protein Cytoplasm 
transmembrane 
receptor 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 136 
9.3. Protein interaction partners of LINC00920 as identified by ChIRP-MS 
Supplementary Table 9-3. Proteins interacting with LINC00920 as identified by ChIRP-
MS*  
Replicate AA0074 Replicate AA2864 Replicate AA0097 
Protein 
Enrichment 
fold-change 
(LINC00920 vs. 
lacZ) 
Protein 
Enrichment 
fold-change 
(LINC00920 vs. 
lacZ) 
Protein 
Enrichment 
fold-change 
(LINC00920 vs. 
lacZ) 
CLMN 54.256 CLMN 132.02 PURA 97 
HNRNPH1 8.4646 HNRNPA2B1 8.5829 
RBMX; 
RBMXL1; 
RBMXL2 
2.70 
HNRNPF 8.1897 HNRNPH1 7.7861 HNRNPK 2.50 
HNRNPH3 7.7915 
HNRNPA1; 
HNRNPA1L2 
7.3625 HNRNPA2B1 2.49 
HNRNPM 6.4508 HNRNPA3 6.4529 HNRNPH1 2.41 
HNRNPA3 6.3449 HNRNPF 5.1694 YBX1 2.35 
HNRNPA2B1 6.3104 
RAB1B;RAB1A;
RAB1C 
4.8331 HNRNPF 2.35 
HNRNPL 6.3095 EEF1G 3.8563 CALR 2.24 
HNRNPK 6.1481 TPM3 3.6192 HNRNPH3 2.21 
HNRNPA1; 
HNRNPA1L2 
6.0889 
NME1-NME2; 
NME2; 
NME1; 
NME2P1 
3.6111 
APOBEC3C; 
APOBEC3D; 
bK150C2.9; 
APOBEC3F 
2.21 
SFPQ 5.993 PDIA3 3.4972 
HNRNPA1; 
HNRNPA1L2 
2.16 
HNRNPU 5.9732 PRKCSH 3.4643 RPLP2 2.12 
HNRNPC 5.791 PRDX1 3.31 HNRNPU 2.08 
FUS 5.6598 CLTC;CLTCL1 3.2165 HNRNPA3 2.07 
HNRNPDL 5.5687 PRDX3 3.1902 HNRNPD 1.90 
GRSF1 5.4929 CLIC1 3.1075 ELAVL1 1.89 
NONO 5.4928 PFN1 3.0106 HNRNPC 1.89 
RBMX; 
RBMXL1 
5.1306 YWHAZ 2.9884 HSPA5 1.86 
DDX5; 
DDX17 
4.9802 
SLC25A5; 
SLC25A4; 
SLC25A6 
2.978 HNRNPAB 1.86 
HNRNPR; 
SYNCRIP 
4.959 ANXA7 2.9746 HSP90B1 1.71 
HNRNPAB 4.6391 
HSPA8; 
HSPA2 
2.9432 DDX39A 1.71 
HNRNPD 4.1919 PPIA 2.9307 PPA1 1.67 
KRT6B 4.0641 VDAC2 2.9271 SNRPD3 1.65 
KHSRP 3.8019 LDHA 2.9054 ERP29 1.65 
SRSF1 3.5474 TXNRD1 2.8951 NPM1 1.64 
YBX1;YBX3 3.008 
ACTG1; 
ACTB 
2.8943 HNRNPM 1.59 
ILF3 2.7134 LDHB 2.8848 PDIA3 1.57 
PCBP1 2.6766 PRDX2 2.8059 KHSRP 1.57 
RPS3 2.6245 GOT2 2.8055 DDX5 1.55 
EIF4A1; 
EIF4A2 
2.5963 PHGDH 2.8049 TPI1 1.52 
PCBP2; 
PCBP3 
2.5653 ATP5B 2.8049 HSP90AB1 1.51 
DDX39A; 
DDX39B 
2.26 P4HB 2.7907 CFL1 1.45 
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MCCC1 2.1346 PIP 2.7742 HSPA8 1.45 
PABPC1 2.1112 PKM 2.76 PEBP1 1.42 
PCCA 2.0685 HSP90AB1 2.7244 HSP90AA1 1.40 
PC 2.0549 CFL1 2.7101 CCT3 1.40 
TUFM 1.9764 ALDOA 2.7009 
YWHAZ; 
SFN; 
YWHAE; 
YWHAB; 
YWHAQ; 
YWHAH; 
YWHAG 
1.40 
HSPA9 1.9733 LZIC 2.6976 ACTN1 1.37 
ALDH1A3; 
ALDH1A2 
1.9722 ARHGDIA 2.6818 ARHGDIA 1.37 
PRMT1 1.9707 TKT 2.6757 MYDGF 1.36 
HSPD1 1.9293 FSCN1 2.6534 GSTP1 1.34 
ACACA 1.914 PRDX5 2.6518 FLNA 1.34 
PCCB 1.9079 HSPA5 2.6481 ATP5F1 1.34 
CS 1.8781 MDH2 2.6161 PABPC1 1.33 
MCCC2 1.8265 
EEF1A1P5; 
EEF1A1; 
EEF1A2 
2.612 
NME2;NME1-
NME2;NME1; 
NME2P1 
1.33 
NCL 1.8248 
ANXA2; 
ANXA2P2 
2.5998 
EIF4A1; 
EIF4A2 
1.32 
PGK1 1.7991 TAGLN2 2.5738 CCT8 1.32 
FH 1.7838 TRAP1 2.5682 EEF1G 1.31 
HSP90B1 1.7819 EEF1D 2.5573 PPIB 1.31 
ACTN1; 
ACTN4; 
ACTN3 
1.7777 VDAC1 2.4503 P4HB 1.30 
TRAP1 1.7722 HSP90AA1 2.3703 TALDO1 1.30 
TUBB4A; 
TUBB4B; 
TUBB8 
1.7394 TUFM 2.3645 PCBP1 1.30 
EEF2;EFTUD2 1.7279 
HSPE1; 
HSPE1-MOB4 
2.35 PAICS 1.30 
PPIA 1.7205 VCL 2.3464 TKT 1.29 
ENO1 1.6963 PC 2.3431 CLIC1 1.28 
MSN; 
RDX; 
EZR 
1.6942 HSPA9 2.3428 
HIST1H2AJ; 
HIST1H2AH; 
H2AFJ; 
HIST2H2AC; 
HIST2H2AA3; 
HIST1H2AD; 
HIST1H2AG; 
H2AFV; 
H2AFZ; 
HIST1H2AC; 
HIST3H2A; 
HIST1H2AB; 
HIST1H2AA; 
H2AFX 
1.25 
LDHA 1.6931 CS 2.3132 TAGLN2 1.25 
PDIA3 1.6926 HSP90B1 2.3132 
CALM2; 
CALM3; 
CALM1 
1.25 
FLNA 1.6869 PCCB 2.2846 
RPLP0; 
RPLP0P6 
1.25 
HSP90AB1 1.6708 MCCC1 2.2676 RAN 1.25 
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RAN 1.6384 PGK1 2.2278 ACTG1 1.24 
TUBB;TUBB3; 
TUBB2B; 
TUBB2A 
1.6338 
TUBB; 
TUBB2B; 
TUBB2A 
2.2164 EEF1D 1.23 
HSP90AA1 1.6267 ENO1 2.2084 FSCN1 1.23 
HSPA8 1.6203 PCCA 2.1811 PRDX2 1.23 
CALM2; 
CALM3; 
CALM1 
1.6025 MCCC2 2.181 
S100A7; 
S100A7A 
1.22 
DSTN 1.5932 HSPD1 2.1802 LDHB 1.22 
EEF1G 1.5884 TUBB3 2.1721 PLEC 1.22 
FSCN1 1.576 FH 2.1462 XRCC6 1.21 
ANXA7 1.5655 
TUBA1B; 
TUBA1C; 
TUBA1A; 
TUBA4A; 
TUBA3C; 
TUBA8; 
TUBA3E 
2.1278 ANXA5 1.20 
RPSA 1.5472 CALR 2.0788 
  
VIM 1.5124 NPM1 2.0308 
  
MDH2 1.5084 PLEC 1.9837 
  
EEF1A1P5; 
EEF1A1; 
EEF1A2 
1.4991 GAPDH 1.9614 
  
PLEC 1.494 ACACA 1.9443 
  
TUBA1B; 
TUBA1C; 
TUBA1A; 
TUBA3C; 
TUBA4A; 
TUBA3E 
1.4835 LCN1;LCN1P1 1.9188 
  
FLNB 1.474 YWHAE 1.8876 
  
ACTG1 1.4729 
ACTN1; 
ACTN4 
1.838 
  
PRDX6 1.4636 FLNA 1.8187 
  
P4HB 1.4508 TIMM44 1.6966 
  
ATP5B 1.4363 FLT1 1.6598 
  
LMNA 1.4301 IGHG1 1.6398 
  
RPS20 1.4183 FABP5 1.6301 
  
NME1;NME2; 
NME1-NME2 
1.4033 IARS2 1.5835 
  
PKM 1.3952 ALDH7A1 1.5545 
  
ATP5A1 1.3892 EEF2 1.3601 
  
CLIC1 1.3881 
UBB;RPS27A; 
UBC;UBA52 
1.2394 
  
PFN1 1.3663 
    
VCL 1.3548 
    
SLC25A5 1.3258 
    
CFL1 1.3214 
    
GSTP1 1.3181 
    
CLTC 1.3164 
    
HSPE1 1.3123 
    
ALDOA 1.2998 
    
TKT 1.2964 
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PEBP1 1.2784 
    
LDHB 1.2746 
    
NPM1 1.2577 
    
AHCY 1.2531 
    
PRDX3 1.2525 
    
EEF1D 1.2356 
    
RPS12 1.2338 
    
YWHAZ 1.2234 
    
ANXA2; 
ANXA2P2 
1.2142 
    
RAB1B; 
RAB8B; 
RAB1A; 
RAB10; 
RAB1C; 
RAB13; 
RAB8A; 
RAB15 
1.2111 
    
* With enrichment fold-change values greater than 1.2. Proteins in bold are common to all replicates. 
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9.4. FOXO1 is the predominant FOXO isoform in PC-3 cells and remains unchanged upon 
LINC00920 knockdown 
 
 
Supplementary Figure 9-1. FOXO1 and FOXO3 protein expression analysis in prostate 
cancer cell lines.  (A) Representative immunoblots of FOXO1 and FOXO3 showing their 
relative expression in VCaP, LNCaP, and PC-3 cells. (B) Normalized quantification of protein 
band intensities in A. (C) Knockdown of LINC00920 does not affect FOXO1 expression in PC-
3 cells. (D) Normalized quantification of protein band intensities in C.  
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9.5. LINC00920-insensitive FOXO targets 
s
iR
N
A
-D
1
s
iR
N
A
-D
3
s
iR
N
A
-D
4
s
iR
N
A
-Q
2
s
iR
N
A
-Q
3
0
2
4
6
8 TNFSF10
NS
NS
Control
Ipatasertib
NS
NS
NS
F
o
ld
 c
h
a
n
g
e
 o
v
e
r 
c
o
n
tr
o
l
(n
o
rm
a
li
z
e
d
 b
y 
H
P
R
T
1
)
s
iR
N
A
-D
1
s
iR
N
A
-D
3
s
iR
N
A
-D
4
s
iR
N
A
-Q
2
s
iR
N
A
-Q
3
0
2
4
6
8 CCNG2
NS
*
Control
Ipatasertib
NS
NS
NS
F
o
ld
 c
h
a
n
g
e
 o
v
e
r 
c
o
n
tr
o
l
(n
o
rm
a
li
z
e
d
 b
y 
H
P
R
T
1
)
s
iR
N
A
-D
1
s
iR
N
A
-D
3
s
iR
N
A
-D
4
s
iR
N
A
-Q
2
s
iR
N
A
-Q
3
0
2
4
6
8
10 CDKN1B
NSNS**
Control
Ipatasertib
NS
NS
F
o
ld
 c
h
a
n
g
e
 o
v
e
r 
c
o
n
tr
o
l
(n
o
rm
a
li
z
e
d
 b
y 
H
P
R
T
1
)
 
Supplementary Figure 9-2. FOXO targets indifferent to combined LINC00920 
knockdown and AKT inhibition. 
9.6. Tissue-specific expression of LINC00920 
 
Supplementary Figure 9-3. RNA-seq quantitation of LINC00920 expression across 
human tissues [319]. TPM: Transcripts Per Kilobase Million. 
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9.7. Replicates of ChIRP-seq coverage alignment 
 
Supplementary Figure 9-4. Normalized LINC00920 read coverage across genic regions in 
the human genome build hg19, shown in triplicate. Top: Average profiles of LINC00920 
occupancy on genes normalized by length of 10 kbp with 2-kb extensions upstream the TSSs 
and downstream the TESs. Bottom: Heatmaps showing signals for individual genes (heatmap 
rows). Shown data was derived from a representative replicate. Blue: high read coverage, red: 
low read coverage. 
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Supplementary Figure 9-5. ChIRP-seq density clustering reveals LINC00920 binding to a 
subset of promoters (in triplicate). Top: Average profiles of LINC00920 occupancy across 
clustered promoters. Bottom: Segmented heatmaps showing clustered promoters based on 
signal density. Promoter regions in cluster 1 (n=5,287) exhibit positive LINC00920 enrichment 
in all replicates. Cluster 2 (n=20,369) promoters show modest LINC00920 occupancy both 
upstream and downstream the promoter center. Clusters 3 (n=5,549) and 4 (n=4,975) 
promoters exhibit depletion of LINC00920 signal upstream and downstream the promoter 
center, respectively. Blue: high read coverage, red: low read coverage. 
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Supplementary Figure 9-6. Normalized LINC00920 read coverage across annotated 
enhancer regions in the PC-3 genome, shown in triplicate. Top: Average profiles of 
LINC00920 occupancy on enhancers 1-kb extensions upstream and downstream the annotated 
center. Bottom: Segmented heatmaps showing clustered enhancer regions based on signal 
intensity. Cluster 1 (n=10,018) enhancer regions show enrichment of LINC00920 occupancy 
upstream the annotated center. Enhancer regions in cluster 2 (n=10,176) show enrichment 
downstream of the center. The remaining cluster 3 (n=50,302) enhancer regions do not show 
LINC00920 enrichment. Dark blue: high read coverage, yellow: low read coverage. 
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9.8. Vector maps 
 
Supplementary Figure 9-7. Vector map of pAAVpsi2. 
 
 
Supplementary Figure 9-8. Vector map of pcDNA
TM
3.1(+). 
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Supplementary Figure 9-9. Vector map of pCR®2.1-TOPO®. 
 
Supplementary Figure 9-10. Vector map of pCR®4Blunt-TOPO®. 
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Supplementary Figure 9-11. Vector map of pGL4.10[luc2]. 
 
 
 
